Method of drug formulation

Information

  • Patent Grant
  • 10143655
  • Patent Number
    10,143,655
  • Date Filed
    Wednesday, August 10, 2016
    2 years ago
  • Date Issued
    Tuesday, December 4, 2018
    7 days ago
Abstract
Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.
Description
FIELD OF THE INVENTION

This invention relates to drug formulations and is particularly related to methods. More specifically, binding or adsorbing active agents onto the surface of crystalline microparticles is disclosed.


BACKGROUND OF THE INVENTION

Delivery of therapeutic agents has been a major problem. Oral administration is one of the most common and preferred routes of delivery due to ease of administration, patient compliance, and decreased cost. However, the disadvantages of this route include low or variable potency and inefficient adsorption of the therapeutic. This is particularly evident when the compound to be delivered is unstable under conditions encountered in the gastrointestinal tract. A variety of coatings and encapsulation methods have been developed in the art, but only a few are effective in addressing this issue. Still, there are therapeutic compounds that tend to be less active in the conditions of the gastrointestinal tract and must be administered in higher dosages to be adsorbed into the bloodstream in an effective amount.


A broad range of drug formulation systems have been developed to address the problem of optimal drug delivery and are based on incorporation of drug into a matrix that acts as a carrier. Factors considered in drug formulation include requirements that the system be non-toxic and non-reactive with the drug to be delivered, economical to manufacture, formed of readily available components, and consistent with respect to final composition and physical characteristics, including stability and release rate. It is also preferable that the drug delivery system is formed of materials easily removed from the body by normal physiologic processes.


Advancements in microparticle technology have aided in the development of improved drug formulations. However, despite these advances there is still a need in the art for stable drug formulations having long term effectiveness and optimal adsorption when administered as a pharmaceutical, particularly by pulmonary means. One approach in addressing this deficiency is to target the structural characteristics/properties of the active agent that would promote its adsorption to the microparticle surface and decrease its tendency to remain in solution.


SUMMARY OF THE INVENTION

Methods are provided for binding, coating or adsorbing an active agent onto a crystalline microparticle surface. In general, microparticles are coated with an active agent by modifying the system comprising the microparticles and the dissolved active agent such that the active agent has a greater affinity for the microparticle surface than for remaining in solution. In particular the present invention seeks to further promote the adsorption of an active agent to the microparticle surface by modifying/utilizing the properties of the active agent under a number of conditions in solution.


Thus, in the present invention there is provided a method for promoting binding of an active agent to a preformed crystalline microparticle in suspension comprising the steps of: i) modifying the chemical potential of the active agent wherein the modifying allows for an energetically favorable interaction between the active agent and microparticle independent of removal of solvent; and ii) adsorbing the active agent onto the surface of the microparticle.


In particular embodiments of the present invention, modifying the chemical potential comprises modifying the structure, flexibility, rigidity, solubility or stability of the active agent, individually or in combination. Modifying the chemical potential of the active agent comprises altering solution conditions. Altering solution conditions comprises adding an active agent modifier to the solution.


In particular embodiments, the active agent modifier is selected from the group consisting of salts, surfactants, ions, osmolytes, alcohols, chaotropes, kosmotropes, acids, bases, and organic solvents. In one embodiment, the salt is sodium chloride.


In still yet another embodiment of the present invention, the method further comprises the step of dissolving the active agent in the fluid phase of a suspension of microparticles and changing the pH of the fluid phase. In one aspect the step of dissolving the active agent in a fluid phase refers to the dissolving of a solid. In another aspect the step of dissolving the active agent refers to the addition of a concentrated solution of the active agent.


In another embodiment of the present invention, the active agent modifier improves the structural stability of the active agent.


In yet another embodiment of the present invention the active agent is a protein, peptide, polypeptide, small molecule, or nucleic acid molecule. In another embodiment of the present invention the active agent is selected from the group consisting of insulin, ghrelin, growth hormone, and parathyroid hormone (PTH). The active agent can comprise an antibody or antibody fragment. In various aspects of the invention the antibody can recognize a disease-associated antigen including, without limitation, a tumor-associated antigen or an infectious pathogen-related antigen.


In still yet another embodiment of the present invention, the small molecule is an ionizable molecule or a hydrophobic molecule such as, but not limited to, cyclosporin A.


In another embodiment of the present invention, modifying the chemical potential of the active agent comprises modulating one or more energetically favorable interactions such as, but not limited to, electrostatic interactions, hydrophobic interactions, and/or hydrogen bonding interactions between the active agent and the microparticle surface. In one embodiment, the microparticle comprises a diketopiperazine such as, but not limited to, fumaryl diketopiperazine.


In yet another embodiment of the present invention, the method further comprises a step for removing or exchanging the solvent. Solvent, as used herein, refers to the fluid medium in which the active agent and microparticle are “bathed.” It should not be interpreted to require that all components are in solution. Indeed in many instances it may be used to refer to the liquid medium in which the microparticles are suspended.


In another embodiment of the present invention, there is provided a process for preparing a drug delivery composition comprising an active agent and a crystalline microparticle comprising the steps of: providing an active agent solution comprising an active agent molecule; modifying the chemical potential of the active agent; providing a microparticle in a suspension or powder; and combining the active agent solution with the microparticle suspension or powder. The powder can be, for example, filtered but not dried.


In another embodiment of the present invention, the process of modifying the chemical potential of the active agent allows for interaction between the active agent and a microparticle. In one embodiment, modifying the chemical potential of the active agent comprises adding an active agent modifier to the solution. Such an active agent modifier can be selected from the group consisting of salts, surfactants, ions, osmolytes, alcohols, chaotropes, kosmotropes, acid, base, and organic solvents. In yet another embodiment, the modifier decreases the solubility of the active agent molecule, promotes association between the active agent and a microparticle such as a diketopiperazine particle, and/or improves the structural stability of the active agent molecule.





BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the examples disclosed herein. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.



FIGS. 1A-1C depict the effects of chaotropes and kosmotropes on loading curves for active agents onto fumaryl diketopiperazine (FDKP) microparticles as a function of pH and 100 mM chaotropic/kosmotropic agent according to the teachings of the present invention. FIG. 1A depicts the loading of 0.75 mg/mL insulin onto 5 mg/mL FDKP microparticles in the presence of chaotropes and kosmotropes at pH 3.0-5.0. FIG. 1B depicts the loading of 0.25 mg/mL glucagon-like peptide 1 (GLP-1) onto 5 mg/mL FDKP microparticles in the presence of chaotropes and kosmotropes at pH 2.0-4.0. FIG. 1C depicts the loading of 0.25 mg/mL parathyroid hormone (PTH) onto 5 mg/mL FDKP microparticles in the presence of the strong chaotropes, NaSCN and NaClO4, between pH 4.0-5.0.



FIGS. 2A-2C depict the effects of osmolytes on loading curves for active agents onto FDKP microparticles as a function of pH and osmolytes (100 mM) according to the teachings of the present invention. FIG. 2A depicts the loading of 0.75 mg/mL insulin onto 5 mg/mL FDKP microparticles in the presence of osmolytes at pH 3.0-5.0. FIG. 2B depicts the loading of 0.25 mg/mL GLP-1 onto 5 mg/mL FDKP microparticles in the presence of osmolytes between pH 2.0-4.0. FIG. 2C depicts the loading of 0.10 mg/mL ghrelin peptide onto 5 mg/mL FDKP microparticles in the presence of strong osmolytes at pH 4.0-5.0.



FIGS. 3A-3D depict the effects of alcohols on loading curves for active agents onto FDKP microparticles as a function of pH and alcohols according to the teachings of the present invention. FIG. 3A depicts the loading of 0.10 mg/mL ghrelin onto 5 mg/mL FDKP microparticles in the presence of hexafluoroisopropanol (HFIP) at 5%, 10%, 15%, and 20% v/v between pH 2.0-4.0. FIG. 3B depicts the loading of 0.10 mg/mL ghrelin onto 5 mg/mL FDKP microparticles in the presence of trifluoroethanol (TFE) at 5%, 10%, 15%, and 20% v/v between pH 2.0-4.0. FIGS. 3C and 3D depict the loading of 0.25 mg/mL GLP-1 onto 5 mg/mL FDKP microparticles at pH 2.0-5.0 in the presence of HFIP and TFE, respectively.



FIGS. 4A-4D depict the effects of salt on loading curves for active agents onto FDKP microparticles as a function of pH and NaCl concentration according to the teachings of the present invention. FIG. 4A depicts the loading of 0.75 mg/mL insulin onto 5 mg/mL FDKP microparticles in the presence of 0-500 mM NaCl at pH 2.0-5.0. FIG. 4B depicts the loading of 0.25 mg/mL GLP-1 onto 5 mg/mL FDKP microparticles in the presence of 0-500 mM NaCl at pH 2.0-5.0. FIG. 4C depicts the loading of 0.25 mg/mL PTH peptide onto 5 mg/mL FDKP microparticles in the presence of 0-1000 mM NaCl at pH 2.0-5.0. FIG. 4D depicts the secondary structural analysis of PTH at various salt concentrations (20° C.). The far-UV CD of 4.3 mg/mL PTH at pH 5.8 illustrates that as the concentration of NaCl increases the secondary structure of the peptide adopts a more helical conformation.



FIGS. 5A-5B depict the adsorption of hydrophobic molecules onto microparticles according to the teachings of the present invention. FIG. 5A depicts the binding of cyclosporin A to FDKP microparticles with increasing anti-solvent (water) at 60%, 80% and 90% concentration. FIG. 5B depicts the percent of theoretical maximum load achieved for cyclosporin A at varying mass ratios of cyclosporin A/FDKP microparticles in the presence of 90% anti-solvent.



FIG. 6 depicts the pharmacokinetics of single intravenous injection (IV) and pulmonary insufffaltion (IS) in rats using various mass ratios of cyclosporin A/FDKP microparticles at 90% anti-solvent according to the teachings of the present invention.





DETAILED DESCRIPTION OF THE INVENTION

Described herein are methods useful for stabilizing pharmaceutical active agents in combination with crystalline microparticles. The resulting compositions provide stable active agents coated onto the crystalline microparticle surfaces.


The substance to be coated or adsorbed onto the crystalline microparticle is referred to herein as active agent. Examples of classes of active agent include pharmaceutical compositions, synthetic compounds, and organic macromolecules that have therapeutic, prophylactic, and/or diagnostic utility.


Generally, most active agents can be coated or adsorbed onto the surface of crystalline microparticles including, but not limited to, organic macromolecules, nucleic acids, synthetic organic compounds, polypeptides, peptides, proteins, polysaccharides and other sugars, and lipids. Peptides, proteins, and polypeptides are all chains of amino acids linked by peptide bonds. Peptides are generally considered to be less than 30 amino acid residues but may include more. Proteins are polymers that can contain more than 30 amino acid residues. The term polypeptide as is know in the art and as used herein, can refer to a peptide, a protein, or any other chain of amino acids of any length containing multiple peptide bonds, though generally containing at least 10 amino acids. The active agents used in the coating formulation can fall under a variety of biological activity classes, such as vasoactive agents, neuroactive agents, hormones, anticoagulants, immunomodulating agents, cytotoxic agents, antibiotics, antivirals, antigens, and antibodies.


Examples of active agents that may be employed in the present invention include, in a non-limiting manner: growth hormone, antibodies and fragments thereof, alkynes, cyclosporins (e.g. cyclosporin A), PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone), CMFDA (5-chloromethyifluorescein diacetate), Texas Red, clopiogrel, granulocyte macrophage colony stimulating factor (GM-CSF), glucagon-like peptide 1 (GLP-1), ghrelin, parathyroid hormone (PTH), insulin and insulin analogs (e.g., aspart insulin and insulin), and antibodies and fragments thereof, including, but not limited to: humanized or chimeric antibodies; F(ab), F(ab)2, or single-chain antibody alone or fused to other polypeptides; therapeutic or diagnostic monoclonal antibodies to cancer antigens, cytokines, infectious agents, inflammatory mediators, hormones, and cell surface antigens. Non-limiting examples of antibodies to tumor antigens include anti-SSX-241-49 (synovial sarcoma, X breakpoint 2), anti-NY-ESO-1 (esophageal tumor associated antigen), anti-PRAME (preferentially expressed antigen of melanoma), anti-PSMA (prostate-specific membrane antigen), anti-Melan-A (melanoma tumor associated antigen), anti-tyrosinase (melanoma tumor associated antigen), and anti-MOPC-21 (myeloma plasma-cell protein).


Microparticles


Essentially, the term “microparticle” refers to a particle with a diameter of about 0.5-1000 @m, irrespective of the precise exterior or interior structure. Within the broad category of microparticles, “microspheres” refers to microparticles with uniform spherical shape. Crystalline microparticles as used herein refers to microparticles that have the internal structure, though not necessarily the external form, of a crystal and have a regular arrangement of atoms in a space lattice. Ionizable crystalline surfaces refer to crystalline microparticles that have the additional capacity to carry an electrical charge. In some embodiments the microparticle can be a single regularly shaped crystal. In various preferred embodiments the microparticle is irregularly shaped, is porous, has dissolved active agent-accessible interior surfaces, or comprises multiple crystals, in any combination. Such characteristics will generally increase surface area and thereby loading capacity. Such characteristics can also contribute to advantageous aerodynamic properties, important if the active agent is to be delivered by inhalation of a dry powder comprising the microparticles.


Preferably, the chemical substance composing the crystalline microparticle is reversibly reactive with the active agent to be delivered, non-toxic, as well as non-metabolized by rodents and humans. The foregoing notwithstanding, some levels of toxicity are tolerable, depending, for example, on the severity of the condition to be treated or the amount of the substance to which a patient is exposed. Similarly, it is not required that the substance be completely metabolically inert. In addition, the crystalline structure of preferred microparticles is not substantially disrupted in the process of coating or binding with active agent. The composition of the crystalline microparticle determines what type of chemical interactions can be manipulated to drive adsorption of an active agent to the microparticle surface.


A number of substances can be used to form crystalline microparticles. Microparticles as such have surfaces, the properties of which can be manipulated in the coating process as disclosed in copending U.S. patent application Ser. No. 11/532,063, filed on the same date as the instant application, and U.S. Provisional Application Ser. No. 60/717,524 filed on Sep. 14, 2005, each of which is hereby incorporated by reference in its entirety. Representative materials from which crystalline microparticles can be formed include, but are not limited to, aromatic amino acids, or compounds with limited solubility in a defined pH range such as diketopiperazines and morpholine sulfates.


One particular example of microparticles as contemplated in the present invention are diketopiperazine (DKP) microparticles. As discussed herein, DKP microparticles are employed to facilitate the adsorption of the active agent. U.S. Pat. Nos. 5,352,461 and 5,503,852, each of which is incorporated herein by reference in its entirety, describe a drug delivery system based on formation of diketopiperazine (DKP) microparticles from diketopiperazine derivatives such as 3,6-bis[N-fumaryl-N-(n-butyl)amino] (also referred to as fumaryl diketopiperazine or FDKP; also termed (E)-3,6-bis[4-(N-carboxy-2-propenyl)amidobutyl]-2,5-diketopiperazine) that are stable at low pH and dissolve at the pH of blood or the small intestine. A system based on diketopiperazine structural elements or one of its substitution derivatives, including, but not limited to, diketomorpholines and diketodioxanes, forms microparticles with desirable size distributions and pH ranges as well as good payload tolerance. A wide range of stable, reproducible characteristics can be generated with appropriate manipulations of the substituent groups. These patents disclosed precipitation of the DKP in the presence of the active agent to form microparticles comprising the active agent. Further details for synthesis, preparation, and use of diketopiperazines and diketopiperazine microparticles are disclosed in U.S. Pat. Nos. 6,071,497; 6,331,318; 6,428,771 and U.S. Patent Publication Nos. 20060040953 and 20060041133, each incorporated herein by reference in their entirety. Compositions comprising diketopiperazine particles are disclosed in U.S. Pat. No. 6,991,779 and U.S. Patent Publication No. 20040038865; each incorporated herein by reference in their entirety.


Other diketopiperazines contemplated in the present invention include 3,6-di(4-aminobutyl)-2,5-diketopiperazine; 3,6-di(succinyl-4-aminobutyl)-2,5-diketopiperazine (succinyl diketopiperazine or SDKP); 3,6-di(maleyl-4-aminobutyl)-2,5-diketopiperazine; 3,6-di(citraconyl-4-aminobutyl)-2-5-diketopiperazine; 3,6-di(glutaryl-4-aminobutyl)-2,5-diketopiperazine; 3,6-di(malonyl-4-aminobutyl)-2,5-diketopiperazine; 3,6-di(oxalyl-4-aminobutyl)-2,5-diketopiperazine and derivatives therefrom. Diketopiperazine salts may also be utilized in the present invention and may included, for example, a pharmaceutically acceptable salt such as the Na, K, Li, Mg, Ca, ammonium, or mono-, di- or tri-alkylammonium (as derived from triethylamine, butylamine, diethanolamine, triethanolamine, or pyridines, and the like). The salt may be a mono-, di-, or mixed salt. Higher order salts are also contemplated for diketopiperazines in which the R groups contain more than one acid group. In other aspects of the invention, a basic form of the agent may be mixed with the diketopiperazine in order to form a salt linkage between the drug and the diketopiperazine, such that the drug is a counter cation of the diketopiperazine. DKP salts for drug delivery are disclosed in a further detail in U.S. Patent Application Publication No. 20060040953 which is herein incorporated by reference in its entirety.


U.S. Pat. Nos. 6,444,226, and 6,652,885, each herein incorporated by reference in their entirety, describe preparing and providing microparticles of DKP in aqueous suspension to which a solution of active agent is added, and then the critical step of lyophilizing the suspension to yield microparticles having a coating of active agent. The basis for this formulation is that the coating of microparticle with active agent is driven by removal of the liquid medium by lyophilization. (See also U.S. Pat. No. 6,440,463 which is incorporated herein by reference in its entirety). In contrast to teachings in the prior art, the present invention provides means for adjusting the association of active agent with the microparticle prior to solvent removal. Thus, removal of the liquid medium by bulk physical methods (e.g., filtration or sedimentation) or evaporative methods (e.g., lyophilization or spray-drying) can result in comparable loads.


Promoting Adsorption of Active Agents


Adsorbing active agent to the surface of a crystalline microparticle can involve altering the properties of the active agent in a solution or fluid suspension under various solution conditions, thereby promoting adsorption to the microparticle surface and reducing the amount of active agent remaining in solution. Alteration or modifications to the active agent may occur with the use of modifiers such as, but not limited to, chaotropes and kosmotropes, salts, organics such as, but not limited to, alcohols, osmolytes, and surfactants. These modifiers can act on the active agent to alter its chemical potential and thereby its structure, flexibility, rigidity or stability, without chemically altering the agent itself. The term “chemical potential” is well known to one of ordinary skill. In embodiments of the present invention, “chemical potential” refers to the free energy necessary to drive a chemical reaction such as, for example, interaction between an active agent and a solvent or the adsorption of active agent onto a microparticle. The term “energetically favorable” as used herein refers to the lowering of the free energy levels of the absorbed states of the active agent onto the microparticle in relation to the free energy level of uncoated microparticle, or unbound active agent and/or the insoluble forms (including aggregation or precipation) of the active agent. The term “structure” as used herein refers to the secondary structure of the active agent molecule and includes the alpha-helical formation, beta sheets, or random coil (unordered) of the active agent molecule, such as a protein. Additionally, the term structure may also include teritary and quaternary structures of the molecule but is not limited to such and may also refer to the self association, aggregation, multimerization, dimerization, and the like, of a molecule. The term “stability” as used herein refers to the stabilization or destabilization of the structure of the active agent in the presence of the modifier.


In addition, altering the properties of the active agent in a solution or fluid suspension are likely to affect the interactions due to hydrophobic properties, hydrogen bonding properties, and electrostatic properties of the active agent and/or microparticle.


Hydrophobic interactions are associations of non-polar groups with each other in aqueous solutions because of their insolubility in water. Hydrophobic interactions can affect a number of molecular processes including, but not limited to, structure stabilization (of single molecules, complexes of two or three molecules, or larger assemblies) and dynamics, and make important contributions to protein-protein and protein-ligand binding processes. These interactions are also known to play a role in early events of protein folding, and are involved in complex assembly and self-assembly phenomena (e.g., formation of membranes).


Hydrogen bonding interactions are especially strong dipole-dipole forces between molecules; a hydrogen atom in a polar bond (e.g., H—F, H—O or H—N) can experience an attractive force with a neighboring electronegative molecule or ion, which has an unshared pair of electrons (typically an F, O, or N atom on another molecule). Hydrogen bonds are responsible for the unique properties of water and are very important in the organization of biological molecules, especially in influencing the structure of proteins and DNA.


Electrostatic interactions are attractions between opposite charges or repulsions between like charges that grow stronger as the charges come closer to each other. Electrostatic interactions constitute a key component in understanding interactions between charged bodies in ionic solutions. For example, the stability of colloidal particles dispersed in a solvent can be explained by considering the competition between repulsive electrostatic interactions and the attractive van der Waals interactions. Electrostatic interactions are also of importance when considering interaction and adhesion between particles.


Salts


In some embodiments of the present invention, the properties of the active agent are altered using a salt such as, but not limited to, sodium chloride. Active agents, for example, PTH and GLP-1, undergo noticeable structural changes in the presence of salt. As shown in Example 5 (FIG. 4D), the presence of salt increases the secondary structure of PTH by promoting a more helical conformation of the peptide. Salt has also been shown to affect the structure of GLP-1, as disclosed in U. S. Provisional Patent Application Ser. No. 60/744,882, filed on Apr. 14, 2006 and incorportated herein by reference in its entirety. Furthermore, salts and other ionic compounds are capable of either stabilizing or destabilizing proteins and peptides, especially when the difference between the pH of the solution and the pI of the protein or peptide becomes greater, by binding to specifically charged residues (Antosiewiez J, et al., J. Mol. Biol. 238:415-436, 1994).


Chaotropes


Chaotropes, as are well known in the art, are ions that exhibit weak interactions with water and therefore destabilize molecules such as proteins or peptides. These compounds break down the hydrogen-bonded network of water and decrease its surface tension, thus promoting more structural freedom and denaturation of proteins and peptides. Examples of chaotropes include, but are not limited to, NaSCN, (CH3)3N—HCl, Na2NO3, and NaClO4 and cesium chloride (CsCl).


Kosmotropes or lyotropes, on the other hand, are ions that display strong interactions with water and generally stabilize macromolecules such as proteins and peptides. This stabilization effect is brought about by increasing the order of water and increasing its surface tension. Examples of kosmotropes include, but are not limited to, sodium citrate (Na Citrate), and sodium sulfate (Na2SO4).


Alcohols


Another class of modifier of active agent employed in the present invention is alcohols. Alcohols are able to disrupt the native structure of proteins and peptides and are also able to stabilize and induce 6-helical conformations in macromolecules, most notably within unstructured proteins and polypeptides. Such alcohols may include, but are not limited to, methanol (MeOH), ethanol (EtOH), trifluoroethanol (TFE), and hexafluoroisopropanol (HFIP). Of those, TFE and HFIP are two of the most potent alcohols for inducing helical transitions in peptides and proteins (Hirota et al., Protein Sci., 6:416-421; 1997, incorporated herein by reference for all it contains regarding helical transitions in peptides and proteins). These alcohols may affect the structure of proteins and peptides through their ability to disrupt the hydrogen-bonding properties of the solvent (see Eggers and Valentine, Protein Sci., 10:250-261; 2001, incorporated herein by reference for all it contains regarding the effect of alcohols on the structure of proteins).


Osmolytes


Another class of modifier that affects the active agent affinity for the microparticle is osmolytes. Osmolytes, as are well known to the skilled artisan, are small compounds that are produced by the cells of most organisms in high stress situations (such as extreme temperature fluctuations, high salt environments, etc.) to stabilize their macromolecules. They do not interact with the macromolecule directly but act by altering the solvent properties in the cellular environment and so their presence indirectly modifies the stability of proteins. These compounds include various polyols, sugars, polysaccharides, organic solvents, and various amino acids and their derivatives. Although the mechanism of osmolytes are yet to be elucidated, it is speculated that these compounds likely act by raising the chemical potential of the denatured state relative to the native state, thereby increasing the (positive) Gibbs energy difference (ΔG) between the native and denatured ensembles (Arakawa and Timasheff, Biochemistry 29:1914-1923; 1990).


Osmolytes as contemplated in the present invention, include in a non-limiting manner, hexylene-glycol (Hex-Gly), trehalose, glycine, polyethylene glycol (PEG), trimethylamine N-oxide (TMAO), mannitol, and proline.


General Description of the Method


In the methods of the present invention, at least three components are combined in a liquid medium: at least one active agent, (preformed) microparticles, and at least one active agent modifier as described above. The components of this system may be combined in any order. In some embodiments the modifier and active agent are combined with each other prior to that mixture being combined with a suspension of microparticles. In other embodiments the agent and microparticles are first combined and then the modifier is added. In some embodiments the active agent or modifier is provided and combined with another component, or components, as a solution. In other embodiments any of the components can be provided in solid form and dissolved, or in the case of the microparticles, suspended, in the liquid medium containing another of the components. Further variations will be apparent to one of skill in the art.


The microparticles are formed prior to being combined with the other components of the system, and as such are present as a suspension. Nonetheless the liquid medium in which the microparticles are suspended is at times referred to herein as a solvent. The liquid medium utilized in the method is most often aqueous. However in some instances the liquid medium can comprise more of an organic compound, for example an alcohol used as a modifier, than it does water.


Upon assembly of all components of the system, the active agent will adsorb to the surface of the microparticle. In increasingly preferred embodiments of the present invention, at least 50, 60, 70, 80, 90, 95%, or substantially all, of the active agent in the system will adsorb to the microparticles, up to 100%. In some embodiments of the present invention, the accessible surface area of the microparticles with be sufficient for all of the adsorbed active agent to be in direct contact with the microparticle surface, that is, the coating is a monolayer. However it is to be understood that additional interactions can be present. In some instances, for example, self-association of the active agent can also be energetically favored so that multiple layers of active agent coat the particle. It is not required that any of these layers be complete or that the thickness of the coating be uniform. Two forms of self-association can be recognized: multimerization and aggregation. Multimerization is characterized by specific intermolecular interactions and fixed stoichiometry. Aggregation is characterized by unspecific intermolecular interactions and undefined stoichiometry. It should be understood that multimeric active agents can be adsorbed in the multimeric state, or dissociated into monomers, or lower order multimers, and adsorbed to the surface in that state. In either case aggregation can mediate layering of the active agent onto the microparticle.


The loaded microparticles constitute a drug delivery composition that can be utilized in a variety of forms. The particles can be used as powders, in solid dosage forms such as tablets or contained in capsules, or suspended in a liquid carrier. Generally this will require exchange and/or removal of the liquid medium in which the loading took place. This can be accomplished by any of a variety of means including physical methods such as, but not limited to, sedimentation or filtration, and evaporative methods such as, but not limited to, lyophilization or spray-drying. These techniques are known to those skilled in the art. In one embodiment of the present invention, solvent is removed by spray-drying. Methods of spray-drying diketopiperazine microparticles are disclosed in, for example, U.S. Provisional Patent Application No. 60/776,605 filed on Feb. 22, 2006, incorporated by reference herein for all it contains regarding spray-drying diketopiperazine microparticles.


If loading is not substantially complete, embodiments of the invention, using physical methods of solvent removal will typically loose the unadsorbed active agent, but for example can be useful to ensure that coating does not progress beyond a monolayer. Conversely, embodiments using evaporative drying for solvent removal can in some cases deposit additional active agent on the particle and thereby avoid its loss, but the adsorptive interactions involved can differ from those established by the molecules bound in the earlier steps of the method. In other embodiments evaporative solvent removal does not result in significant further deposition of active agent, including the case in which substantially all of the active agent was already adsorbed to the particle.


EXAMPLES

The following examples are included to demonstrate preferred embodiments of the present invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. While discussion may focus on a particular mechanism it should be understood that some modifiers can have multiple effect on the agent, or indeed on the particle surface as well, each of which can contribute to promoting adsorption of the agent to the particle. However, those of skill in the art, in light of the present disclosure, will appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.


Example 1
Experimental Procedure: Active Agent/FDKP Microparticle Adsorption Studies

The active agents insulin, PTH, ghrelin and GLP-1 were either purchased from American Peptide (Sunnyvale, Calif.) or AnaSpec (San Jose, Calif.), or prepared in house (MannKind Corporation, Valencia, Calif.). Aqueous samples at varying pH and at 20° C. (unless otherwise noted) were analyzed. Samples were generally prepared fresh and were mixed with the particular additive (e.g., salt, pH buffer, etc., if any), prior to the addition of FDKP microparticles.


The association of active agent with diketopiperazine (DKP) particles in suspension was evaluated by conducting adsorption studies. The parameters investigated in the adsorption studies explored the effects of electrostatic interactions, hydrogen bonding, water structure, protein flexibility, and specific salt-pairing interactions on the active agent/fumaryl diketopiperazine (FDKP) microparticle interaction. In addition, several common protein stabilizers were tested for interference with active agent adsorption to FDKP microparticle surfaces.


Varying conditions promoting adsorption of active agent onto the surfaces of preformed FDKP particles were studied. A 15 mg/mL FDKP microparticle suspension was combined with 3× pH buffer and 3× solution of an additive or excipient. The final solution contained a FDKP microparticle concentration of 5 mg/mL and a GLP-1 concentration of 0.25 mg/mL (5% w/w), or a PTH concentration of 0.25 mg/mL (5% w/w), or an insulin concentration of 0.75 mg/mL (15% w/w) or a ghrelin concentration of 0.10 mg/mL (2% w/w). Unbound active agent in the supernatant was filtered off the suspension. The FDKP particles with the associated active agent were dissolved (reconstituted) in 100 mM ammonium bicarbonate and filtered to separate out any aggregated active agent molecules. The amount of active agent in both the supernatant and reconstituted fractions was quantitated by HPLC. A series of experiments were conducted in which conditions employed included use of additives such as salts, osmolytes, chaotropes and kosmotropes, and alcohols. The results from these studies are described below.


Example 2
Effect of Chaotropes and Kosmotropes on Adsorption of Active Agent onto FDKP Particles

Ionic species that affect the structure of water and proteins (chaotropes and kosmotropes) were studied to investigate the adsorption of active agent onto a FDKP microparticle surface by a hydrophobic mechanism (at low pH). Loading of the active agent onto FDKP particles was performed at 5 mg/mL microparticles and a GLP-1 concentration of 0.25 mg/mL (5% w/w), or a PTH concentration of 0.25 mg/mL (5% w/w), or an insulin concentration of 0.75 mg/mL (15% w/w). The concentration of the chaotrope or kosmotrope in the samples was held constant at 100 mM and the pH varied from 2.0 to 5.0. Chaotropes or kosmotropes were selected from the following: NaSCN, CsCl, Na2SO4, (CH3)3N—HCl, Na2NO3, Na Citrate, and NaClO4. The control indicates no chaotrope or kosmotrope were added.



FIGS. 1A-1C depict the loading curves for insulin, GLP-1 and PTH respectively, onto the FDKP microparticle surface as a function of pH in the presence of the various chaotropes or kosmotropes. At low pH (3.0) all chaotropes and kosmotropes analyzed improved the affinity of insulin for the microparticle surface and showed significant loading compared to the control. At pH 4, this effect was not observed (FIG. 1A). At higher pH (5.0), the chaotropes and kosmotropes interfered with the adsorption of insulin to the microparticle surface, as compared to control, by precipitating the insulin protein. Thus these agents promoted binding of insulin to the FDKP particles at lower pH, but have little or even a detrimental effect at the higher pH conditions.


GLP-1, in the presence of chaotropes and kosmotropes, showed an improved affinity for the FDKP microparticles at pH 2.0-4.0 with a greater effect at lower pH (FIG. 1B). Similar observations were disclosed in U.S. Provisional Application Ser. No. 60/744,882. There it was noted, that approximately 0.02-0.04 mg/mL of the GLP-1 peptide (which corresponds to mass ratios of 0.004 to 0.008) was detected in the reconstituted microparticle-free control samples in the presence of NaSCN, NaClO4, Na2SO4, NaNO3 and Na citrate, indicating that a small proportion of the GLP-1 precipitated rather than adsorbing to the particle.


The affinity of PTH for the FDKP microparticle surface was greater at pH of 4.0 to about 4.5 in the presence of strong chaotropes NaSCN and NaClO4 (FIG. 1C).


The data supports that chaotropic and kosmotropic agents play a role in promoting adsorption of the active agent to FDKP microparticle surfaces, most notably at low pH. Since these modifiers have a greater effect at low pH, where the microparticle surface is less ionic, it is likely that adsorption results from a hydrophobic mechanism. The decrease in adsorption observed at higher pH may result from the more highly charged surface of the particle in combination with effects chaotropic and kosmotropic agents have on increasing the hydrophobicity of the active agents. Additionally, as ionic species, these agents may compete with the active agent for binding to the microparticle, or disrupt the electrostatic interactions between the active agent and the microparticle. Finally it is also noted that Debye shielding can contribute to the decrease in adsorption to the more highly charged surface.


Example 3
Effect of Osmolytes on Adsorption of Active Agent to FDKP Particles

To assess the importance of active agent stability on adsorption, the effect of osmolytes on the binding of active agent to FDKP particles was examined by HPLC analysis. FIGS. 2A-2C show the loading curves for insulin (FIG. 2A), GLP-1 (FIG. 2B) and ghrelin (FIG. 2C) onto FDKP particles as a function of pH in the presence of common stabilizers (osmolytes). Loading of the active agent onto FDKP microparticles was performed at 5 mg/mL of microparticles and an insulin concentration of 0.75 mg/mL (15% w/w), or a GLP-1 concentration of 0.25 mg/mL (5% w/w) or a ghrelin concentration of 0.10 mg/mL (2% w/w). The concentration of the osmolyte (stabilizer) in the samples was held constant at 100 mM and the pH varied from about 2.0 to about 5.0. The osmolytes were selected from hexylene-glycol (Hex-Gly), trehalose, glycine, PEG, TMAO, mannitol and proline; the control indicates no osmolyte.


Of the active agents studied, insulin showed significantly improved affinity for the FDKP particle surface in the presence of osmolytes (PEG, glycine, trehalose, mannitol and Hex-Gly) over a pH range of 3.0 to 5.0 (FIG. 2A). Of the osmolytes studied, PEG and proline improved the affinity for adsorption of the GLP-1 onto FDKP particle surface over a pH range from 2.0 to 4.0. The osmolyte TMAO was more effective than PEG or proline at binding GLP-1 onto the FDKP microparticle surface at low pH (2.0) but was modestly detrimental at pH 3.0 and above (FIG. 2B). Ghrelin however, showed greater affinity for the microparticle surface in the presence of 100 mM mannitol, PEG, glycine, Hex-Gly, and trehalose when compared to the control over the pH range of about 4.0 to 5.0 (FIG. 2C).


These loading curves suggested that osmolytes are capable of enhancing the adsorption of the active agent to FDKP microparticle surface. It is likely that this effect resulted from the modifiers ability to stabilize the active agent, which enabled adsorption to be more energetically favorable.


Example 4
Effect of Alcohols on Affinity of Active Agent to FDKP Particles

In assessing the effect of modifiers on the active agent that allows for adsorption to the microparticle surface by a hydrophobic mechanism, the effect of alcohols were examined. Alcohols known to induce helical conformation in unstructured peptides and proteins by increasing hydrogen-bonding strength were evaluated to determine the role that helical confirmation plays in adsorption of active agent to FDKP particles surface. Active agents such as GLP-1 and ghrelin were analyzed. Loading of the active agent on FDKP particles was performed at 5 mg/mL of microparticles and a GLP-1 concentration of 0.25 mg/mL (5% w/w) or a ghrelin concentration of 0.10 mg/mL (2% w/w). The effect of each alcohol was observed over a pH range of 2.0 to 5.0. The alcohols used were trifluoroethanol (TFE) and hexafluoroisopropanol (HFIP). Each alcohol was evaluated at varying concentrations which include 5%, 10%, 15%, or 20% v/v.



FIGS. 3A-3D show the loading curves for active agent onto FDKP microparticles as a function of pH for each alcohol and each active agent. At pH 2.0-4.0, ghrelin showed greatly improved affinity for the microparticle surface in the presence of HFIP and TFE at all concentrations tested (5%, 10%, 15% and 20%), as demonstrated by the mass ratio of ghrelin to FDKP particles (FIGS. 3A-3B).


At pH 2.0-5.0, GLP-1 showed improved affinity for the microparticle surface in the presence of HFIP and TFE at the concentrations shown (5% and 10%) (FIGS. 3C-3D). The effect of TFE was less pronounced, and at the lower pHs tested was detrimental. It was noted that a substantial amount of GLP-1 peptide (0.13-0.19 mg/mL, which corresponds to mass ratios of 0.026 to 0.038) was detected in the reconstituted microparticle-free control samples in the presence of 10% HFIP and TFE at pH 4.0, indicating that some of the GLP-1 had precipitated. However, at lower pH (2.0-3.0), the amount of GLP-1 peptide detected in the reconstitued microparticle-free control in the presence of 10% HFIP or TFE was significantly decreased. At pH 3.0, GLP-1 peptide at 0 to 0.02 mg/mL, (which corresponding to a mass ratio of 0 to 0.004) was detected, whereas no GLP-1 was detected for the control samples at pH 2.0. The mass ratios in FIGS. 3C-D reflect both adsorbed and precipitated active agent although precipitation is an increasingly minor component as the pH decreased toward 3.0.


The data indicated that alcohols are able to improve the adsorption of the active agent onto FDKP microparticles. This increase in adsorption likely resulted from enhanced hydrophobic interactions between the active agent and surface of the microparticle in the presence of alcohols.


Example 5
Effect of Salt on Adsorption of Active Agent to FDKP Particles

To further address the hydrophobic mechanism of binding, the effects of salt on adsorption of active agent to FDKP microparticles were observed by HPLC analysis.


Loading of the active agent onto FDKP microparticles was performed at 5 mg/mL of microparticles and an insulin concentration of 0.75 mg/mL (15% w/w), or a GLP-1 concentration of 0.25 mg/mL (5% w/w) or a PTH concentration of 0.25 mg/mL (5% w/w) in the presence of 0, 25, 50, 100, 250, and 500 mM NaCl (FIGS. 4A-4C). Loading of PTH onto FDKP particles was also assessed at 1000 mM NaCl. The amount of active agent detected in reconstituted microparticle-free control samples as a function of pH and NaCl concentration was assessed. The pH was controlled with a 20 mM potassium phosphate/20 mM potassium acetate mixture.


As observed in FIG. 4A, increased binding (adsorption) of insulin onto FDKP particles was evident at high salt concentrations of 100-500 mM at pH from about 2.5 to about 3.5. At a pH from about 4.0 to about 5.0, for all salt concentrations tested, a reduction in the adsorption of insulin to the FDKP particle was observed.


At a pH from about 2.0 to about 3.5 enhanced binding (adsorption) of GLP-1 to FDKP particles was evident at all the salt concentrations tested (FIG. 4B). At pH 4.0 and above, a reduction in binding was also noted.


Similar studies using PTH as the active agent showed enhanced binding of PTH to the FDKP particles at high salt concentrations of 250 to 1000 mM at pH from about 2.0 to about 3.5 (FIG. 4C). At pH from about 3.5 to about 5.0 binding of PTH to the microparticle decreased in the presence of salt.


At low pH, where adsorption is not favorable, the addition of salt was able to modify the chemical potential of the active agent so as to increase its affinity for the microparticle surface. Such enhancement of binding likely resulted from a hydrophobic mechanism. Furthermore, the data indicated that as the pH was raised, adsorption decreased with increased salt concentration. As the microparticle surface became more charged with increasing pH, the hypothesized hydrophobic mechanism can be expected to be less effective at promoting the adsorption of the active agent. This reduction may also have resulted from salt competing for the binding sites on the surface of the microparticle. It is noted that Debye shielding may also contribute to the reduced adsorption observed


The data also showed that salt is capable of altering the structure of active agents. For example, circular dichroism measurements with PTH showed that as the salt concentration increased the secondary structure of the peptide adopted a more helical conformation (FIG. 4D). This suggests that change in the structure of PTH may promote its binding to the microparticle surface at low pH.


In an aqueous solution, the presence of salt was also shown to partition the dye Texas Red onto the surface of the microparticle.


Example 6
Effects on Cyclosporin A Adsorption to FDKP Particles

The effects on the adsorption of small hydrophobic molecules onto FDKP particles was investigated both in vitro and in vivo using cyclosporin A as the active agent. Adsorption was promoted by altering the solubility of the active agent.


Cyclosporin A, a lipophilic cyclic polypeptide, was studied in order to show how a hydrophobic molecule can be made to adsorb to microparticles. In addition, the size of cyclosporin A (1202.61 MW) was utilized to demonstrate the loading capacities of microparticles for smaller compounds.


To accomplish loading, a solvent/anti-solvent method was employed. The basic principle of this methodology is to dissolve the compound in a solvent (methanol) and then use anti-solvent (water) to drive the compound out of solution and onto the surface of the microparticles. Utilizing this solvent/anti-solvent approach, cyclosporin A was successfully loaded onto the surface of microparticles.


In a preliminary experiment to determine a solubility profile, cyclosporin A was dissolved to 10 mg/mL in methanol and its solubility at 1 mg/mL with varying concentrations of anti-solvent (10-90% H2O in 10% increments) was analyzed by HPLC. The cyclosporin A peak areas were compared against the sample containing methanol alone, to determine the percent loss to precipitation. It was observed that solubility was largely retained below 60% H2O. At 70% H2O, a significant majority of the agent was insoluble and at 80-90% H2O less than 5% solubility remained.


To assess particle loading, FDKP microparticles were suspended in methanol solutions of cyclosporin A. Water was then added in a stepwise fashion to final concentrations of 60, 80, and 90%. Half of the sample was pelleted and the other half lyophilized. Each half was then redissolved such that the final percentages were 20% FDKP microparticles/cyclosporin A, 20% 0.5 M ammonium bicarbonate (AmBicarb), and 60% methanol (the concentrations necessary for the dissolution of both microparticle and cyclosporin A). The cyclosporin A content of each was analyzed by HPLC and compared to determine the proportion that had become adsorbed to the particle. The results are presented in FIG. 5A. At 60% H2O it was observed that about 20% of the cyclosporin A had bound to the particle. At 80% and 90% H2O the loads were about 90% and 95%, respectively, indicating the strong binding of cyclosporin A to FDKP microparticles.


The loading capacity of the microparticles for cyclosporin A was analyzed at the 90% anti-solvent level by varying the input of cyclosporin A so that the final content of the recovered solids would be from 2% to 20%, assuming all of the cyclosporin A became adsorbed. It was observed that as the input increased over this range the percent of available cyclosporin A bound to the microparticle increased from 50% to 95% of the input (FIG. 5B). It is to be noted that, taking into account that the solubility of cyclosporin A is 0.05 mg/mL at 90% H2O, these results indicated that substantially all of the insoluble cyclosporin A became adsorbed to the particles rather than precipitating out.


Example 7
Pulmonary Insufflation of Cyclosporin A/DKP Particles

To examine the pharmacokinetics of cyclosporin A/FDKP microparticles, plasma concentrations of cyclosporin A were evaluated in female Sprague Dawley rats administered various formulations of cyclosporin A/FDKP microparticles via pulmonary insufflation or intravenous injection. These studies were conducted using cyclosporin A/FDKP microparticles made at 90% anti-solvent and a theoretical maximum mass ratio of 0.05, 0.10 or 0.20 as described in the example above. These are referred to as the 5%, 10% and 20% loads.


A single dose of 2.5 mg cyclosporin A/FDKP microparticles was delivered to eight groups of rats via pulmonary insufflation or intravenous injection. Blood samples were taken on the day of dosing for each group at pre-dose (time 0), and at 5, 20, 40, 60, 240, 480 minutes and at 24 hrs post dose. At each time point, approximately 100 @L whole blood was collected from the lateral tail vein into a cryovial, inverted and stored on ice. Blood samples were centrifuged at 4000 rpm and approximately 40 @L plasma was pipetted into 96-well plates which were stored at −80° C. until analyzed.


As shown in FIG. 6, administration of 2.5 mg FDKP microparticles/cyclosporin A via pulmonary insufflation resulted in maximal serum cyclosporin levels 24 hours post dose in female Sprague Dawley rats. The 10% load achieved a Cmax of 32.4 ng/mL at that time point. Animals administered 2.5 mg of FDKP microparticles/cyclosporin A in 0.1 mL via intravenous injection showed minimal levels of cyclosporin out to 24 hours post dose. It was observed that FDKP microparticle levels peaked at 20 minutes post dose and returned to baseline levels in 4 hours for both the intravenous and pulmonary insufflation groups.


Overall, the data shows the bioavailability of cyclosporin A/FDKP microparticle. It is noted that the single peak at 240 minutes is an anomaly. For all animals treated, the pathology as determined by gross and microscopic observation was normal.


Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.


The terms “a” and an and the and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.


The use of the term or in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.”


Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.


Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on those preferred embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.


Specific embodiments disclosed herein may be further limited in the claims using consisting of or consisting essentially of language. When used in the claims, whether as filed or added per amendment, the transition term “consisting of” excludes any element, step, or ingredient not specified in the claims. The transition term “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the invention so claimed are inherently or expressly described and enabled herein.


Furthermore, numerous references have been made to patents and printed publications throughout this specification. Each of the above cited references and printed publications are herein individually incorporated by reference in their entirety.


Further, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.

Claims
  • 1. A method for making a microparticle coated with an active agent, the method comprising: i. combining (a) a microparticle comprising crystalline fumaryl diketopiperazine, (b) an active agent, and (c) a solvent for said active agent thereby forming a suspension of said microparticles with said active agent;ii. adding an active agent modifier to said suspension wherein adding said active agent modifier causes adsorption of said active agent onto said microparticle.
  • 2. The method of claim 1, wherein said active agent modifier is a salt, surfactant, ion, osmolyte, alcohol, chaotrope, kosmotrope, acid, base, or anti-solvent.
  • 3. The method of claim 1 further comprising removing said solvent subsequent to said adsorption of the active agent.
  • 4. The method of claim 2, wherein said anti-solvent is an aqueous solvent.
  • 5. The method of claim 4 wherein said anti-solvent is an organic solvent.
  • 6. The method of claim 2, wherein said anti-solvent is an organic solvent.
  • 7. The method of claim 6 wherein said anti-solvent is water.
  • 8. The method of claim 2, wherein said salt is sodium chloride.
  • 9. The method of claim 2, wherein said osmolyte is hexylene-glycol, trehalose, glycine, polyethylene glycol, trimethylamine N-oxide, mannitol, or proline.
  • 10. The method of claim 2, wherein said alcohol is methanol, ethanol, trifluoroethanol, or hexafluoroisopropanol.
  • 11. The method of claim 2, wherein said chaotrope is NaSCN, (CH3)3N—HCl, Na2NO3, NaClO4, or CsCl.
  • 12. The method of claim 2, wherein said kosmotrope is sodium citrate or sodium sulfate.
  • 13. The method of claim 1, wherein at least 70% of said active agent becomes adsorbed to said microparticle.
  • 14. The method of claim 1, wherein at least 80% of said active agent becomes adsorbed to said microparticle.
  • 15. The method of claim 1, wherein at least 90% of said active agent becomes adsorbed to said microparticle.
  • 16. The method of claim 1, wherein all of said active agent becomes adsorbed to said microparticle.
  • 17. The method of claim 1, wherein said microparticle is coated with a monolayer of said active agent.
  • 18. The method of claim 1, wherein adding said active agent modifier favorably modulates one or more energetic interactions with said microparticle.
  • 19. The method of claim 18, wherein said one or more energetically favorable interactions between said active agent and said microparticle comprises a hydrophobic interaction.
  • 20. The method of claim 18, wherein said one or more energetically favorable interactions between said active agent and said microparticle comprises a hydrogen bonding interaction.
  • 21. The method of claim 18, wherein said one or more energetically favorable interactions between said active agent and said microparticle comprises an electrostatic interaction.
  • 22. The method of claim 1, wherein adding said active agent modifier modifies the structure, flexibility, rigidity, solubility or stability of said active agent.
  • 23. The method of claim 1, wherein said active agent is a peptide or a protein.
  • 24. The method of claim 1, wherein said active agent is an insulin and an insulin analog.
CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 14/746,656 filed Jun. 22, 2015, which is a divisional of U.S. patent application Ser. No. 12/883,369 filed Sep. 16, 2010, which is a continuation of U.S. patent application Ser. No. 11/532,065 filed Sep. 14, 2006 and claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application Ser. Nos. 60/717,524 filed on Sep. 14, 2005, and No. 60/744,882, filed on Apr. 14, 2006, the entire contents of each which are hereby incorporated by reference in their entirety.

US Referenced Citations (1190)
Number Name Date Kind
2549303 Friden Apr 1951 A
2754276 Joseph et al. Jul 1956 A
D189076 Altman Oct 1960 S
3337740 Gray et al. Aug 1967 A
3407203 Buijle Oct 1968 A
3518340 Raper Jun 1970 A
3622053 Ryden Nov 1971 A
3673698 Guerard Jul 1972 A
3669113 Altounyan et al. Aug 1972 A
3823816 Controullis et al. Jul 1974 A
3823843 Stephens et al. Jul 1974 A
3856142 Vessalo Dec 1974 A
3873651 Mosley, Jr. et al. Mar 1975 A
3906950 Cocozza Sep 1975 A
3921637 Bennie et al. Nov 1975 A
3976773 Curran et al. Aug 1976 A
3980074 Watt et al. Sep 1976 A
3998226 Harris Dec 1976 A
4013075 Cocozza Mar 1977 A
4018619 Webster et al. Apr 1977 A
4022749 Kuechler May 1977 A
4040536 Schwarz Aug 1977 A
4047525 Kulessa et al. Sep 1977 A
4066756 Orr et al. Jan 1978 A
4078128 Hoyt et al. Mar 1978 A
4091077 Smith et al. May 1978 A
4098273 Glenn Jul 1978 A
4102953 Johnson et al. Jul 1978 A
4110240 Leo et al. Aug 1978 A
4148308 Sayer Apr 1979 A
4153689 Hirai May 1979 A
D252707 Besnard Aug 1979 S
4168002 Crosby Sep 1979 A
4171000 Uhle Oct 1979 A
4175556 Freezer Nov 1979 A
4187129 Bost et al. Feb 1980 A
4196196 Tiholiz Apr 1980 A
4206758 Hallworth et al. Jun 1980 A
4210140 James et al. Jul 1980 A
4211769 Okada Jul 1980 A
4268460 Boiarski et al. May 1981 A
4272398 Jaffe Jun 1981 A
4275820 LeBlond Jun 1981 A
4289759 Heavener Sep 1981 A
4294829 Suzuki Oct 1981 A
4300546 Kruber Nov 1981 A
4356167 Kelly Oct 1982 A
D269463 Young et al. Jun 1983 S
4407525 Hoppe Oct 1983 A
4456007 Nakao et al. Jun 1984 A
4481139 Folkers et al. Nov 1984 A
4483922 Carpenter Nov 1984 A
D276654 Snellman-Wasenius et al. Dec 1984 S
4487327 Grayson Dec 1984 A
4524769 Wetterlin Jun 1985 A
4526804 Escallon Jul 1985 A
4534345 Wetterlin Aug 1985 A
D282209 Newell et al. Jan 1986 S
4581020 Mittleman Apr 1986 A
4592348 Waters, IV et al. Jun 1986 A
4613500 Suzuki Sep 1986 A
4615817 McCoy Oct 1986 A
4624861 Yale et al. Nov 1986 A
4637996 Konishi Jan 1987 A
D288852 Miyoshi Mar 1987 S
4659696 Hirai et al. Apr 1987 A
4668218 Virtanen May 1987 A
4671954 Goldberg et al. Jun 1987 A
4681752 Melillo Jul 1987 A
D295321 Hallworth Apr 1988 S
4742156 Wright May 1988 A
4757066 Shiokari et al. Jul 1988 A
4792451 Kim Dec 1988 A
4811731 Newell et al. Mar 1989 A
D301273 Leonard May 1989 S
4835312 Itoh et al. May 1989 A
4841964 Hurka et al. Jun 1989 A
4847091 Illum Jul 1989 A
4849227 Cho Jul 1989 A
4861627 Mathiowitz Aug 1989 A
4866051 Hunt et al. Sep 1989 A
4873087 Morishita et al. Oct 1989 A
4887722 Greenward, Sr. Dec 1989 A
4900730 Miyauchi Feb 1990 A
4907583 Wetterlin et al. Mar 1990 A
4925673 Steiner May 1990 A
4926852 Zoltan et al. May 1990 A
4927555 Colarusso, Jr. May 1990 A
4927928 Shroot et al. May 1990 A
4946828 Markussen Aug 1990 A
4981295 Belman et al. Jan 1991 A
4981625 Rhim et al. Jan 1991 A
4983402 Steiner et al. Jan 1991 A
4984158 Hillsman Jan 1991 A
4991605 Keritsis Feb 1991 A
4998624 Capes et al. Mar 1991 A
5006343 Benson Apr 1991 A
D316902 Hoefling May 1991 S
5017383 Ozawa et al. May 1991 A
5019400 Gombotz et al. May 1991 A
5021376 Nienburg et al. Jun 1991 A
5027806 Zoltan et al. Jul 1991 A
5042975 Chien Aug 1991 A
D321570 Blasdell et al. Nov 1991 S
5067500 Keritsis Nov 1991 A
5069204 Smith et al. Dec 1991 A
5074418 Buan et al. Dec 1991 A
5075027 Dixit et al. Dec 1991 A
5098590 Dixit et al. Mar 1992 A
5105291 Matsumoto et al. Apr 1992 A
D326517 Funai et al. May 1992 S
5110007 Law et al. May 1992 A
5110823 Hamaguchi et al. May 1992 A
5118666 Habener Jun 1992 A
5120712 Habener Jun 1992 A
5124291 Bremer et al. Jun 1992 A
5131539 Karita et al. Jul 1992 A
5139878 Kim Aug 1992 A
5145684 Liversidge et al. Sep 1992 A
5152284 Valentini et al. Oct 1992 A
D331106 Fuchs Nov 1992 S
5167506 Kilis et al. Dec 1992 A
5170801 Casper et al. Dec 1992 A
5188837 Domb Feb 1993 A
5196049 Coombs et al. Mar 1993 A
5201308 Newhouse Apr 1993 A
5203768 Haak et al. Apr 1993 A
5204108 Ilium Apr 1993 A
5208998 Dyler, Jr. May 1993 A
5215739 Kamishita et al. Jun 1993 A
D337636 Kocinski Jul 1993 S
D338062 Yair Aug 1993 S
D338268 Kobayashi et al. Aug 1993 S
5239992 Bougamont et al. Aug 1993 A
5239993 Evans Aug 1993 A
5244653 Berke et al. Sep 1993 A
5250287 Cocozza Oct 1993 A
D340975 Sladek Nov 1993 S
5260306 Boardman et al. Nov 1993 A
5270305 Palmer Dec 1993 A
5287850 Haber et al. Feb 1994 A
D344796 Sochon et al. Mar 1994 S
D344797 Sochon et al. Mar 1994 S
D345013 Huck et al. Mar 1994 S
5301666 Lerk et al. Apr 1994 A
5306453 Shulman Apr 1994 A
D347057 Yair May 1994 S
D348100 Clarke Jun 1994 S
5320094 Laube et al. Jun 1994 A
D348928 Ashley et al. Jul 1994 S
D348929 Paton Jul 1994 S
5327883 Williams et al. Jul 1994 A
5328464 Kriesel et al. Jul 1994 A
5331953 Andersson et al. Jul 1994 A
5333106 Lanpher et al. Jul 1994 A
D349572 Jagnandan et al. Aug 1994 S
D350193 Huck et al. Aug 1994 S
5337740 Armstrong et al. Aug 1994 A
D350602 Hobbs et al. Sep 1994 S
D350821 Wright et al. Sep 1994 S
5351683 Chiesi et al. Oct 1994 A
5352461 Feldstein et al. Oct 1994 A
5354562 Platz Oct 1994 A
5358734 Lenox et al. Oct 1994 A
D352107 Meier et al. Nov 1994 S
5360614 Fox et al. Nov 1994 A
5363842 Mishelevich et al. Nov 1994 A
5364838 Rubsamen Nov 1994 A
5372128 Haber et al. Dec 1994 A
D355029 Kinneir et al. Jan 1995 S
5385904 Andersson et al. Jan 1995 A
5394868 Ambrosio et al. Mar 1995 A
5401516 Milstein et al. Mar 1995 A
D357603 Wolff Apr 1995 S
5404871 Goodman et al. Apr 1995 A
D358880 Mulhauser et al. May 1995 S
5413804 Rhodes May 1995 A
5415162 Casper et al. May 1995 A
D359153 Viggiano Jun 1995 S
D359555 Funai et al. Jun 1995 S
5424286 Eng Jun 1995 A
5437271 Hodson et al. Aug 1995 A
5443841 Milstein et al. Aug 1995 A
D362500 Cook et al. Sep 1995 S
5447150 Bacon Sep 1995 A
5447151 Bruna et al. Sep 1995 A
5447728 Milstein et al. Sep 1995 A
5451410 Milstein et al. Sep 1995 A
D363775 Hobbs Oct 1995 S
5454871 Liaw et al. Oct 1995 A
5455335 Kahne et al. Oct 1995 A
5458135 Patton et al. Oct 1995 A
5469750 Lloyd et al. Nov 1995 A
5469971 Chilton et al. Nov 1995 A
5476093 Laniken Dec 1995 A
5477285 Riddle et al. Dec 1995 A
D365876 Chawla Jan 1996 S
5482032 Smith et al. Jan 1996 A
5482927 Maniar et al. Jan 1996 A
5483954 Mecikalski Jan 1996 A
5484606 Dhaber et al. Jan 1996 A
5487378 Robertson et al. Jan 1996 A
5492112 Mecikalski et al. Feb 1996 A
D368364 Reitano et al. Apr 1996 S
5503144 Bacon Apr 1996 A
5503852 Steiner et al. Apr 1996 A
5505194 Adjei et al. Apr 1996 A
5506203 Backstorm et al. Apr 1996 A
D370255 Yamamoto et al. May 1996 S
5514646 Chance et al. May 1996 A
5518998 Backstorm et al. May 1996 A
5524613 Haber et al. Jun 1996 A
5532461 Crummenauer et al. Jul 1996 A
5533502 Piper Jul 1996 A
5533505 Kallstrand et al. Jul 1996 A
5541155 Leone-Bay Jul 1996 A
5542411 Rex Aug 1996 A
5542539 Early Aug 1996 A
5545618 Buckley et al. Aug 1996 A
5547929 Anderson, Jr. et al. Aug 1996 A
5562909 Allcock et al. Oct 1996 A
5562918 Stimpson Oct 1996 A
5568884 Bruna Oct 1996 A
5570810 Lambelet, Jr. et al. Nov 1996 A
5571795 Kahne et al. Nov 1996 A
5574008 Johnson et al. Nov 1996 A
5577497 Mecikalski et al. Nov 1996 A
5578323 Milstein et al. Nov 1996 A
5584417 Graf et al. Dec 1996 A
D377215 Rand Jan 1997 S
D377686 Waldeck et al. Jan 1997 S
5595175 Malcher et al. Jan 1997 A
5596701 Augusteijn et al. Jan 1997 A
D377861 Jacober Feb 1997 S
5598835 von Schrader Feb 1997 A
5601846 Milstein et al. Feb 1997 A
5610271 Dooley et al. Mar 1997 A
5614492 Habener Mar 1997 A
5615670 Rhodes et al. Apr 1997 A
5617844 King Apr 1997 A
5619984 Hodson et al. Apr 1997 A
5622164 Kilis et al. Apr 1997 A
5622166 Eisele et al. Apr 1997 A
5623724 Gurkovich et al. Apr 1997 A
5623920 Bryant Apr 1997 A
D379506 Maher May 1997 S
5629020 Leone-Bay May 1997 A
5631224 Efendic et al. May 1997 A
5632971 Yang May 1997 A
5634900 Makino et al. Jun 1997 A
5639441 Sievers et al. Jun 1997 A
5641861 Dooley et al. Jun 1997 A
D381416 Hansson et al. Jul 1997 S
5642727 Datta et al. Jul 1997 A
5642728 Andersson et al. Jul 1997 A
5643957 Leone-Bay et al. Jul 1997 A
5645051 Schultz Jul 1997 A
5651359 Bougamont et al. Jul 1997 A
5653961 McNally et al. Aug 1997 A
5655516 Goodman et al. Aug 1997 A
5655523 Hodson et al. Aug 1997 A
5657748 Braithwaite Aug 1997 A
5658878 Backstrom et al. Aug 1997 A
5660169 Kallstrand et al. Aug 1997 A
5672581 Rubsamen et al. Sep 1997 A
5673686 Villax et al. Oct 1997 A
5679377 Bernstein et al. Oct 1997 A
5687710 Ambrosio et al. Nov 1997 A
5690910 Ahmed et al. Nov 1997 A
5693338 Milstein Dec 1997 A
5699789 Hendricks Dec 1997 A
D389238 Kirk, III et al. Jan 1998 S
D389570 Savolainen Jan 1998 S
5705483 Galloway et al. Jan 1998 A
D390651 Smith et al. Feb 1998 S
D390653 Blasdell et al. Feb 1998 S
5714007 Pletcher et al. Feb 1998 A
5714167 Milstein et al. Feb 1998 A
5715811 Ohki et al. Feb 1998 A
5727333 Folan Mar 1998 A
5727546 Clarke et al. Mar 1998 A
5740793 Hodson et al. Apr 1998 A
5740794 Smith et al. Apr 1998 A
5746197 Williams May 1998 A
5746227 Rose et al. May 1998 A
5747445 Backstrom et al. May 1998 A
5752505 Ohki et al. May 1998 A
5755218 Johansson et al. May 1998 A
D395147 Vidgren et al. Jun 1998 S
D395499 Eisele et al. Jun 1998 S
5758638 Kreamer Jun 1998 A
5763396 Weiner et al. Jun 1998 A
5766620 Heiber et al. Jun 1998 A
5766633 Milstein et al. Jun 1998 A
5769073 Eason et al. Jun 1998 A
5772085 Bryant et al. Jun 1998 A
RE35862 Steiner et al. Jul 1998 E
5775320 Patton et al. Jul 1998 A
5785049 Smith et al. Jul 1998 A
5785989 Stanley et al. Jul 1998 A
D397435 Naumann Aug 1998 S
5792451 Sarubbi et al. Aug 1998 A
5794613 Piskorski Aug 1998 A
5797391 Cook et al. Aug 1998 A
D398992 Feret Sep 1998 S
5799821 Lambelet, Jr. et al. Sep 1998 A
5807315 Va Antwerp et al. Sep 1998 A
5809997 Wolf Sep 1998 A
5811127 Milstein et al. Sep 1998 A
5813397 Goodman et al. Sep 1998 A
5817343 Burke Oct 1998 A
5824345 Milstein et al. Oct 1998 A
5839429 Marnfeldt et al. Nov 1998 A
5840279 Narodylo et al. Nov 1998 A
5840340 Milstein et al. Nov 1998 A
5846447 Beatty Dec 1998 A
5848589 Welnetz Dec 1998 A
5849322 Ebert et al. Dec 1998 A
5857457 Hyppola Jan 1999 A
5858099 Sun et al. Jan 1999 A
5865012 Hansson et al. Feb 1999 A
5868774 Reil Feb 1999 A
5874064 Edwards et al. Feb 1999 A
5875776 Vaghefi Mar 1999 A
5877174 Ono et al. Mar 1999 A
5881719 Gottenauer et al. Mar 1999 A
5881721 Bunce et al. Mar 1999 A
5884620 Gonda et al. Mar 1999 A
5888477 Gonda et al. Mar 1999 A
5896855 Hobbs et al. Apr 1999 A
5901703 Ohki et al. May 1999 A
5904139 Hauser May 1999 A
D410541 Moulin Jun 1999 S
D411005 Coe Jun 1999 S
5908639 Simpkin et al. Jun 1999 A
5912011 Makino et al. Jun 1999 A
5918594 Asking et al. Jul 1999 A
5919897 Dooley et al. Jul 1999 A
5921237 Eisele et al. Jul 1999 A
5922253 Herbert et al. Jul 1999 A
5924419 Kotliar Jul 1999 A
5929027 Takama et al. Jul 1999 A
D412572 Gray Aug 1999 S
D412744 Braithwaite Aug 1999 S
D412978 Cameron Aug 1999 S
D412979 Weinstein et al. Aug 1999 S
5934273 Andersson et al. Aug 1999 A
5942242 Mizushima et al. Aug 1999 A
5972242 Mizushima et al. Aug 1999 A
5948749 Igarashi et al. Sep 1999 A
5952008 Backstrom et al. Sep 1999 A
5954047 Armer et al. Sep 1999 A
5965701 Junien Oct 1999 A
5971951 Ruskewicz Oct 1999 A
D416085 Forssell et al. Nov 1999 S
D416621 Forssell et al. Nov 1999 S
D416998 Hodson et al. Nov 1999 S
D417271 Denyer et al. Nov 1999 S
5975347 Lambelet, Jr. et al. Nov 1999 A
5976569 Milstein Nov 1999 A
5976574 Gordon Nov 1999 A
5977071 Galloway et al. Nov 1999 A
5980865 Ahmed et al. Nov 1999 A
5981488 Hoffman Nov 1999 A
5983893 Wetterlin Nov 1999 A
5985248 Gordon et al. Nov 1999 A
5985309 Edwards et al. Nov 1999 A
5990077 Drucker Nov 1999 A
D417732 Dagsland et al. Dec 1999 S
D417912 Dagsland et al. Dec 1999 S
5996577 Ohki et al. Dec 1999 A
5997848 Patton et al. Dec 1999 A
6001336 Gordon Dec 1999 A
6006747 Eisele et al. Dec 1999 A
6006753 Efendic Dec 1999 A
D418600 Haerle Jan 2000 S
D420736 Moulin Feb 2000 S
6026809 Abrams et al. Feb 2000 A
6029663 Eisele et al. Feb 2000 A
D421800 Doat Mar 2000 S
6039208 Lambelet et al. Mar 2000 A
6043214 Jensen et al. Mar 2000 A
6045828 Bystorm et al. Apr 2000 A
6051256 Platz et al. Apr 2000 A
6051551 Hughes et al. Apr 2000 A
6055980 Mecikalski et al. May 2000 A
6056169 Bruna et al. May 2000 A
6060069 Hill et al. May 2000 A
6063910 Debenedetti et al. May 2000 A
6071497 Steiner et al. Jun 2000 A
6073629 Hardy et al. Jun 2000 A
6076521 Lindahl et al. Jun 2000 A
6077543 Gordon et al. Jun 2000 A
6080762 Allen et al. Jun 2000 A
6085745 Levander et al. Jun 2000 A
D428486 Schuckmann Jul 2000 S
6087334 Beeley et al. Jul 2000 A
6087351 Nye Jul 2000 A
6089228 Smith et al. Jul 2000 A
6095136 Virtanen Aug 2000 A
6098618 Jennings et al. Aug 2000 A
6098619 Britto et al. Aug 2000 A
6102035 Asking et al. Aug 2000 A
6105571 Coffee Aug 2000 A
6105574 Jahnsson Aug 2000 A
6109261 Clarke et al. Aug 2000 A
6109481 Alexander et al. Aug 2000 A
6099517 Daughtery Sep 2000 A
6116237 Schultz Sep 2000 A
6116238 Jackson et al. Sep 2000 A
6116239 Volgyesi Sep 2000 A
6119684 Nohl et al. Sep 2000 A
6119688 Whaley et al. Sep 2000 A
6131567 Gonda et al. Oct 2000 A
6132766 Sankaram et al. Oct 2000 A
6133235 Galloway et al. Oct 2000 A
6142145 Dagsland Nov 2000 A
6152130 Abrams Nov 2000 A
6153613 Ono et al. Nov 2000 A
6155423 Katzne et al. Dec 2000 A
6156114 Bell et al. Dec 2000 A
6158431 Poole Dec 2000 A
6159360 Gerteis et al. Dec 2000 A
RE37053 Hanes et al. Feb 2001 E
6182655 Keller et al. Feb 2001 B1
6187291 Weinstein et al. Feb 2001 B1
6191102 DiMarchi et al. Feb 2001 B1
6192876 Denyer et al. Feb 2001 B1
6193844 McLaughlin et al. Feb 2001 B1
6193957 Ahmed Feb 2001 B1
D438612 Suh Mar 2001 S
D439325 Frost Mar 2001 S
D439656 Andersson et al. Mar 2001 S
6198847 Washizawa Mar 2001 B1
D441446 Dagsland et al. May 2001 S
D441859 Pera May 2001 S
D442685 Sladek May 2001 S
6235725 Ahmed May 2001 B1
D444226 Geert-Jensen et al. Jun 2001 S
6247598 Hosaka et al. Jun 2001 B1
6250300 Andersson et al. Jun 2001 B1
6254854 Edwards et al. Jul 2001 B1
6257232 Andersson et al. Jul 2001 B1
6258816 Singh et al. Jul 2001 B1
6263871 Brown et al. Jul 2001 B1
6269952 Watt et al. Aug 2001 B1
6273084 Frid Aug 2001 B1
6273085 Eisele et al. Aug 2001 B1
6273086 Ohki et al. Aug 2001 B1
6277819 Efendic Aug 2001 B1
6279511 Loughnane Aug 2001 B1
D448076 von Schuckmann Sep 2001 S
6286506 MacAndrew et al. Sep 2001 B1
6286507 Jahnsson Sep 2001 B1
6294204 Rossling et al. Sep 2001 B1
D449684 Christup et al. Oct 2001 S
6298846 Ohki et al. Oct 2001 B1
6298847 Datta et al. Oct 2001 B1
D450117 Braithwaite et al. Nov 2001 S
D451597 Suh Dec 2001 S
6328034 Eisele et al. Dec 2001 B1
6331318 Milstein Dec 2001 B1
D452910 Braithwaite et al. Jan 2002 S
6335316 Hughes et al. Jan 2002 B1
D453264 Acevedo, Jr. Feb 2002 S
6347629 Braithwaite Feb 2002 B1
6348447 Hellstorm et al. Feb 2002 B1
6357442 Casper et al. Mar 2002 B1
6358058 Strupat et al. Mar 2002 B1
6358924 Hoffman Mar 2002 B1
6360743 Andersson et al. Mar 2002 B1
6360929 McCarthy Mar 2002 B1
D455208 Bacon et al. Apr 2002 S
6363932 Forchione et al. Apr 2002 B1
6365190 Gordon et al. Apr 2002 B1
6372258 Platz et al. Apr 2002 B1
6375975 Modi Apr 2002 B1
6380357 Hermeling et al. Apr 2002 B2
6386195 Coffee May 2002 B1
6388053 Galloway et al. May 2002 B1
6394085 Hardy et al. May 2002 B1
6395300 Straub et al. May 2002 B1
6395744 Adams et al. May 2002 B1
6395774 Milstein May 2002 B1
6410513 Galloway et al. Jun 2002 B1
D460173 Harrison et al. Jul 2002 S
6415784 Christup et al. Jul 2002 B1
6418926 Chawla Jul 2002 B1
6423344 Platz et al. Jul 2002 B1
D461239 Cassidy Aug 2002 S
6427688 Ligotke et al. Aug 2002 B1
6428771 Steiner et al. Aug 2002 B1
6428805 Dohi et al. Aug 2002 B1
6432383 Modi Aug 2002 B1
6436443 Edwards et al. Aug 2002 B2
6439227 Myrman et al. Aug 2002 B1
6440463 Feldstein et al. Aug 2002 B1
6441172 Nefzi et al. Aug 2002 B1
D463544 Engelberth et al. Sep 2002 S
6443143 Ishida et al. Sep 2002 B1
6443307 Burridge Sep 2002 B1
6444226 Steiner Sep 2002 B1
6446626 Virtanen Sep 2002 B1
6446627 Bowman et al. Sep 2002 B1
6447750 Cutie et al. Sep 2002 B1
6447751 Weinstein et al. Sep 2002 B1
6447753 Edwards et al. Sep 2002 B2
6451337 Smith et al. Sep 2002 B1
6457470 Coffee Oct 2002 B1
6468507 Cutie et al. Oct 2002 B1
6470884 Horlin Oct 2002 B2
6479049 Platz et al. Nov 2002 B1
6484715 Ritsche et al. Nov 2002 B1
6484717 Dagsland et al. Nov 2002 B1
D469527 Keller et al. Jan 2003 S
6503480 Edwards et al. Jan 2003 B1
6509006 Platz et al. Jan 2003 B1
6509313 Smith Jan 2003 B1
D469866 Albulet et al. Feb 2003 S
6514482 Bartus et al. Feb 2003 B1
6518239 Kuo et al. Feb 2003 B1
6523536 Fugelsang et al. Feb 2003 B2
D471273 Albulet et al. Mar 2003 S
6528096 Musa et al. Mar 2003 B1
6532437 Clardy et al. Mar 2003 B1
6536427 Davies et al. Mar 2003 B2
D473298 Bowman et al. Apr 2003 S
D473640 Cuffaro et al. Apr 2003 S
6540672 Simonsen et al. Apr 2003 B1
6540982 Adjei et al. Apr 2003 B1
6540983 Adjei et al. Apr 2003 B1
6543448 Smith et al. Apr 2003 B1
6546929 Burr et al. Apr 2003 B2
6555127 Steiner Apr 2003 B2
6555521 Hermeling et al. Apr 2003 B2
D474536 Albulet et al. May 2003 S
D475133 McLuckie May 2003 S
6557549 Schmidt et al. May 2003 B2
6561186 Casper et al. May 2003 B2
6567686 Sexton May 2003 B2
6568390 Nichols et al. May 2003 B2
6569406 Stevenson et al. May 2003 B2
6571793 Nilsson et al. Jun 2003 B1
6572893 Gordon et al. Jun 2003 B2
6575160 Volgyesi Jun 2003 B1
6575162 Rand Jun 2003 B1
6578571 Watt Jun 2003 B1
6582728 Platz et al. Jun 2003 B1
6583111 DiMarchi Jun 2003 B1
D477665 Myrman et al. Jul 2003 S
6589560 Foster et al. Jul 2003 B2
6591832 DeJonge Jul 2003 B1
6592904 Platz et al. Jul 2003 B2
6595205 Andersson et al. Jul 2003 B2
6595208 Coffee et al. Jul 2003 B1
D478983 Whitehall et al. Aug 2003 S
6606992 Schuler et al. Aug 2003 B1
D479745 Albulet et al. Sep 2003 S
6613308 Bartus et al. Sep 2003 B2
6615987 Greenhill et al. Sep 2003 B1
6620910 Calas et al. Sep 2003 B1
6626173 Genova et al. Sep 2003 B2
D480806 Engelberth et al. Oct 2003 S
6630169 Bot et al. Oct 2003 B1
6632258 Wheelock et al. Oct 2003 B1
6632456 Backstrom et al. Oct 2003 B1
6635283 Edwards et al. Oct 2003 B2
6637431 Ekelius et al. Oct 2003 B2
6640050 Nichols et al. Oct 2003 B2
6644309 Casper et al. Nov 2003 B2
6645468 Cutie et al. Nov 2003 B2
6645504 Weiner et al. Nov 2003 B1
6652838 Weinstein et al. Nov 2003 B2
6652885 Steiner et al. Nov 2003 B2
D483860 Knoch Dec 2003 S
6655379 Clark et al. Dec 2003 B2
6655380 Andersson et al. Dec 2003 B1
6655381 Keane et al. Dec 2003 B2
6660716 Yakubu-Madus et al. Dec 2003 B1
6663898 Milstein Dec 2003 B2
6668826 Myrman et al. Dec 2003 B1
6672304 Casper et al. Jan 2004 B1
6676931 Dugger, III. Jan 2004 B2
6679255 Pera Jan 2004 B2
6681767 Patton et al. Jan 2004 B1
6681768 Haaije de Boer et al. Jan 2004 B2
6685967 Patton et al. Feb 2004 B1
6696090 Nilsson et al. Feb 2004 B1
6698421 Attolini Mar 2004 B2
6698422 Fugelsang et al. Mar 2004 B2
6698425 Widerstorm Mar 2004 B1
6701917 O'Leary Mar 2004 B2
6703361 Weiner et al. Mar 2004 B2
6703365 Galloway et al. Mar 2004 B2
6703381 Ekwuribe et al. Mar 2004 B1
6705313 Niccolai Mar 2004 B2
6715486 Gieschen et al. Apr 2004 B2
6715487 Nichols et al. Apr 2004 B2
6718972 O'Leary Apr 2004 B2
6720407 Hughes et al. Apr 2004 B1
6722363 von Schuckmann Apr 2004 B1
D489448 Shayan May 2004 S
6729324 Casper et al. May 2004 B2
6729328 Raul May 2004 B2
6737045 Patton May 2004 B2
6745761 Christup et al. Jun 2004 B2
6747006 Efendic Jun 2004 B2
6748946 Rand et al. Jun 2004 B1
6748947 Keane et al. Jun 2004 B2
6752145 Bonney et al. Jun 2004 B1
6755190 Rasmussen Jun 2004 B2
D492769 Hatanaka Jul 2004 S
D493220 Burge et al. Jul 2004 S
D493519 Jonsson et al. Jul 2004 S
6774112 Gougoutas Aug 2004 B2
6787152 Kirby et al. Sep 2004 B2
6790496 Levander et al. Sep 2004 B1
6792945 Davies et al. Sep 2004 B2
6794357 Backstrom et al. Sep 2004 B1
6797258 Platz et al. Sep 2004 B2
6799572 Nichols et al. Oct 2004 B2
6800643 Cuenoud et al. Oct 2004 B2
6803044 Catania et al. Oct 2004 B1
6821949 Bridon et al. Nov 2004 B2
6823863 Huxham et al. Nov 2004 B2
D499802 Pinon et al. Dec 2004 S
6830046 Blakley et al. Dec 2004 B2
6835372 Kuo et al. Dec 2004 B2
6838075 Stevenson et al. Jan 2005 B2
6838076 Platton et al. Jan 2005 B2
6847595 Tanaka Jan 2005 B2
6848443 Schmidt et al. Feb 2005 B2
6849708 Habener Feb 2005 B1
6852690 Nauck et al. Feb 2005 B1
6858199 Edwards et al. Feb 2005 B1
6860262 Christup et al. Mar 2005 B2
6866037 Aslin et al. Mar 2005 B1
6871646 Keane et al. Mar 2005 B2
6871647 Allan et al. Mar 2005 B2
6880554 Coffee Apr 2005 B1
6881423 Dohi et al. Apr 2005 B2
6884435 O'3 Hagan et al. Apr 2005 B1
6887459 Haeberlin May 2005 B1
6887849 Bridon et al. May 2005 B2
6889687 Olsson May 2005 B1
6892728 Helgesson et al. May 2005 B2
6896906 Hastedt et al. May 2005 B2
D506680 Saelzer Jun 2005 S
6904907 Speldrich et al. Jun 2005 B2
6906030 Milstein Jun 2005 B2
6916354 Elliot Jul 2005 B2
6918991 Chickering, III et al. Jul 2005 B2
6921458 Chickering, III et al. Jul 2005 B2
6921528 Edwards et al. Jul 2005 B2
6923175 Poole et al. Aug 2005 B2
D509296 Minshull et al. Sep 2005 S
D509898 Bunce et al. Sep 2005 S
6948496 Eason et al. Sep 2005 B2
6949258 Zhang Sep 2005 B2
6951215 Hoffman Oct 2005 B1
6953812 Joregenson et al. Oct 2005 B2
D511208 Pardonge et al. Nov 2005 S
D511977 Saelzer Nov 2005 S
6962006 Chickering, III et al. Nov 2005 B2
D512777 Beisner et al. Dec 2005 S
6979437 Bartus et al. Dec 2005 B2
D514222 Andersson et al. Jan 2006 S
6981499 Andersson et al. Jan 2006 B2
6989155 Ganderton et al. Jan 2006 B1
6991779 Steiner et al. Jan 2006 B2
D515696 Lucking et al. Feb 2006 S
D515924 Grant Feb 2006 S
D516211 Minshull et al. Feb 2006 S
6998387 Goke et al. Feb 2006 B1
D518170 Clarke et al. Mar 2006 S
D518171 Anderson et al. Mar 2006 S
7022674 DeFelippis et al. Apr 2006 B2
7025056 Eason et al. Apr 2006 B2
7028686 Gonda et al. Apr 2006 B2
7030084 Ekwuribe et al. Apr 2006 B2
7032593 Johnston et al. Apr 2006 B2
7035294 Dove et al. Apr 2006 B2
7047967 Knudsen May 2006 B2
7048908 Basu et al. May 2006 B2
7060274 Blumberg et al. Jun 2006 B2
7067129 Blumberg et al. Jun 2006 B2
7077130 Nichols et al. Jul 2006 B2
7080642 Hodson et al. Jul 2006 B2
7084243 Glaesner et al. Aug 2006 B2
7093594 Harrison et al. Aug 2006 B2
7093595 Nesbitt Aug 2006 B2
D527817 Ziegler et al. Sep 2006 S
7101843 Glaesner et al. Sep 2006 B2
7101866 Biggadike et al. Sep 2006 B2
7105489 Hathaway Sep 2006 B2
7107988 Pinon et al. Sep 2006 B2
7109161 Gayed Sep 2006 B1
D529604 Young et al. Oct 2006 S
7125566 Etter Oct 2006 B2
7128067 Byron et al. Oct 2006 B2
7131441 Keller et al. Nov 2006 B1
7132115 Musa et al. Nov 2006 B2
7140365 Poole et al. Nov 2006 B2
D533268 Olfati Dec 2006 S
7143764 Dagsland et al. Dec 2006 B1
7143765 Asking et al. Dec 2006 B2
7144863 DeFelippis et al. Dec 2006 B2
7146978 Edwards et al. Dec 2006 B2
7151456 Godfrey Dec 2006 B2
7163014 Nichols et al. Jan 2007 B2
D537522 Cox et al. Feb 2007 S
7171965 Young et al. Feb 2007 B2
7172768 Hastedt et al. Feb 2007 B2
7179788 DeFelippis et al. Feb 2007 B2
D537936 Cox et al. Mar 2007 S
D538423 Berube et al. Mar 2007 S
7185650 Huber et al. Mar 2007 B2
D540671 Born Apr 2007 S
D541151 Born Apr 2007 S
7198806 Berndt Apr 2007 B2
7211557 DiMarchi et al. May 2007 B2
7219664 Ruckdeschel et al. May 2007 B2
7223728 Yakubu-Madus et al. May 2007 B2
D544093 Eriksen Jun 2007 S
7231919 Giroux Jun 2007 B2
7232897 Hotamisligil et al. Jun 2007 B2
7234459 Del Bon Jun 2007 B2
7234460 Greenleaf et al. Jun 2007 B2
7234464 Goede et al. Jun 2007 B2
7238663 DeFelippis et al. Jul 2007 B2
7246617 Hammer et al. Jul 2007 B1
D548330 Cox et al. Aug 2007 S
D548618 Ferguson et al. Aug 2007 S
D548619 Ferguson et al. Aug 2007 S
D548833 Young et al. Aug 2007 S
D549111 Ferguson et al. Aug 2007 S
7258118 Goede et al. Aug 2007 B2
7259233 Dodd et al. Aug 2007 B2
D550835 Tanaka et al. Sep 2007 S
7265087 Goke et al. Sep 2007 B1
7270124 Rasmussen Sep 2007 B2
D552729 Cox et al. Oct 2007 S
7276534 Milstein Oct 2007 B2
7278419 Gonda Oct 2007 B2
7278426 Mryman et al. Oct 2007 B2
7278843 Feldstein et al. Oct 2007 B2
7279457 Pohl et al. Oct 2007 B2
7284553 Hochrainer Oct 2007 B2
D557799 Greenhalgh et al. Dec 2007 S
7305986 Steiner Dec 2007 B1
7306787 Tarara et al. Dec 2007 B2
D560793 Pearl et al. Jan 2008 S
7314859 Green et al. Jan 2008 B2
7316748 Li et al. Jan 2008 B2
7331340 Barney Feb 2008 B2
7334577 Gumaste et al. Feb 2008 B2
7344734 Heijerman et al. Mar 2008 B2
D566549 Russell Apr 2008 S
7368102 Tarara et al. May 2008 B2
7373938 Nichols et al. May 2008 B2
7377277 Hickey et al. May 2008 B2
7387122 Nishibayashi et al. Jun 2008 B2
7399528 Caponetti et al. Jul 2008 B2
7401712 Kaye et al. Jul 2008 B2
7401713 Ede et al. Jul 2008 B2
7402564 Schteingart et al. Jul 2008 B1
7414720 Wachtel et al. Aug 2008 B2
D577815 Gokhale et al. Sep 2008 S
7422013 Burr et al. Sep 2008 B2
D579549 Birath et al. Oct 2008 S
7448375 Gonda et al. Nov 2008 B2
7448379 Yamashita et al. Nov 2008 B2
7451761 Hickey et al. Nov 2008 B2
7453556 Hochrainer et al. Nov 2008 B2
D583463 Wood et al. Dec 2008 S
7461653 Oliva Dec 2008 B2
7462367 Schmidt et al. Dec 2008 B2
7464706 Steiner et al. Dec 2008 B2
7469696 Yang et al. Dec 2008 B2
7500479 Nichols et al. Mar 2009 B2
7503324 Barney et al. Mar 2009 B2
7504538 Chang et al. Mar 2009 B2
7517874 Beckett et al. Apr 2009 B2
7520278 Crowder et al. Apr 2009 B2
7521069 Patton et al. Apr 2009 B2
7533668 Widerstrom May 2009 B1
D594753 Eadicicco et al. Jun 2009 S
7556798 Edwards et al. Jul 2009 B2
7559322 Foley et al. Jul 2009 B2
D597418 Stojek Aug 2009 S
D597657 Kinsey et al. Aug 2009 S
D598785 Stojek Aug 2009 S
7584846 Senter Sep 2009 B2
7598222 Prouty, Jr. et al. Oct 2009 B2
D604832 Smutney Nov 2009 S
D604833 Polidoro Nov 2009 S
D605752 Polidoro Dec 2009 S
D605753 Smutney Dec 2009 S
7625865 Colombo Dec 2009 B2
7648960 Steiner et al. Jan 2010 B2
D613849 Smutney Apr 2010 S
D614045 Gaudenzi et al. Apr 2010 S
D614760 Smutney et al. Apr 2010 S
7694676 Wachtel Apr 2010 B2
7708014 Yamashita et al. May 2010 B2
7709639 Stevenson May 2010 B2
7713937 Schteingart et al. May 2010 B2
7727963 Schteingart et al. Jun 2010 B2
7735485 Yamashita et al. Jun 2010 B2
D620812 Gaudenzi et al. Aug 2010 S
7794754 Feldstein et al. Sep 2010 B2
7799344 Oberg Sep 2010 B2
7803404 Hokenson Sep 2010 B2
7820676 Leone-Bay et al. Oct 2010 B2
D626836 Lien Nov 2010 S
D628090 Stuiber et al. Nov 2010 S
7833549 Steiner et al. Nov 2010 B2
7833550 Steiner et al. Nov 2010 B2
7842662 Schteingart et al. Nov 2010 B2
D629505 Adamo Dec 2010 S
D629506 Adamo Dec 2010 S
D629886 Adamo Dec 2010 S
D629887 Adamo Dec 2010 S
D629888 Adamo Dec 2010 S
D635241 McLean Mar 2011 S
D635242 Adamo Mar 2011 S
D635243 Kinsey Mar 2011 S
7913688 Cross Mar 2011 B2
D636867 Polidoro et al. Apr 2011 S
D636868 Kinsey et al. Apr 2011 S
D636869 Laurenzi et al. Apr 2011 S
7919119 Straub et al. Apr 2011 B2
7943178 Steiner et al. May 2011 B2
7943572 Cheatham et al. May 2011 B2
7954491 Hrkach Jun 2011 B2
7959609 Gaydos et al. Jun 2011 B2
D641076 Grunstad et al. Jul 2011 S
D643308 Bergey Aug 2011 S
D645954 Hately Sep 2011 S
D647195 Clarke et al. Oct 2011 S
D647196 Clarke et al. Oct 2011 S
8037880 Zhu et al. Oct 2011 B2
8037881 Pentafragas Oct 2011 B2
8039431 Wilson et al. Oct 2011 B2
8047203 Young et al. Nov 2011 B2
D652322 Stuiber et al. Jan 2012 S
8109267 Villax et al. Feb 2012 B2
8119593 Richardson Feb 2012 B2
D655622 Sadler et al. Mar 2012 S
8133514 Milstein Mar 2012 B2
8146588 Steiner et al. Apr 2012 B2
8156936 Steiner et al. Apr 2012 B2
D659020 Kemner May 2012 S
D659022 Kemner May 2012 S
D660956 Zuyderhoudt May 2012 S
8166970 Poole et al. May 2012 B2
8172817 Michaels et al. May 2012 B2
8196576 Kriksunov et al. Jun 2012 B2
8201555 Chawla Jun 2012 B2
8202992 Stevenson Jun 2012 B2
D663830 Sears Jul 2012 S
D664640 Smutney et al. Jul 2012 S
8215300 Steiner et al. Jul 2012 B2
8217007 Schteingart et al. Jul 2012 B1
8227409 Kraft Jul 2012 B2
8236766 Schteingart et al. Aug 2012 B2
8252916 Simard et al. Aug 2012 B2
8258095 Boss et al. Sep 2012 B2
8278308 Leone-Bay et al. Oct 2012 B2
8293869 Bossard Oct 2012 B2
8314106 Kraft Nov 2012 B2
D671842 Bergey Dec 2012 S
D674893 Kinsey et al. Jan 2013 S
8372804 Richardson Feb 2013 B2
8377869 Richardson Feb 2013 B2
8389470 Steiner Mar 2013 B2
8394414 Steiner et al. Mar 2013 B2
8408200 Clark et al. Apr 2013 B2
8420604 Hokenson Apr 2013 B2
8424518 Smutney Apr 2013 B2
8485180 Smutney et al. Jul 2013 B2
8486894 Schteingart et al. Jul 2013 B2
8499757 Smutney Aug 2013 B2
8512932 Wilson et al. Aug 2013 B2
8522775 Malhotra et al. Sep 2013 B2
8536131 Schteingart et al. Sep 2013 B2
8538707 Adamo et al. Sep 2013 B2
8539946 Esteve et al. Sep 2013 B2
8551528 Grant et al. Oct 2013 B2
8563101 Spallek Oct 2013 B2
8636001 Smutney Jan 2014 B2
8642548 Richardson et al. Feb 2014 B2
8671937 Steiner et al. Mar 2014 B2
8677992 Villax Mar 2014 B2
8763606 Mosier et al. Jul 2014 B2
8778403 Grant et al. Jul 2014 B2
8783249 Poole et al. Jul 2014 B2
D711740 Lien Aug 2014 S
8808786 Jinks et al. Aug 2014 B2
8820324 Smith et al. Sep 2014 B2
8900555 Kuo et al. Dec 2014 B2
8909487 Adamo et al. Dec 2014 B2
8925726 Bergey Jan 2015 B2
9041925 Adamo et al. May 2015 B2
9138407 Caponetti et al. Sep 2015 B2
D771237 Smutney et al. Nov 2016 S
D802116 Smutney et al. Nov 2017 S
20010020147 Staniforth et al. Sep 2001 A1
20010039442 Gorge et al. Nov 2001 A1
20020000225 Schuler et al. Jan 2002 A1
20020015737 Shih et al. Feb 2002 A1
20020033177 Ohki et al. Mar 2002 A1
20020052381 Bar-Or et al. May 2002 A1
20020053344 Davies et al. May 2002 A1
20020053347 Ziaee May 2002 A1
20020065239 Caplan et al. May 2002 A1
20020088462 Genova et al. Jul 2002 A1
20020101590 Shimaoka Aug 2002 A1
20020144680 Nilsson et al. Oct 2002 A1
20020161001 Kanstrup et al. Oct 2002 A1
20030000524 Andersson et al. Jan 2003 A1
20030010794 Herdtle et al. Jan 2003 A1
20030013641 Steiner et al. Jan 2003 A1
20030017211 Steiner Jan 2003 A1
20030053960 Heijerman et al. Mar 2003 A1
20030064097 Patel et al. Apr 2003 A1
20030068378 Chen et al. Apr 2003 A1
20030099636 Epshtein et al. May 2003 A1
20030136405 Goede et al. Jul 2003 A1
20030168370 Merboth et al. Sep 2003 A1
20030194420 Holl et al. Oct 2003 A1
20030216542 Patton et al. Nov 2003 A1
20030235538 Zirenberg Dec 2003 A1
20040022861 Williams et al. Feb 2004 A1
20040024180 Drauz Feb 2004 A1
20040025875 Reber et al. Feb 2004 A1
20040034014 Kanstrup et al. Feb 2004 A1
20040038865 Gelber et al. Feb 2004 A1
20040053819 Dodd et al. Mar 2004 A1
20040062722 Gonda et al. Apr 2004 A1
20040076588 Batycky et al. Apr 2004 A1
20040077528 Steiner et al. Apr 2004 A1
20040096403 Steiner May 2004 A1
20040107963 Finlay et al. Jun 2004 A1
20040121964 Madar et al. Jun 2004 A1
20040138099 Draeger Jul 2004 A1
20040151059 Robert, II et al. Aug 2004 A1
20040151774 Pauletti et al. Aug 2004 A1
20040157928 Kim et al. Aug 2004 A1
20040163648 Burton Aug 2004 A1
20040182387 Steiner et al. Sep 2004 A1
20040187869 Bjorndal et al. Sep 2004 A1
20040204439 Staniforth et al. Oct 2004 A1
20040204440 Staniforth et al. Oct 2004 A1
20040211419 Eason et al. Oct 2004 A1
20040211420 Minshull et al. Oct 2004 A1
20040234615 Sabetsky Nov 2004 A1
20040234616 Sabetsky Nov 2004 A1
20040235956 Quay Nov 2004 A1
20040241232 Brown et al. Dec 2004 A1
20040247628 Lintz et al. Dec 2004 A1
20040250812 Davies et al. Dec 2004 A1
20050000518 Dunkley et al. Jan 2005 A1
20050003003 Basu et al. Jan 2005 A1
20050039743 Taylor Feb 2005 A1
20050043228 DeFelippis et al. Feb 2005 A1
20050043247 Trunk et al. Feb 2005 A1
20050056281 Snow Mar 2005 A1
20050070469 Bloom Mar 2005 A1
20050080000 Thurow et al. Apr 2005 A1
20050119604 Bonney et al. Jun 2005 A1
20050124644 Nilsson et al. Jun 2005 A1
20050147581 Zamiri et al. Jul 2005 A1
20050153874 Cheatham et al. Jul 2005 A1
20050155601 Steiner et al. Jul 2005 A1
20050183723 Pinon et al. Aug 2005 A1
20050187749 Singley Aug 2005 A1
20050203002 Tzannis et al. Sep 2005 A1
20050214251 Pohl et al. Sep 2005 A1
20050252508 Koerner Nov 2005 A1
20050265927 Lee Dec 2005 A1
20050274378 Bonney et al. Dec 2005 A1
20060000469 Tseng Jan 2006 A1
20060003316 Simard et al. Jan 2006 A1
20060040953 Leone-Bay et al. Feb 2006 A1
20060041133 Stevenson et al. Feb 2006 A1
20060062740 Rand Mar 2006 A1
20060099269 Cheatham et al. May 2006 A1
20060102511 Pasbrig et al. May 2006 A1
20060120969 Nilsson et al. Jun 2006 A1
20060130838 Lee et al. Jun 2006 A1
20060153778 Gelber et al. Jul 2006 A1
20060160722 Green et al. Jul 2006 A1
20060165756 Catani et al. Jul 2006 A1
20060219242 Zierenberg Oct 2006 A1
20060239933 Nilsson et al. Oct 2006 A1
20060239934 Cheatham et al. Oct 2006 A1
20060243275 Ruckdeschel et al. Nov 2006 A1
20060249419 Taylor et al. Nov 2006 A1
20060260777 Rashba-Step Nov 2006 A1
20060283758 Pasbrig Dec 2006 A1
20070006876 Finlay et al. Jan 2007 A1
20070017506 Bell et al. Jan 2007 A1
20070020191 Boss et al. Jan 2007 A1
20070027063 Boss et al. Feb 2007 A1
20070044793 Kleinstreuer et al. Mar 2007 A1
20070049576 Barlow et al. Mar 2007 A1
20070059373 Oberg Mar 2007 A1
20070059374 Hokenson et al. Mar 2007 A1
20070074989 Merboth et al. Apr 2007 A1
20070077219 Fahl et al. Apr 2007 A1
20070086952 Steiner Apr 2007 A1
20070099454 Gordon May 2007 A1
20070125375 Finlay et al. Jun 2007 A1
20070128193 O'Neil et al. Jun 2007 A1
20070151562 Jones Jul 2007 A1
20070160789 Merical et al. Jul 2007 A1
20070175314 Wanne Aug 2007 A1
20070190163 Malakhov et al. Aug 2007 A1
20070191462 Hettiarachchi Aug 2007 A1
20070196503 Wilson et al. Aug 2007 A1
20070207958 Bridon et al. Sep 2007 A1
20070225587 Burnell et al. Sep 2007 A1
20070235029 Zhu et al. Oct 2007 A1
20070240708 Schuckmann Oct 2007 A1
20070243216 Kepka et al. Oct 2007 A1
20070272763 Dunne et al. Nov 2007 A1
20070277820 Crowder et al. Dec 2007 A1
20070277821 Oliva et al. Dec 2007 A1
20070295332 Ziegler Dec 2007 A1
20070299074 Netz et al. Dec 2007 A1
20080008764 Milstein Jan 2008 A1
20080015457 Silva Jan 2008 A1
20080039368 Steiner et al. Feb 2008 A1
20080039402 Mossalayi et al. Feb 2008 A1
20080047550 Steiner et al. Feb 2008 A2
20080066739 LeMahieu et al. Mar 2008 A1
20080108554 Jackson et al. May 2008 A1
20080108574 Barlow et al. May 2008 A1
20080115785 Eason et al. May 2008 A1
20080127970 Steiner et al. Jun 2008 A1
20080127974 Lastow Jun 2008 A1
20080129791 King et al. Jun 2008 A1
20080168987 Denny et al. Jul 2008 A1
20080190424 Lucking et al. Aug 2008 A1
20080197044 Hickey et al. Aug 2008 A1
20080216824 Ooida Sep 2008 A1
20080217199 Burress et al. Sep 2008 A1
20080255468 Derchak et al. Oct 2008 A1
20080260838 Hokenson et al. Oct 2008 A1
20080260840 Alessi Oct 2008 A1
20080295833 Rohrschneider et al. Dec 2008 A1
20080312155 Kitada et al. Dec 2008 A1
20080314384 Harris et al. Dec 2008 A1
20080319333 Gavish et al. Dec 2008 A1
20090025720 Chen Jan 2009 A1
20090068274 Edwards et al. Mar 2009 A1
20090084379 Goeckner et al. Apr 2009 A1
20090084380 Gieschen et al. Apr 2009 A1
20090099077 Sur et al. Apr 2009 A1
20090134051 Rapp et al. May 2009 A1
20090149727 Truitt et al. Jun 2009 A1
20090151720 Inoue et al. Jun 2009 A1
20090178676 Villax et al. Jul 2009 A1
20090205657 Barney et al. Aug 2009 A1
20090209502 Haeberlin et al. Aug 2009 A1
20090232891 Gelber et al. Sep 2009 A1
20090241949 Smutney Oct 2009 A1
20090250058 Lastow Oct 2009 A1
20090258818 Surolia et al. Oct 2009 A1
20090294521 De La Huerga Dec 2009 A1
20090314291 Anderson et al. Dec 2009 A1
20090314292 Overtield Dec 2009 A1
20090320837 Smith et al. Dec 2009 A1
20100012120 Herder Jan 2010 A1
20100051027 Remmelgas et al. Mar 2010 A1
20100065048 Walz et al. Mar 2010 A1
20100086609 Steiner et al. Apr 2010 A1
20100113363 Hoist et al. May 2010 A1
20100163042 Bhowmick et al. Jul 2010 A1
20100180894 Jones et al. Jul 2010 A1
20100181225 Spallek et al. Jul 2010 A1
20100190701 Day et al. Jul 2010 A1
20100193380 Sullivan et al. Aug 2010 A1
20100197565 Smutney et al. Aug 2010 A1
20100212667 Smith et al. Aug 2010 A1
20100215588 Skaliter Aug 2010 A1
20100235116 Adamo et al. Sep 2010 A1
20100238457 Adamo et al. Sep 2010 A1
20100278924 Oberg Nov 2010 A1
20100288276 Ganderton et al. Nov 2010 A1
20100326438 Dunne Dec 2010 A1
20110000482 Gumaste et al. Jan 2011 A1
20110003004 Hokenson Jan 2011 A1
20110011394 Edwards et al. Jan 2011 A1
20110023876 Vehring et al. Feb 2011 A1
20110061653 Schuckmann Mar 2011 A1
20110083667 Briant Apr 2011 A1
20110155129 Stedman et al. Jun 2011 A1
20110158935 Kraft Jun 2011 A1
20110183901 Cheatham Jul 2011 A1
20120014999 Grant et al. Jan 2012 A1
20120040899 Costello Feb 2012 A1
20120071510 Leone-Bay et al. Mar 2012 A1
20120094905 Costello Apr 2012 A1
20120115777 Richardson May 2012 A1
20120122775 Boss et al. May 2012 A1
20120160241 Oliva Jun 2012 A1
20120164186 Grant et al. Jun 2012 A1
20120178935 Stevenson Jul 2012 A1
20120192865 Steiner et al. Aug 2012 A1
20120207913 Smyth Aug 2012 A1
20120240929 Steiner et al. Sep 2012 A1
20120247235 Adamo et al. Oct 2012 A1
20120247465 Wachtel Oct 2012 A1
20120328676 Leone-Bay et al. Dec 2012 A1
20130012710 Freeman et al. Jan 2013 A1
20130053309 Kraft Feb 2013 A1
20130104887 Smutney et al. May 2013 A1
20130118491 Richardson et al. May 2013 A1
20130125886 Richardson et al. May 2013 A1
20130143801 Steiner et al. Jun 2013 A1
20130189365 Hokenson Jul 2013 A1
20130199527 Smutney et al. Aug 2013 A1
20130221097 Day et al. Aug 2013 A1
20130243828 Lipp et al. Sep 2013 A1
20130289278 Kraft Oct 2013 A1
20130291866 Smutney Nov 2013 A1
20130291867 Smutney Nov 2013 A1
20130303445 Wilson et al. Nov 2013 A1
20130338065 Smutney Dec 2013 A1
20140007873 Smutney Jan 2014 A1
20140014106 Smutney Jan 2014 A1
20140083421 Smutney Mar 2014 A1
20140096771 Remmelgas et al. Apr 2014 A1
20140100158 Richardson et al. Apr 2014 A1
20140187490 Richardson et al. Jul 2014 A1
20140199398 Grant et al. Jul 2014 A1
20140227359 Leone-Bay et al. Aug 2014 A1
20140243530 Stevenson et al. Aug 2014 A1
20140271888 Grant et al. Sep 2014 A1
20140290654 Poole et al. Oct 2014 A1
20140302151 Leone-Bay et al. Oct 2014 A1
20140308358 Oberg et al. Oct 2014 A1
20140315953 Leone-Bay et al. Oct 2014 A1
20150031609 Steiner et al. Jan 2015 A1
20150045295 Smutney et al. Feb 2015 A1
20150052977 Adamo et al. Feb 2015 A1
20150065422 Kraft Mar 2015 A1
20150080298 Costello et al. Mar 2015 A1
20150108023 Bergey Apr 2015 A1
20150122258 Steiner et al. May 2015 A1
20150150980 Leone-Bay et al. Jun 2015 A1
20150174210 Boss et al. Jun 2015 A1
20150196724 Adamo et al. Jul 2015 A1
20150226656 Adamo et al. Aug 2015 A1
20150231067 Mann Aug 2015 A1
20150246188 Steiner et al. Sep 2015 A1
20150283069 Smutney et al. Oct 2015 A1
20150283213 Costello et al. Oct 2015 A1
20150290132 Gelber et al. Oct 2015 A1
20150359744 Hokenson et al. Dec 2015 A1
20160008557 Smutney et al. Jan 2016 A1
20160031833 Wilson et al. Feb 2016 A1
20160067183 Kraft Mar 2016 A1
20160095990 Smutney et al. Apr 2016 A1
20160101049 Wilson et al. Apr 2016 A1
20160151287 Oberg et al. Jun 2016 A1
20160158156 Fabio et al. Jun 2016 A1
20160175079 Adamo et al. Jun 2016 A1
20160193432 Harris et al. Jul 2016 A1
20160221967 Stevenson et al. Aug 2016 A1
20160228659 Smutney et al. Aug 2016 A1
20160243322 Smutney et al. Aug 2016 A1
20160250297 Leone-Bay et al. Sep 2016 A1
20160256640 Overfield et al. Sep 2016 A1
20160287820 Smutney et al. Oct 2016 A1
20160346394 Grant et al. Dec 2016 A1
20170087217 Cheatham et al. Mar 2017 A1
20170143804 Boss et al. May 2017 A1
20170189395 Grant et al. Jul 2017 A1
20170189492 Boss et al. Jul 2017 A1
20170209525 Leone-Bay et al. Jul 2017 A1
20170216280 Kraft Aug 2017 A1
20170216538 Kinsey et al. Aug 2017 A1
20170232001 Guarneri et al. Aug 2017 A1
20170274050 Leone-Bay et al. Sep 2017 A1
20170281549 Oberg et al. Oct 2017 A1
20170304404 Costello et al. Oct 2017 A1
20170369452 Stevenson et al. Dec 2017 A1
Foreign Referenced Citations (255)
Number Date Country
2536047 Mar 2005 CA
2551182 Aug 2010 CA
2917673 Jul 2007 CN
101290219 Oct 2008 CN
101317821 Dec 2008 CN
101851213 Oct 2010 CN
102436238 May 2012 CN
103110611 May 2013 CN
2840442 Feb 1982 DE
3639836 Jun 1988 DE
19519840 Dec 1996 DE
69715 Jan 1983 EP
122036 Oct 1984 EP
143524 Jun 1985 EP
180543 May 1986 EP
220958 May 1987 EP
237507 Aug 1987 EP
257915 Feb 1988 EP
308637 Mar 1989 EP
360340 Mar 1990 EP
364235 Apr 1990 EP
387222 Sep 1990 EP
388621 Sep 1990 EP
606486 Dec 1993 EP
581473 Feb 1994 EP
655237 May 1995 EP
666085 Aug 1995 EP
748213 Dec 1996 EP
558879 May 1997 EP
844007 Dec 1998 EP
1060741 Dec 2000 EP
1114644 Jul 2001 EP
0837710 Nov 2001 EP
640354 Dec 2001 EP
1348428 Oct 2003 EP
1364967 Nov 2003 EP
825885 Mar 2004 EP
96911738 Jun 2004 EP
1598066 Nov 2005 EP
833652 Feb 2008 EP
1923087 May 2008 EP
2060268 May 2009 EP
2314298 Apr 2011 EP
475440 Nov 1937 GB
716815 Oct 1954 GB
2072536 Oct 1981 GB
2148841 Jun 1985 GB
2240337 Jul 1991 GB
2253200 Sep 1992 GB
2262452 Jun 1993 GB
2398065 Aug 2004 GB
S55-156085 Nov 1980 JP
63-020301 Jan 1988 JP
2115154 Apr 1990 JP
2-149545 Feb 1992 JP
H07-041428 Feb 1995 JP
09-208485 Aug 1997 JP
10234827 Sep 1998 JP
2002322294 Nov 2002 JP
2003-503420 Jan 2003 JP
2004-121061 Apr 2004 JP
2006-280620 Oct 2006 JP
2007-061281 Mar 2007 JP
200505517 Feb 2005 TW
1990013285 Nov 1990 WO
1991004011 Apr 1991 WO
1991006287 May 1991 WO
1991016038 Oct 1991 WO
1991016882 Nov 1991 WO
1991019524 Dec 1991 WO
1992004069 Mar 1992 WO
1992008509 May 1992 WO
1993002712 Feb 1993 WO
1993014110 Jul 1993 WO
1993017728 Sep 1993 WO
1993018754 Sep 1993 WO
1994000291 Jan 1994 WO
1994008552 Apr 1994 WO
1994008599 Apr 1994 WO
1994019041 Sep 1994 WO
1994023702 Oct 1994 WO
1994025005 Nov 1994 WO
1995000127 Jan 1995 WO
1995005208 Feb 1995 WO
1995011666 May 1995 WO
1995024183 Sep 1995 WO
1995031979 Nov 1995 WO
1995034294 Dec 1995 WO
1996001105 Jan 1996 WO
1996005810 Feb 1996 WO
1996013250 May 1996 WO
1996022802 Aug 1996 WO
1996027386 Sep 1996 WO
1996032149 Oct 1996 WO
1996036314 Nov 1996 WO
1996036317 Nov 1996 WO
1996040206 Dec 1996 WO
1997001365 Jan 1997 WO
1997004747 Feb 1997 WO
1997025086 Jul 1997 WO
1997030743 Aug 1997 WO
1997035562 Oct 1997 WO
1997046206 Dec 1997 WO
1997049386 Dec 1997 WO
1998026827 Jun 1998 WO
1998034661 Aug 1998 WO
1998039043 Sep 1998 WO
1998041255 Sep 1998 WO
1998043615 Oct 1998 WO
1999014239 Mar 1999 WO
1999018939 Apr 1999 WO
1999032510 Jul 1999 WO
1999033862 Jul 1999 WO
1999052506 Oct 1999 WO
200012116 Mar 2000 WO
2000033811 Jun 2000 WO
2000059476 Oct 2000 WO
2000071154 Nov 2000 WO
2001000654 Jan 2001 WO
2001081321 Jan 2001 WO
2001032144 May 2001 WO
2001049274 Jul 2001 WO
2001051071 Jul 2001 WO
2001052813 Jul 2001 WO
2001066064 Sep 2001 WO
2001068169 Sep 2001 WO
2001097886 Dec 2001 WO
2001007107 Feb 2002 WO
2002011676 Feb 2002 WO
2002012201 Feb 2002 WO
2002047659 Jun 2002 WO
2002058735 Aug 2002 WO
2002059574 Aug 2002 WO
2002067995 Sep 2002 WO
2002085281 Oct 2002 WO
2002098348 Dec 2002 WO
2002102444 Dec 2002 WO
2003000202 Jan 2003 WO
2003015857 Feb 2003 WO
2003018059 Mar 2003 WO
2003022304 Mar 2003 WO
2003055547 Jul 2003 WO
2003057170 Jul 2003 WO
2003061578 Jul 2003 WO
2003072195 Sep 2003 WO
2003080149 Oct 2003 WO
2003084502 Oct 2003 WO
2003086345 Oct 2003 WO
2003094951 Nov 2003 WO
2004012672 Feb 2004 WO
2004012720 Feb 2004 WO
2004033010 Apr 2004 WO
2004035121 Apr 2004 WO
2004041338 May 2004 WO
2004050152 Jun 2004 WO
2004054605 Jul 2004 WO
2004054647 Jul 2004 WO
2004056314 Jul 2004 WO
2004060458 Jul 2004 WO
2004064862 Aug 2004 WO
2004075919 Sep 2004 WO
2004080401 Sep 2004 WO
2004080482 Sep 2004 WO
2004103304 Dec 2004 WO
2005002654 Jan 2005 WO
2005020964 Mar 2005 WO
2005023348 Mar 2005 WO
2005028699 Mar 2005 WO
2005067964 Jul 2005 WO
2005081977 Sep 2005 WO
2005089722 Sep 2005 WO
2005089843 Sep 2005 WO
2005102428 Nov 2005 WO
2005102429 Nov 2005 WO
2005113042 Dec 2005 WO
2005113043 Dec 2005 WO
2005120616 Dec 2005 WO
2006010248 Feb 2006 WO
2006017688 Feb 2006 WO
2006023849 Mar 2006 WO
2006023943 Mar 2006 WO
2006023944 Mar 2006 WO
2006037636 Apr 2006 WO
2006059939 Jun 2006 WO
2006061637 Jun 2006 WO
2006086107 Aug 2006 WO
2006090149 Aug 2006 WO
2006105501 Oct 2006 WO
2007007110 Jan 2007 WO
2007016600 Feb 2007 WO
2007019229 Feb 2007 WO
2007024953 Mar 2007 WO
2007030706 Mar 2007 WO
2007033316 Mar 2007 WO
2007033372 Mar 2007 WO
2007042822 Apr 2007 WO
2007068896 Jun 2007 WO
2007075534 Jul 2007 WO
2007093310 Aug 2007 WO
2007098500 Aug 2007 WO
2007100535 Sep 2007 WO
2007118342 Oct 2007 WO
2007118343 Oct 2007 WO
2007121411 Oct 2007 WO
2007132217 Nov 2007 WO
2007144607 Dec 2007 WO
2007144614 Dec 2007 WO
2008001744 Jan 2008 WO
2008008021 Jan 2008 WO
2008014613 Feb 2008 WO
2008020217 Feb 2008 WO
2008060484 May 2008 WO
2008092864 Aug 2008 WO
2008110809 Sep 2008 WO
2009005546 Jan 2009 WO
2009008001 Jan 2009 WO
2009009013 Jan 2009 WO
2009047281 Apr 2009 WO
2009055030 Apr 2009 WO
2009055740 Apr 2009 WO
2009055742 Apr 2009 WO
2009095684 Aug 2009 WO
2009121020 Oct 2009 WO
2009140587 Nov 2009 WO
2009152477 Dec 2009 WO
2009155581 Dec 2009 WO
2010021879 Feb 2010 WO
2010078373 Jul 2010 WO
2010080964 Jul 2010 WO
2010102148 Sep 2010 WO
2010105094 Sep 2010 WO
2010108046 Sep 2010 WO
2010125103 Nov 2010 WO
2010144785 Dec 2010 WO
2010144789 Dec 2010 WO
2011017554 Feb 2011 WO
2011056889 May 2011 WO
2011082328 Jul 2011 WO
2011163272 Dec 2011 WO
2012064892 May 2012 WO
2012135765 Oct 2012 WO
2012174472 Dec 2012 WO
2012174556 Dec 2012 WO
2013016754 Feb 2013 WO
2013063160 May 2013 WO
2014012069 Jan 2014 WO
2014036323 Mar 2014 WO
2014066856 May 2014 WO
20140144895 Sep 2014 WO
2015010092 Jan 2015 WO
2015021064 Feb 2015 WO
2015063100 May 2015 WO
2015148905 Oct 2015 WO
2017132601 Aug 2017 WO
2017201463 Nov 2017 WO
Non-Patent Literature Citations (636)
Entry
Nathan DM et al. “Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy.” Diabetes Care 29:1963-1972, 2006.
Nathan DM et al. “Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy.” Diabetes Care 31:173-175, 2008.
Nathan DM et al. “Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy.” Diabetes Care 32:193-203, 2009.
Nathan et al. “Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes.” New Eng. J. Med. 353:2643-2653, 2005.
Nathan, “Initial Management of Glycemia in Type 2 Diabetes Melllitus” N. Eng. J. Med., 2002, 347, 1342-9.
Nauck “Is glucagon-like peptide 1 an incretin hormone?” Diabetologia 42:373-379, 1999.
Nauck et al. “Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.” Am J Physiol 273 (Endocrinol Metabl 36):E981, 1997.
Nauck et al. “Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.” Diabetologia 29:46-52, 1986.
Nauck et al., Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin. Endocrinol Metab., 87:1239-1246, 2002.
Nauck et al., Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia, 39:1546-1553, 1996.
Nauck et al., Normalization of fasting hyperglycemia by exogenous GLP-1 (7-36 amide) in type 2 diabetic patients. Diabetologia, 36:741-744, 1993.
Nemmar et al., Passage of inhaled particles into the blood circulation in humans. Circulation pp. 411-414 (2002).
Newman, Principles of metered-dose inhaler design. Respiratory Care, vol. 50, No. 9, pp. 1177-1190 (2005).
Next Generation Inhaler Nears Market, Manufacturing Chemist, Cambridge Consultants, Polygon Media Ltd. (2006).
NHS Clinical Guidelines, “Type 1 diabetes diagnosis and mangement of type 1 diabetes in children and young people”, National Collaborating Centre for Women's and Children's Health Commissioned by the National Institute for Clinical Excellence, Sep. 2004, p. 1-217.
Non-covalent interactions from UC Davis ChemWiki, pp. 1-5. Accessed by Examiner on Jul. 23, 2013 and related case U.S. Appl. No. 12/830,557.
Nystrom et al. “Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetic patients with stable coronary artery disease.” Am J Physiol Endocrinol Metabl 287:E1209, 2004.
Oberdorster et al., Correlation between particle size, in vivo particle persistence, and lung injury. Environ Health Perspect 102 Suppl 5, pp. 173-179 (1994).
Oberdorster et al.,Pulmonary effects of inhaled ultrafine particles. International Archives of Occupational and Environmental Health, vol. 74, pp. 1-8 (2001).
Okumura et al., Intratracheal delivery of insulin: absorption from solution and aerosol by rat lung. Int. J. Pharmaceuticals 88: 63-73 (1992).
O'Neill, Air pollution and inflammation in type 2 diabetes: a mechanism for susceptibility. Occup Environ Med. vol. 64, pp. 373-379 (2007).
Orgsoltab et al., Division of Organic Chemistry. Ohio Northern University. Nov. 24, 2009. Available from: <http://www.2.onu.edu/˜b-meyers/organic_solvents.html>.
Oshima et al. “Comparison of half-disappearance times, distribution volumes and metabolic clearance rates of exogenous glucagon-like peptide 1 and glucagon in rats.” Regulatory Peptides 21:85, 1988.
Ostrovsky, Gene. Mannkind Inhalation Insulin Going to FDA to Seek Approval [on-line]. MedGadget.com, posted on Mar. 17, 2009, Retrieved from the Internet: <URL:http://medgadget.com/2009/03mannkind_inhalation_insulin_going_to_fda_to_seek_approval.html>.
Owens et al. “Inhaled human insulin.” Nature Reviews, Drug Discovery, vol. 5, No. 5, pp. 371-372, May 2006.
Owens et al. “Alternative routes of insulin delivery.” Diabetic Medicine 20:886-898, 2003.
Ozyazgan et al. “Effect of glucagon-like peptide-1)7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.” Pharmacology 74:119, 2005.
Pacini P, Marino MT. Evaluation of endogenous and exogenous components to peripheral insulin concentration during administration of inhaled insulin. ADA 2010; Abstract 2094-PO.
Patton “Mechanisms of macromolecule absorption by the lungs.” Advanced Drug Delivery Reviews 19:3, 1996.
Patton “Unlocking the opportunity of tight glycaemic control. Innovative delivery of insulin via the lung.” Diabetes Obesity and Metabolism 7:S5, 2005.
Patton & Platz, Routes of Delivery: Case studies: pulmonary delivery of peptides and proteins for systemic action. Adv. Drug. Del. Rev. 8: 179-196 (1992).
Patton et al. “The lungs as a portal of entry for systemic drug delivery.” Proc Am Thorac Soc 1:338, 2004.
Patton et al. “Clinical pharmacokinetics and pharmacodynamics of inhaled insulin.” Clin Pharmacokinet 43:781-801, 2004.
Patton et al., “Inhaled Insulin”, Advanced Drug Delivery Reviews, 35, Feb. 1999, p. 235-247.
Onoue et al., Dry powder inhalation systems for pulmonary delivery of therapeutic peptides and proteins. Expert Opin. Ther. Patents 18(4):429-442 (2008).
Pearson et al., Systematically Initiating Insulin, supplemental to vol. 32, No. 1, 19S-28S, 2006.
Perera et al. “Absorption and Metabolic Effect of Inhaled Insulin.” Diabetes Care, vol. 25, No. 12, Dec. 2002, p. 2276-2281.
Pesic, Inhaler delivers more drug to the deep lung, says Cambridge Consultants. in-Pharma Technologist.com, http://www/in-pharmatechnologist.com/content/view/print/344335, Dec. 1, 2010.
Petkowicz et al., “Hypoglycemic effect of liposome-entrapped insulin adminstered by various routes into normal rats”, Pol. J. Pharmacol. Pharm. 41:299-304 (1989).
Petrucci R, Amin N, Lovertin P. et al. Pulmonary function tests remain similar in patients who received Technosphere® insulin and in patients currently receiving standard antidiabetic therapy. Diabetologia 2009; 52 (suppl 1).
Peyrot et al. “Resistance to insulin therapy among patients and providers.” Diabetes Care 28:2673-2679, 2005.
Peyrot M, Rubin RR, Otterbach K. Effect of Technosphere® inhaled insulin on treatment satisfaction, glycemic control and quality of life. Diabetes 2006; 55:Abstract 423-P.
Pezron et al., Insulin aggregation and asymmetric transport across human bronchial epithelial cell monolayers (Calu-3). J. Pharmaceutical Sci. 91: 1135-1146 (2002).
Pfeiffer MA et al. Insulin secretion in diabetes mellitus. Am J Med 70:579-88, 1981.
Pfutzner et al., Abstract 812: Influence of small dose i.v.s.c. and pulmonary insulin treatment on grandial glucose control in patients with type 2 diabetes. Internet Article [Online] 2001, 37th Annual Meeting of the EASD, Glasgow, Sep. 9-13, 2001.
Pfutzner A et al. “Pulmonary insulin delivery by means of the Technosphere(TM) drug carrier mechanism.” Expert Opin Drug Deliv 2:1097-1106, 2005.
Pfützner A et al. “Technosphere® /Insulin—a new approach for effective delivery of human insulin via the pulmonary route.” Diab Tech Ther 4:589-594, 2002.
Pfützner A et al. “Lung distribution of radiolabeled Technosphere™/Insulin.” Diabetes 52 Supplement, Jun. 2003, A107.
Pfützner A et al. Pilot study with Technosphere/PTH(1-34)—a new approach for effective pulmonary delivery of parathyroid hormone (1-34). Horm Metab Res 35:319-323, 2003.
Pfützner A et al. “Variability of insulin absorption after subcutaneous and pulmonary application in patients with type 2 diabetes.” Diabetes 51 Supplement, Jun. 2002, A47-48.
Standl et al. “Good Glycemic Control With Flexibility in Timing of Basal Insulin Supply.” Diabetes Care, vol. 28, No. 2, Feb. 2005.
Stanley et al. “Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY and pacretic peptide.” Am J Physiol Gastrointest Liver Physiol 286:G693, 2004.
Steinberg et al. “A new approach to the safety assessment of pharmaceutical excipients.” Reg Toxicol Pharmacol 24:149,1996.
Steiner et al. “A novel glucagon delivery system for the management of hyperinsulinemia.” Diabetes 49 Supplement 1, Abstract 1545-PO, A368, 2000.
Steiner et al. “Bioavailability and pharmacokinetic properties of inhaled dry powder Technosphere®/Insulin.” Diabetes 49 Supplement, May 2000, A126.
Steiner et al. “Technosphere®, a novel drug delivery system for oral administration of calcitonin.” Pharmaceutical Res 11:S299, 1994.
Steiner et al. Technosphere(TM)/Insulin—proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes, 110:17-21, 2002.
Steiner, K. et al. “The relative importance of first- and second-phase insulin secretion in countering the action of glucagon on glucose turnover in the conscious dog.” Diabetes 31:964-972, 1982.
Steiner S, Rave K, Heise T, et al. Pharmacokinetic properties and bioavailablility of inhaled drug powder Technosphere™/insulin. Exp Clin Endocrinol Diabetes 2000; 108:S161.
Steiner S, Rave K, Heise T, et al. Technosphere™/insulin: Bioavailability and pharmacokinetic properties in healthy volunteers. Diabetologia 2000;43:Abstract 511-P.
Steiner SS, Burrell BB, Feldstein R, et Al. Pulmonary delivery of Technosphere™/insulin: Increased bioefficacy and bioavailability in clinical trials using the PDC Medtone™ inhaler. Proceed Int'l Symp Control Rel Bioact Mater 2000; 27:1000-1001.
Stowell et al. “Development of GLP-1 Technosphere(TM) powder: an inhaled GLP-1 product.” Diabetes Technology Meeting, San Francisco, Oct. 2007.
Strack “Inhaled Human Insulin.” Drugs of Today 2006, 42 (4): 207-221.
Sturis et al., GLP-1 deriative liraglutide in rats with beta-cell deficiences: influence of metabolic state on beta-cell mass dynamics. British Journal of Pharmacology, 140: 123-132 (2003).
Svartengren et al., Added External Resistance Reduces Oropharyngeal Deposition and Increases Lung Deposition of Aerosol Particles in Asthmatics. Am. J. Respir. Crit. Care Med., vol. 152, pp. 32-37, 1995.
Sympatecs. Dry Dispersion for Laser Diffraction and Image Analysis, 2011. XP-002586530.
Leone-Bay et al., Innovation in drug delivery by inhalation. Ondrugdelivery, No. 7, pp. 4-8 (2010).
Tack CJ, Boss AH, Baughman RA, et al. A randomized, double blind, placebo controlled study of the forced titration of prandial Technosphere®/Insulin in patients with type 2 diabetes mellitus. Diabetes 2006;55:Abstract 428-P.
Tack CJ, Christov V, deGalan BE, et al. Randomized forced titration to different doses of Technosphere® insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol 2008; 2(1) :47-57.
Tang-Christensen et al. “Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.” Am J Physiol 271 (Regulatory Integrative Comp Physiol 40):R848, 1996.
Taylor et al. “Aerosols for macromolecule delivery. Design challenges and solutions.” Am J Drug Deliv 2:143-155, 2004.
Teeter et al. “Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy.” Am J Resp Crit Care Med 173:1194, 2006.
Telko et al., Dry Powder Inhaler Formulation. Respiratory Care, Sep. 2005, vol. 50, No. 9, 1209-1227.
The American Diabetes Association “Insulin Administration” Diabetes Care, vol. 27, Supplement 1, S106-S109 (2004).
Gerber et al., Treatment satisfaction with inhaled insulin in patients with type 1 diabetes. Diabetes Care 24:1556-1559 (2001).
The Lancet. 1989, vol. 333, p. 1235-1236.
Thorens “Expression cloning of the pancreatic b-cell receptor for the gluco-incretin hormone glucagon-like peptide-1.” PNAS 89:8641, 1992.
Thorens B et al. “Cloning and function expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor.” Diabetes 42:1678, 1993.
Todd et al. “Glucagon-like peptide-1 (GLP-1: a trial of treatment in non-insulin-dependent diabetes mellitus.” Eur J Clin Invest 27:533, 1997.
Todd et al. Subcutaneous glucagon-like peptide-1 improves postprandial glucaemic control over a 3-week period in patients with early type 2 diabetes. Clinical Science 95:325, 1998.
Toft-Nielson et al. “Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.” J Clin Endocrinol Metab 86:3853, 2001.
Toft-Nielson et al. “Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglcaemia.” Diabetologia 41:1180, 1998.
Toft-Nielson et al. “The effect of glucagon-like peptide-1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.” Diabetes 45:552, 1996.
Tornusciolo D.R. et al., Biotechniques 19(5):800-805, 1995. Simultaneous detection of TDT-mediated dUTP-biotin nick end-labeling (TUNEL)-positive cells and multiple immunohistochemical markers in single tissue sections.
Triantafyllidis et al., Structural, compositional and acidic characteristics of nanosized amorphous or partially crystalline ZSM-5 zeolite based materials. Microporous and Mesoporous Materials, 75:89-100 (2004).
Tu N, Kramer DA, Baughman RA. Inhaled Technosphere® Insulin improves glycemic control without weight gain. Diabetes 2007;56:Abstract 471-P.
Tuley et al., Experimental observations of dry powder inhaler dose fluidisation. International Journal of Pharmaceutics, 358, pp. 238-247 (2007).
Utah Valley University. Saponification. © 2009. Available from: <http://science.uvu.edu/ochem/index.php/alphabetical/s-t/saponification/printpage/>.
Vaczek, Accelerating drug delivery firms exploring new drug-delivery routes and devices intently awaiting the commercial launch of Exubera. Pharmaceutical & Medical Packaging News, vol. 14, No. 6 (2006).
Vahl et al. “Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.” J Clin Endocrinol Metabol 88:1772, 2003.
Van Alfen-Van Der Velden et al. “Successful treatment of severe subcutaneou insulin resistance with inhaled insulin therapy”, Pediatric Diabetes 2010: 11:380-382.
Vara E et al. “Glucagon-like peptide-1 (7-36) amide stimulates surfactant secretion in human type II pneumocytes.” Am J Resp Crit Care Med 163:840-846, 2001.
Vella A et al. “Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.” Diabetes 49:611, 2000.
Vella A et al. “The gastrointestinal tract and glucose tolerance.” Curr Opin Clin Nutr Metab Care 7:479, 2004.
Vendrame et al. “Prediabetes: prediction and prevention trials.” Endocrinol Metab Clin N Am, 2004, vol. 33, pp. 75-92.
Verdich C, et al., A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab., 86:4382-4389, 2001.
Vilsboll et al. “Reduced postprandial concentrations of intact biologically active glucagon-like peptide-1 in type 2 diabetic patients.” Diabetes 50:609, 2001.
Vilsboll et al. “Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.” J Clin Endocrinol Metab 88:220, 2003.
Vilsboll et al., “Evaluation of β-Cell Secretary Capacity Using Glucagon-Like Peptide 1”, Diabetes Care, vol. 23, No. 6, pp. 807-812, Jun. 2000.
Vilsboll et al., “Incretin secretion in Relation to Meal Size and Body Weight in Healthy Subjects and People with Type 1 and Type 2 diabetes Mellitus”, The Journal of Clinical Endrocronology & Metabolism, vol. 88, No. 6, pp. 2706-2713, 2003.
“An inhaled insulin formulation (Technosphere Insulin) effectively improves glycaemic control in patients with type 2 diabetes mellitus.” Inpharma Weekly, vol. 1522, Jan. 28, 2006, p. 8.
ACTOS Product Insert. Aug. 2008.
Adjusting Mealtime Insulin Doses. BD Diabetes. http://www.bd.com/diabetes/page.aspx?cat=7001&id=7280 (2014).
Ahren “GLP-1 and extra-islet effects.” Horm. Med Res 36:842, 2004.
Ahren B et al. “Characterization of GLP-1 effects on b-cell function after meal ingestion in humans.” Diabetes Care 26:2860, 2003.
Ahren B., Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. BioEssays, V. 20, pp. 642-651 (1998).
Akerlund et al., Diketopiperazine-based polymers from common acids. Journal of Applied Polymer Science (2000), 78(12), 2213-2218.
Alabraba et al. Diabetes Technology & Therapeutics. Jul. 2009, 11(7): 427-430.
Alcohols limited. Alcohol speciality solvents—Go green! Jul. 24, 2010. Available from: <http://webarchive.org/web/20100724193725/http://www.alcohols.co.uk/speciality_solvents.php>.
Aljada et al. “Insulin inhibits the pro-inflammatroy transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations.” The Journal of Clinical Endocrinology and Metabolism, vol. 87, No. 3, p. 1419-1422, 2002.
Al-Showair et al., Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respiratory Medicine, vol. 101, No. 11, p. 2395-2401 (2007).
American Diabetes Association, “Standards of medical care in diabetes—2009”, Diabetes Care, Jan. 2009, 32 Suppl 1: S13-61.
Amin N, Boss AH, Petrucci R, et al. Pulmonary functions (over 2 years) in diabetic subjects treated with AFRESA® or usual antidiabetic treatment ADS 2009; Poster 570.
Amin N, et al. Long-term sustained safety and efficacy of continued use of Technosphere insulin in subjects with type 2 diabetes. Abstract—Oral Presentation 215, 48th EASD Annual Meeting, Sep. 29-Oct. 2, 2009, Vienna Austria.
Amin N, Marino MT, Cassidy JP, et al. Acute pulmonary effects of Technosphere® insulin inhalation powder administered using a Gen2B inhaler compared to MedTone® C inhaler. Diabetes Technology Meeting 2010; poster.
Amin N, Phillips M, Boss AH, et al. Pulmonary functions (over 2 years) in diabetic patients treated with Technosphere® insulin (TI) or usual antidiabetic treatment. Third International Conference on Advanced Technologies and Treatments for Diabetes. 2010; Poster 290.
Angelo et al., Technosphere Insulin: Defining the Role of Technosphere Particles at the Celluar Level. J. Diabetes Sci. Technol., vol. 3, Issue 3, pp. 545-554 (2009).
Angelo et al. Technosphere® insulin inhalation powder: Defining the mechanism of action. ADA 2008; 57: Poster 428-P.
Antosiewiez et al., Prediction of pH-dependent properties of proteins. J Mol. Biol., 238:415-436 (1994).
Arakawa et al., Preferential interactions determine protein solubility in three-component solutions: the MgCI2 system. Biochemistry, 29:1914-1923 (1990).
Ashwell et al. “Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.” 2006 Diabetes UK, Diabetic Medicine, 23, 879-886.
Ashwell et al., “Optimal timing of injection of once-daily insulin gargine in people with Type 1 diabetes using insulin ispro at meal-times” 2005 Diabetes UK, Diabetic Medicine, 23, 46-52.
Atherton, F. et al. “Synthesis of 2(R)-A3(S)-Acylamino-2-OXO-1-Azetidinyloxy U-Acetic Acids.” Tetrahedron, vol. 40, No. 6, Jan. 1, 1984, pp. 1039-1046.
ACANDIA Product Insert, Oct. 2008.
Baggio et al. “A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostatsis.” Diabetes 53:2492, 2004.
Baggio et al. “Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and noneneteral glucose clearance in mice.” Endocrinology 141:3703, 2000.
Baggio et al. “Harnessing the therapeutic potential of glucagon-like peptide-1.” Treat Endocrinol 1:117, 2002.
Drucker et al., Minireview: The glucagon-like peptides. Endocrinology, vol. 142, No. 2, pp. 521-527 (2001).
Balkan B et al. “Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms.” Am J. Physiol Regulatory Integrative Comp Physiol 279:R1449, 2000.
Barnett Ah et al. “An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with Type 2 diabetes poorly controlled on metformin.” Diabetes Care 29(8):1818-1825, 2006.
Barnett et al., An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care, 29(6): 1282-1287 (2006).
Barragan et al. “Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats.” Am J. Physiol 266 (Endocrinol Metab 29):E459, 1994.
Basu A et al. “Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance.” J Clin Invest 97:2351-2361, 1996.
Bauer et al., “Assessment o beta-adrenergic receptor blockade after isamoitane, a 5-HT1-receptor active compound, in healthy volunteer”, Clin. Pharmacol Ther 53:76-83 (1993).
Bauer et al., “Pharmacodynamic effects of inhaled dry powder formulations of fenterol and colforsin in asthma”, Clin Pharmacol Ther 53:76-83, 1993.
Baughman R, Cassidy J, Amin N, et al. A phase I, open-label study of the effect of albuterol or fluticasone on the pharmacokinetics of inhaled Technosphere® insulin inhalation powder in healthy subjects. ADA 2010; Poster 528.
Baughman R, Cassidy J, Levy B, et al. Technosphere® insulin inhalation powder pharmacokinetics unchanged in subjects who smoke. Diabetes 2008; 57: A128.
Baughman R, Haworth P, Litwin J, et al. No cardiac effects found with therapeutic and suprtherapeutic doses of Technosphere® inhalation powder: results from a thorough QTc clinical study. ADA 2011. Poster 933-P.
Baughman, RA, Evans, SH, Boss, AH, et al. Technosphere insulin does not affect pulmonary function in a 6 month study of patients with type 2 diabetes. Diabetologia 2006;49:177-118.
Bayés M et al. “Gateways to clinical trials” Methods Find Exp Clin Pharmacol 24:431-455, 2002.
Beers et al., Section 2—Chapter 13—Diabetes Mellitus, The Merck Manual of Diagnosis and Therapy, Merck Research Laboratories, pp. 165-177 (1999).
Behme et al. “Glucagon-like peptide-1 improved glycemic control in type 1 diabetes.” BMC Endocrine Disorders 3:3, 2003.
Bellary et al. “Inhaled insulin:new technology, new possibilities.” Int J Clin Pract 60:728, 2006.
Belmin J et al. “Novel drug delivery systems for insulin. Clinical potential for use in the elderly.” Drugs Aging 20:303-12, 2003.
Benita, Charaterization of Drug-Loaded Poly(d,l-lactide) Microspheres. J. Pharm. Sci., 73: 1721-1724 (1984).
Benito E et al. “Glucagon-like peptide-1-(7-36) amide increases pulmonary surfactant secretion through a cyclic adenosine 3′,5′-monophosphate-dependent protein kinase mechanism in rat type II pneumocytes.” Endocrinology 139:2363,1998.
Bensch et al., Absorption of intact protein molecules across the pulmonary air-tissue barrier, Science 156: 1204-1206 (1967).
Berge et al., “Pharmaceutical Salts”, J. Pharmaceutical Sciences, Review Article, 66(1):1-19 (1977).
Bergenstal R, Kapsner P, Rendell M, et al., Comparative efficacy and safety of AFRESA® and a rapid-acting analog both given with glargine in subjects with T1 DM in a 52-week study ADA 2009; Poster 479.
Bergeron et al. “Macromolecular Self-Assembly of Diketopiperazine Tetrapeptides.” J. Am. Chem. Soc. 116, 8479-8484, 1994.
Johnson et al., “Turbuhaler a new device for dry powder terbutaline inhalation”, Allergy 43(5):392-395 (1988).
Johnson et al: RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets. J Biol Chem., 279 (23):24794-802, 2004.
Johnson, Keith A., Preparation of peptide and protein powders for inhalation. Advanced Drug Delivery Reviews 1997; 26:3-15.
Jones et al., An investigation of the pulmonary absorption of insulin in the rat. Third European Congress of Biopharmaceutics and Pharmacokinetics, (1987).
Joseph et al. “Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice.” Diabetologia 43:1319-1328, 2000.
Joy et al. “Incretin mimetics as emerging treatments for type 2 diabetes.” Annal Pharmacother 39:110, 2005.
Juntti-Berggren et al. “The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients.” Diabetes Care 19:1200-1206, 1996.
Kanse et al. “Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung.” FEBS Letters 241:209, 1988.
Kapitza C et al. “Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol.” Diabetes Tech Ther 6:119, 2004.
Kapitza et al. “Dose-response characteristics for a new pulmonary insulin formulation and inhaler.” Presented at the 35th Annual Meeting of the EASD, Sep. 2000, abstract OP29 184.
Kapsner P, Bergenstal RM, Rendell M, et al. Comparative efficacy and safety of Technosphere® insulin and a rapid-acting analog both given with glargine in subjects with type 1 diabetes in a 52-week study. Diabetologia 2009; 52 (suppl 1).
Katchalski E et al. “Synthesis of lysine anhydride”, J. Amer Chem Soc 68:879-880, 1946.
Katz et al. “Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.” J. Clin. Endocrinol. Metab. 85:5402-2410, 2000.
Kaur et al. “A Delineation of Diketopiperazine Self-Assembly Processes: Understanding the Molecular Events Involved in Ne-(Fumaroyl)diketopiperazine of L-Lys (FDKP) Interactions.” Molecular Pharmaceutics, vol. 5, No. 2, 294-315, Accepted and Received 2007, published on web 2008.
Kawai et al. “Evidence that glucagon stimulates insulin secretion through its own receptor in rats.” Diabetologia 38:274, 1995.
Kawamori et al. “Does hyperinsulinemia accelerate atherosclerosis?” Department of Medicine, Juntendo University School, vol. 13, No. 12, p. 954-960, 1994.
Kelley, D. et al. “Impaired postprandial glucose utilization in non-insulin dependent diabetes mellitus.” Metabolism 43:1549-1557,1994.
Kenny AJ et al. “Dipeptidyl peptidase IV, a kidney brush-border serin peptidase.” Biochem J. 155:169, 1976.
Kim et al. “Development and characterization of a glucagon-like peptide 1-albumin conjugate. The ability to activate the glucagon-like peptide 1 receptor in vivo.” Diabetes 52:751, 2003.
Kinzig et al. “The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness.” J Neurosci 22:10470, 2002.
Kirk et al. “Disparities in HbA1c levels between African-American and non-hispanic white adults with diabetes.” Diabetes Care 29:2130, 2006.
Kitabchi, Proinsulin and C-peptide:a review. May 26, 1977 (5):547-87, http://www/ncbi.nlm.nih.gov/pubmed/403392.
Klinger et al., Insulin-micro and nanoparticles for pulmonary delivery. International Journal of Pharmaceutics, vol. 377, pp. 173-179 (2009).
Knop et al. “No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.” Diabetes Care 26:2581, 2003.
Knop et al. “Reduced incretin effect in type 2 diabetes. Cause or consequence of the diabetic state?” Diabetes 56:1951, 2007.
Kohler D et al. Non-radioactive approach for measuring lung permeability: inhalation of insulin. Atemw Lungenkrkh 13:230-232, 1987. (English translation attached).
Kohler, “Aerosols for Systemic Treatment”, Lung (Suppl.) 677-684 (1990).
Komada et al., Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung. J. Pharm. Sci. 83(6): 863-867 (1994).
Komatsu et al. “Glucagonostatic and insulinotropic action of glucagon-like peptide-1 (7-36)-amide.” Diabetes 38:902, 1989.
Koning et al., Relationship between inspiratory flow through simulated dry powder inhalers and peak maximal inspiratory pressure. Flow Through a Simulated DPI, Chapter 3, pp. 43-56 (2001).
Labiris et al., Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. British Journal of Clinical Pharmacology 56: 588-599 (2003).
Kontny et al., Issues Surrounding MDI Formulation Development with Non-CFC Propellants), J. Aerosol Med 4(3), 181-187 (1991).
Kopple et al. “A convenient synthesis of 2,5-piperazinediones.” J Org Chem p. 962, 1967.
Kraft KS, Grant M. Preparation of macromolecule-containing drug powders for pulmonary delivery Methods in Molecular Biology 2009;480:165-174.
Kreymann B et al. “Glucagon-like peptide-1 7-36: a physiological incretin in man.” The Lancet, Dec. 5, 1987, p. 1300.
Krssak, M. et al. “Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes.” Diabetes 53:3048-3056, 2004.
Krueger et al. “Toxicological profile of pulmonary drug delivery agent.” Presented at the American Diabetes Association 64th Scientific Sessions, Jun. 2004, abstract 465-P.
Kwon et al. “Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets.” Diabetes 53:S225, 2004.
Lankat-Buttgereit B et al. “Molecular cloning of a cDNA encoding for the GLP-1 receptor expressed in rat lung.” Exp Clin Endocrinol 102:241, 1994.
Laureano et al. “Rapid absorption and elimination of insulin from the lung following pulmonary administration of Technosphere® /Insulin: A pharmacokinetic study in a rat model.” Presented at the American Diabetes Association 65th Scientific Sessions, Jun. 2005, abstract 445-P.
Leahy et al. Beta-cell dysfunction in type II diabetes mellitus. Curr Opin Endocrinol Diabetes 2:300-306, 1995.
Lebovitz “Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies.” Endocr Pract 12:142, 2006.
Lee et al. “Synthesis, characterization and pharmacokinetic studies of PEGylated glucagon-like peptide-1.” Bioconjugate Chem 16:377, 2005.
Lee et al., “Development of an Aerosol Dosage Form Containing Insulin”, J. Pharm. Sci. 65(4), 567-572 (1976).
Leiner et al. “Particles facilitate the absorption of insulin in a primary cell culture model of alveolar epithelium without evidence of cytotoxicity.” Presented at the American Diabetes Association 64th Scientific Sessions, Jun. 2004, abstract 467-P.
Leiner et al. “The pharmacokinetic profile of insulin administered by inhalation in the rat.” Diabetes 53 Supplement, Jun. 2004, A111.
Leone-Bay et al. “Evaluation of novel particles as an inhalation system for GLP-1.” Diabetes, Obesity and Metabolism. 11:1050-1059, 2009.
Leone-Bay A, Grant M. Technosphere® Technology: A Platform for inhaled protein therapeutics. OndrugDelivery 2006 (published online).
Leone-Bay A, Grant M. Technosphere® /insulin: mimicking endogenous insulin release. In: Rathbone M, Hadgraft J, Roberts M, et al, eds. Modified Release Drug Delivery, 2e. New York, NY: Informa Healthcare USA, Inc; 2008.
Kieffer et al. “The glucagon-like peptides.” Endocrine Reviews 20:876, 1999.
Shields, Irritable bowel syndrome, archived Jun. 21, 2009, available at: https://web.archive.org/web/200906211 00502/http://www.gastroenterologistpaloalto.com/conditions-diseases-irritable-bowelsyndrome-palo-alto-ca. html; cited on Aug. 26, 2015 is U.S. Appl. No. 14/319,714.
Smith et al., Evaluation of novel aerosol formulations designed for mucosal vaccination against infleunza virus. Vacine, vol. 21, pp. 2805-2812 (2003).
Uwaifo et al., Novel pharmacologic agents for type 2 diabetes. Endocrinology and Metabolism Clinics of North America, vol. 34, No. 1, pp. 155-197 (2005).
Xi-de Tu, et al. Pharmaceutics. Oct. 2002, 3rd edition, second printing, p. 905.
Chan et al., Physical stability of salmon calcitonin spray-dried powders for inhalation. Journal of Pharmaceutical Sciences, vol. 93, No. 3, pp. 792-804 (2004).
Young et al., Encapsulation of lysozyme in a biodegradable polymer by preparation with a vapor-over-liquid antisolvent. Journal of Pharmaceutical Sciences, 88:640-650 (1999).
Hazard Prevention and Control in the Work Environment: Airborne Dust WHO/SDE/OEH/99. 14 Chapter 1—Dust: Definitions and Concepts [retrieved from internet in European case on Sep. 22, 2015]. <URL: http://www.who.int/occupational_health/publications/airdust/en/> published on Oct. 29, 2004 as per Wayback Machine.
Owens et al., Blood glucose self-monitoring in type 1 and type 2 diabetes: reaching a multidisciplinary consensus. Diabetes and Primary Care, vol. 6, No. 1, pp. 8-16 (2004).
Sarala et al., Technosphere: New drug delivery system for inhaled insulin. Future Prescriber, vol. 13, No. 1, pp. 14-16 (2012).
Kim et al., Dose-response relationships of inhaled insulin delivered via the aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care, 26:2842-2847 (2003).
Klonoff, David C. M.D., Afrezza inahled insulin: the fastest-acting FDA-approved insulin on the market has favorable properties. Journal of Diabetes Science and Technology, vol. 8(6): 10-71-1073 (2014).
European Search report for European Application 16203266.8 dated Jul. 5, 2017.
Hawe et al., Towards heat-stable oxytocin formulations: Analysis of degradation kinetics and identification of degradation products. Pharmaceutical Research, vol. 26, No. 7, pp. 1679-1688 (2009).
International Search Report and Written Opinion dated Apr. 28, 2017 for International Application No. PCT/US2017/015486 filed on Jan. 27, 2017.
International Search Report and Written Opinion dated Sep. 21, 2017 for International Application No. PCT/US2017/033627 filed on May 19, 2017.
Journal of Technical Disclosure of Japan Institute of Invention and Innovation; Food Drying Process Techniques; Japan Institute of Invention and Innovation; Independent Administrative Agency; National Center for Industrial Property Information and Training; published Mar. 31, 2005; p. 3-6, 8, 11, and 13 (reference showing well-known technique).
Marconi et al., Chemical composition and nutritional properties of commercial products of mare milk powder. Journal of Food Composition and Analysis 11:178-187 (1998).
Li et al. “GLP-1; a novel zinc finger protein required in somatic cells of the gonad for germ cell development.” Dev Biol 301:106, 2007.
Li, Jun. Chapter 15: Drug Therapy of Metabolic Diseases. Clinical Pharmacotherapy, People's Medical Publishing House, 1st Edition, pp. 333-335 (2007).
Lian et al. “A Self-Complimentary Self-Assembling Microsphere System: Application for Intravenous Delivery of the Antiepilpetic and Neuroprotectant Compound Felbanate.” J Pharm Sci 89:867-875, 2000.
Lim, “Microencapsulation of Living Cells and Tissues”, J. Pharm. Sci., 70: 351-354 (1981).
Linder et al., Increase in serum insulin levels is correlated with lung distribution after pulmonary delivery of Technosphere/Insulin. Diabetologia, No. 46, A277 (2003).
Liu et al., “Pulmonary delivery of free and liposomal insulin”, Pharmaceuticals Res. 10:228-232, 1993.
Lorber D, Howard CP, Ren H, et al. Reduced incidence and frequency of hypoglycemia in an integrated analysis of pooled data from clinical trials of subjects with type 2 diabetes using prandial inhaled Technosphere® insulin. AACE 2010; Poster 270.
Luque et al. “Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.” J. Endocrinol 173:465, 2002.
Luzi, L. and DeFronzo, R.A. “Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans.” Am. J. Physiol. 257 (Endocrinol. Metab. 20):E241-E246, 1989.
Luzio, S.D., et al. “Intravenous insulin simulates early insulin peak and reduces post-prandial hyperglycaemia/hyperinsulinaemia in type 2 (non-insulin-dependent) diabetes mellitus.” Diabetes Res. 16:63-67, 1991.
Malhotra et al., Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini. Regulatory Peptides, 41:149-56, 1992.
Mandal “Inhaled insulin for diabetes mellitus.” Am J Health Sys Pharm 62:1359-64, 2005.
Mann “Pulmonary insulin—the future of prandial insulin therapy.” Presented at the 5th Annual Meeting of the Diabetes Technology Society, Nov. 2005, abstract A94.
Mannkind Corporation “Postprandial hyperglycemia: clinical significance, pathogenesis and treatment.” MannKind Corporation Monograph. 2009.
MannKind Corporation, Pulmonary Delivery: Innovative Technologies Breathing New Life into Inhalable Therapeutics, www.ondrugdelivery.com, 2006.
Burcelin et al., Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analong of glucagon-like peptide-1. Metabolism, vol. 48, No. 2, pp. 252-258 (1999).
Marino MT, Cassidy JP, Smutney CC, et al. Bioequivalence and dose proportionality of Afrezza® inhalation powder administered using a Gen2 inhaler compared to the MedTone® inhaler. Diabetes Technology Meeting 2010; poster.
Marino MT, Cassidy JP, Smutney CC, et al. Improvement in bioavailability of FDKP with the NexGen2A device: Implications for delivery of pulmonary insulin. Third International Conference on Advanced Technologies and Treatments for Diabetes 2010; Poster 108.
Marino MT, Cassidy JP, Smutney CC, et al. Improvement in bioavailability of FDKP and insulin with the NGDSB device. Third International Conference on Advanced Technologies and Treatments for Diabetes 2010; Poster 107.
Marino MT. A pharmacokinetic/pharmacodynamic model of inhaled insulin with application to clinical trial simulation. ADA 2010; Abstract 2105-PO.
Marino MT. Cassidy JP, Baughman RA, et al. C-peptide correction method to determine exogenous insulin levels in pk studies using AFRESA® (Technosphere® insulin [TI]) ADA 2009; Poster 1451.
Marshall “Preventing and detecting complications of diabetes.” BMJ 333:455, 2006.
Mastrandrea “A breath of life for inhaled insulin: severe subcutaneous insulin resistance as an indication.” Pediatric Diabetes 2010: 11: 377-379.
Mathiowitz, Morphology of Polyanhydride Microsphere Delivery Systems, Scanning Microscopy, 4: 329-340 (1990).
Mathiowitz, Novel microcapsules for delivery systems. Reactive Polymers, 6: 275-283 (1987).
Mathiowitz, Polyanhydride microspheres as drug carriers I, hot-melt microencapsulation. J. Controlled Medicine, 5: 13-22 (1987).
Mathiowitz, Polyanhydride microspheres as drug carriers II, microencapsulation by solvent removal. J. Appl. Polymer Sci., 35: 755-774 (1988).
Mathiowitz, Polyanhydride microspheres IV, morphology and characterization systems made by spray drying. J. App. Polymer Sci., 45: 125-134 (1992).
Matsui et al. “Hyperplasia of type II pheumocytes in pulmonary lymphangioleiomyomatosis. Immunohistochemical and electron microscope study.” Arch Pathol Lab Med 124:1642, 2000.
Matthews DR et al. “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.” Diabetologia. Jul. 1985;28(7):412-9.
McElduff A et al. “Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx(R) insulin diabetes management system.” Br J Clin Pharmacol 59:546, 2005.
McMahon et al., “Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM”, Diabetes, vol. 38, pp. 291-303 (1989).
Meier et al. “Absence of a memory effect for the insulinotropic action of glucagon-like peptide-1 (GLP-1) in healthy volunteers.” Horm Metab Res 35:551, 2003.
Meier et al. “Secretion, degradation, and elimination of glucagon-like peptide-1 and gastric inhibitor polypeptide in patients with chronic renal insufficiency and healthy control subjects.” Diabetes 53:654, 2004.
Meier et al. “The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.” Am J Physiol Endocrinol Metab 290:E1118, 2006.
Mendes et al., A non-dimensional functional relationship for the fine particle fraction produced by dry powder inhalers, Aerosol Science 38, pp. 612-624 (2007).
Mentlein et al., Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem., 214:829-835, 1993.
Merck Manual 17th, Japanese Edition, NIKKEI BP Corp., 1999, p. 167-179.
Mitchell et al. “Intranasal Insulin: PK Profile Designed Specifically for Prandial Treatment of Type 2 Diabetes.” Drug Development Research 69(3):143-152 (2008).
Monnier et al. “Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.” JAMA 295:1681, 2006.
Montrose-Rafizadeh et al. Diabetes, 45(Suppl. 2):152A, 1996.
Moren, Aerosols in Medicine (2nd Ed.), Elsevier, pp. 321-350 (1993).
Mudaliar et al., Insulin Therapy in Type 2 Diabetes. Endocrinology and Metabolism Clinics, vol. 30, No. 4, pp. 1-32 (2001).
Nagai et al., “Powder Dosage Form of Insulin for Nasal Administration”, J. Control Ref., 1:15-22 (1984).
Narayan et al. “Impact of recent increase in incidence on future diabetes burden.” Diabetes Care 29:2114, 2006.
Naslund E et al. “GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans.” Am J Physiol (Regulatory Integrative Comp Physiol 46):R910, 1999.
Naslund E et al. “Prandial subcutaneous injections of glucagon-like petide-1 cause weight loss in obese human subjects.” Br J Nutrition 91:439, 2004.
International Search Report dated Nov. 21, 2013 for International Application No. PCT/US2013/057397 filed on Aug. 29, 2013.
Eavarone et al., A voxel-based monte carlo model of drug release from bulk eroding nanoparticles. Journal of Nanoscience and Nanotechnology, vol. 10, pp. 5903-5907 (2010).
Marino MT, Cassidy JP, Smutney CC, et al. Improvement in bioavailability of FDKP with the NexGen2A device: Implications for delivery of pulmonary insulin. Diabetes Technology Meeting 2009; poster.
Bilheimer DW, Ren H, Boss AH. Analysis of cardiovascular adverse events in patients with type 1 or type 2 diabetes enrolled in selected therapeutic trials in the phase 2/3 Technosphere® insulin development program. ADA 2011. Poster 922-P.
Billings CC, Smutney CC, Howard CP, et al. Handleability and characterization of inhalation profiles using the Gen2 delivery system in a pediatric population. Diabetes Technology Meeting 2010; poster.
Biodel's Intellecutal Property position strengthened for ultra-rapid-acting insulin programs by notice of intent to grant from European Patent Office. Newswire Feed, published May 2, 2012.
Blazquez E et al. “Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide.” Mol Neurobio 18:157, 1998.
Bloomgarden “Gut-derived incretin hormones and new therapeutic approaches.” Diabetes Care 27:2554, 2004.
Boer et al., Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols. International Jornal of Pharmaceutics 249, pp. 233-245 (2002).
Boer et al., Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistance. Int. J. Pharm. 130 (1996) 231-244.
Bojanowska “Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity and stress.” Med Sci Monit 11:RA271, 2005.
Bonner-Weir S et al. “New sources of pancreatic beta-cells.” Nat Biotechnol 23:857-61, 2005.
Boss AH et al. “Inhaled Technosphere®/Insulin: Glucose elimination at the right time?” Poster presented at the American Diabetes Association 65th Scientific Sessions, Jun. 2005, abstract 443-P.
Boss AH et al. “Insulin bio-effect is limited by speed of absorption and elimination: similarities between an inhaled insulin formulation that mimics first-phase kinetics and i.v. insulin.” Diabetologia 47:A314, 2004.
Boss AH et al. “Mimicry of the early phase insulin response in humans with rapidly available inhaled insulin accelerates post prandial glucose disposal compared to slower bioavailable insulin.” Presented at the American Diabetes Association 65th Scientific Sessions, Jun. 2005, abstract 1373-P.
Boss AH et al. “Does kinetics matter? Physiological consequences of the ability of Technosphere® /Insulin inhalation to mimic first phase insulin release.” Presented at the 5th Annual Meeting of the Diabetes Technology Society, Nov. 2005, abstract A14.
Boss AH et al. “Markedly reduced post prandial glucose excursions through inhaled Technosphere® /Insulin in comparison to SC injected regular insulin in subjects with type 2 diabetes.” 1st Annual Meeting of the European 4ssociation for the Study of Diabetes, Sep. 2005, abstract 816.
Boss AH et al. “The variability and time-action profile of inhaled Technosphere® /Insulin compares favorably to that of subcutaneous human regular insulin.” Presented at the American Diabetes Association 65th Scientific Sessions, Jun. 2005, abstract 358-OR.
Boss et al. “Prandial Insulin: Is Inhaled Enough?” Drug Development Research 69(3):138-142 (2008).
Boss A H, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. Journal of diabetes science and technology 2012;6:773-779.
Boss AH, Baughman RA, Evans SH, et al. A 3 month comparison in type 1 diabetes of inhaled Technosphere® / Insulin (TI) to Sc administered rapid-acting insulin analogue (RAA) as prandial insulin in a basal/prandial regimen. Diabetes 2006; 55:A97.
Boss AH, Evans SH, Firsov I, et al. Technosphere® insulin as effective as sc rapid acting insulin analogue in providing glycemic control in a 6-month study of patients with type 2 diabetes. Diabetes Technology Meeting 2006; poster.
Boss AH, Evans, SH, Ren, H, et al. Superior post prandial glucose control in patients with type 1 diabetes when using prandial technosphere insulin compared to NovoLog. Diabetologia 2006; Abstract 181.
Boss AH, Marino MT, Cassidy JP, et al. C-peptide correction method to determine exogenous insulin levels in pharmacokinetic studies using Technosphere® insulin. Diabetologia 2009; 52 (suppl 1).
Boss AH, Raskin P, Philips M, et al. Glycosylated hemoglobin and hypoglycaemia in patients with Type 2 diabetes mellitus: Technosphere® insulin and usual antihyperglycaemic regimen vs usual antihyperglycaemic regimen. Diabetologia 2010;53(suppl 1).
Brandt D, Boss AH. The next generation insulin therapy. OndrugDelivery 2006 (published online).
Brange et al., “Insulin Structure and Stability”, Pharm Biotechnol, 5:315-50 (1993).
Bray “Exanatide” Am J Health-Sys Pharm 63:411, 2006.
Brownlee et al. “Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications.” JAMA 295:1707, 2006.
Bruce, D.G., et al.“Physiological importance of deficiency of early prandial insulin secretion in non-insulin-dependent diabetes.” Diabetes 37:736-44, 1988.
Bullock BP et al. “Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.” Endocrinology 137:2968, 1996.
Burcelin et al. “Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus.” Ann N Y Acad Sci. Jun. 18, 1999;875:277-85.
Calles-Escandon, J. and Robbins, D.C. “Loss of early phase insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose.” Diabetes 36:1167-72, 1987.
Camilleri, Clinical Practice: Diabetic Gastroparesis. The New England Journal of Medicine, 356: 820-829 (2007).
Campos et al. “Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon0like peptide-1 in the mouse.” Endocrinology 134:2156, 1994.
Cassidy J P. Amin N, Marino M, et al. Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration. Pharmaceutical Research 2011; 28:2157-2164.
Cassidy J, Amin N, Baughman R, et al. Insulin kinetics following Technosphere® insulin inhalation powder administration unchanged in albuterol-treated asthmatics. ADA 2010; Poster 522.
Cassidy J, Baughman RA, Tonelli G, et al. Use of rapid acting insulin analog as the baseline infusion during glucose clamping improves pharmacokinetic evaluation. ADA 2007; 56: Abstract 602-P.
Cassidy JP, Baughman RA, Schwartz SL, et al. AFRESA® (Technosphere® insulin) dosage strengths are interchangeable ADA 2009; Poster 433.
Cassidy JP, Marino MT, Amin N, et al. Lung deposition and absorption of insulin from AFRESA® (Technosphere® insulin) ADA 2009; Poster 425.
Cassidy JP, Potocka E, Baughman RA, et al. Pharmacokinetic characterization of the Technosphere® inhalation platform Diabetes Technology Meeting 2009. poster.
Caumo et al. “First-phase insulin secretion: does it exist in real life” Considerations on shape and function. Am J Physiol Endocrinol Metab 287:E371-E385, 2004.
Cefalu “Concept, Strategies and Feasibility of Noninvasive Insulin Delivery.” Diabetes Care 27:239-246, 2004.
Cefalu “Novel routes of insulin delivery for patients with type 1 or type 2 diabetes.” Ann Med 33:579-586, 2001.
Cefalu et al., Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann. Int. Med., 2001, 134(3): 203-207.
Ceglia et al. “Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus.” Ann Intern Med 145:665, 2006.
Cerasi, et al. Decreased sensitivity of the pancreatic beta cells to glucose in prediabetic and diabetic subjects. A glucose dose-response study. Diabetes 21(4):224-34, 1972.
Cernea et al. “Dose-response relationship of oral insulin spray in healthy subjects.” Diabetes Care 28:1353-1357, 2005.
Cernea et al. “Noninjectable Methods of Insulin Administration.” Drugs of Today 2006, 42 (6): 405-424.
Chan et al., “Pharmacological Management of Type 2 Diabetes Mellitus: Rationale for Rational Use of Insulin”, Mayo Clin Proc, 2003, 78, 459-467.
Chase et al., “Redefining the clinical remission period in children with type 1 diabetes”, Pediatric Diabetes, 2004, 5, 16-19.
Cheatham et al. “Desirable Dynamics & Performance of Inhaled Insulin Compared to Subcutaneous Insulin Given at Mealtime in Type 2 Diabetes: A Report from the Technosphere/Insulin Study Group.” Diabetes Technology and Therapeutics, vol. 6, p. 234 (2004).
Cheatham et al. “A novel pulmonary insulin formulation replicates first phase insulin release and reduces s-proinsulin levels.” Presented at the American Diabetes Association 64th Scientific Sessions, Jun. 2004, abstract 457-P.
Rosenstock et al. “Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled with Oral Agents.” Diabetes Care, vol. 31, No. 11, pp. 2177-2182, 2008.
Rosenstock et al. “Inhaled Insulin Improves Glycemic Control when Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes.” Ann Intern Med 143:549-558, 2005.
Rosenstock et al., “Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes”, Diabetes Care, 28(4):950-5 (2005).
Rosenstock J, Baughman RA, Ribera-Schaub T, et Al. A randomized, double-blind, placebo controlled study of the efficacy and safety of inhaled Technosphere® insulin in patients with type 2 diabetes (T2DM). Diabetes 2005;54: Abstract 357-OR.
Rosenstock J, Lorber D, Petrucci R, et al. Basal/bolus with prandial inhaled Technosphere® insulin (TI) plus insulin glargine qd vs biaspart 70/30 insulin bid in T2 DM inadequately controlled on insulin with/without oral agents ADA 2009; Poster 466.
Rosenstock J, Larger DL. Gnudi L, et al.Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet 2010;375:2244-2253.
Rossiter A, Amin N, Harris R, et al. Pulmonary safety of inhaled Technosphere® insulin therapy in adults with diabetes using high-resolution computerized tomography of the chest. Diabetologia 2009; 52 (suppl 1).
Rossiter A, Howard C, Amin N, et al. Technosphere® insulin: Safety in type 2 diabetes mellitus. ADA 2010; Poster 523.
Roumeliotis, New inhaler launched with a bag, in-Pharma Technologist.com, Decision News Media SAS (2006).
Rousseau et al. “Drug delivery by fumaryl diketopiperazine particles: evidence for passive transport.” Presented at the American Diabetes Association 64th Scientific Sessions, Jun. 2004, abstract 484-P.
Rubin RR, Peyrot M. Psychometric properties of an instrument for assessing the experience of patients treated with inhaled insulin: The inhaled insulin treatment questionnaire (INTQ) Health & Quality of Life Outcomes 2010.8:32.
Rubin RR, Peyrot M; Patient reported outcomes in adults with type 1 diabetes using mealtime AFRESA® (inhaled Technosphere® insulin) or rapid acting insulin with basal insulin ADA 2009; Poster 1881.
Ryan EA et al. “Successful islet transplantation. Continued insulin reserve provides long-term glycemic control.” Diabetes 51:2148-2157, 2002.
Sajeesh et al., Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. International Journal of Pharmaceuticals, 2006, 325, pp. 147-154.
Sakagami M et al. “Respirable microspheres for inhalation: the potential of manipulating pulmonary disposition for improved therapeutic efficacy.” Clin Pharmacokinet 44(3):263-277, 2005.
Sakr, A new approach for insulin delivery via the pulmonary route: design and pharmacokinetics in non-diabetic rabbits. International Journal of Pharmaceutics, 86: 1-7 (1992).
Salib, Utilization of sodium alginate in drug microencapsulation. Pharazeutische Industrie, 40(11a): 1230-1234 (1978).
Saraceni C et al. “Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function.” Drugs R D 8:145, 2007.
Sarrach et al., “Binding and entrapment of insulin by liposomes made of lecithin-phosphotidix acid in acid solution” Pharmazie 40:642-645, 1985 (German and English Abstract).
Savage et al., “Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying healthy volunteers”, Gut, vol. 28, pp. 166-170, 1987.
Sawhney et al., Bioerodible hydrogels based on photopolymerized poly(ethylene glycol)-co-poly(a-hydroxy acid) diacrylate macromers. Macromolecules, 26: 581-587 (1993).
Schaffer et al. “Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks.” PNAS 100:4435-4439, 2003.
Schepp et al., Eur. J. Pharmacol., 269:183-91, 1994.
Scherbaum “Unlocking the opportunity of tight glycaemic control. Inhaled insulin: clinical efficacy.” Diabetes Obesity and Metabolism 7:S9-S13, 2005.
Schirra et al. “Gastric emptying and release of incretin hormones after glucose ingestion in humans.” J Clin Invest 97:92-103, 1996.
Schluter et al., “Pulmonary Administration of Human Insulin in volunteers and Type I Diabetics”, Diabetes, 33, (Suppl) 298 (1984).
Schneider et al., “Stimulation by proinsulin of expression of plasminogen activator inhibitor type 1 in endothelial cells”, Diabetes 41(7):890-895 (1992).
Schon, Istvan et al. “Formation of Aminosuccinyl Peptides During Acidolytic Deprotection Followed by their Tranformation to Piperazine-2, 5-dione Derivatives in Neutral Media.” International Journal of Peptide & Protein Research, 14(5), 485-494, 1979.
Schroder, “Crystallized carbohydrate spheres as a slow release matrix for biologically active substances”, Biomaterials 5:100-104, 1984.
Scrocchi et al. “Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.” Nature Medicine 2:1254-1258, 1996.
Seshiah & Balaji, “Early Insulin Therapy in Type 2 Diabetics”, Int. J. Diabetes in Developing Countries, 2003, 23, 90-93.
Seville, P.C. et al., Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray drying. J. Gene Medicine 2002; 4:428-437.
Shah et al. “Lack of suprression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.” J Clin Indocrinol Metab 85:4053, 2000.
Shelly et al. “Polysorbate 80 hypersensitivity.” The Lancet 345:1312, 1995.
Shimada et al. Translocation pathway of the intertracheally instilled ultrafine particles from the lung into the blood circulationin the mouse. Toxicologic Pathology pp. 949-957 (2006).
Shojania et al. “Effect of quality improvement strategies for type 2 diabetes on glycemic control.” JAMA 296:427, 2006.
Silverstein et al., “Care of Children and Adolescens with Type 1 Diabetes, A Statement of the American Diabetes Association”, Diabetes Care, Jan. 2005, vol. 28, p. 186-212.
Singh et al., Use of 125I-[Y39]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig. Regul. Pept. 53 : 47-59 (1994).
Simms JR, Carballo I, Auge CR, et al. Assessment of immunotoxic effects on humoral and cellular immune parameters following repeated inhalation of Technosphere insulin in the rat. Diabetes 2005;54:Abstract 2078-PO.
Skyler, Pulmonary insulin: current status. Diabetes Voice, vol. 51, Issue I, p. 23-25, 2006.
Skyler “Pulmonary Insulin Delivery—State of the Art 2007.” Diabetes Tecnology & Therapeutics, vol. 9, Supplement 1, pp. S1-S3. 2007.
Skyler JS et al. “Use of inhaled insulin in a basal/bolus insulin regimen in Type 1 diabetic subjects.” Diabetes Care 28:1630-1635, 2005.
Smith et al. “New-onset diabetes and risk of all-cause and cardiovascular mortality.” Diabetes Care 29:2012, 2006.
Smutney CC, Friedman EM, Amin N. Inspiratory efforts achieved in use of the Technosphere® insulin inhalation system. Diabetes Technology Meeting 2008; Poster SMUT8052.
Smutney CC, Friedman EM, Amin N. Inspiratory efforts achieved in use of the Technosphere® insulin inhalation system. Journal of Diabetes Science and Technology 2009 3(5):1175-1189.
Smutney CC, Polidoro JM, Adamo B, et al. In-vitro performance improvement realized in a next generation dry powder delivery system. Diabetes Technology Meeting 2009; poster.
Smutney CC, Polidoro JM, Adamo B, Shah S. In vitro performance improvement realized in a next generation dry powder delivery system. Third International Conference on Advanced Technologies and Treatments for Diabetes 2010; Poster 122.
Smutney CC, Polidoro JM. Easy-to-use next-generation pulmonary insulin delivery system. ADA 2010; Abstract 2093.
Smutney CC, Polidoro JM. Improvements realized in a next-generation pulmonary insulin delivery system. ADA 2010; Abstract 2097.
Sodium chloride is a natural product from http://www.wqpmag.com/potassium-chloride-vs-sodium-chloride, pp. 1-3. Accessed on May 16, 2014 and in Non-Final Office Action dated May 22, 2014 for U.S. Appl. No. 13/797,657, and in Non-Final Office Action dated May 22, 2014 for U.S. Appl. No. 12/883,369.
Amodeo et al., Pain peptides. Solution structure of orphanin FQ2. FEBS Letters, vol. 473, Issue 2, pp. 157-160 (2000).
Vanderah et al., FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious k opioid agonist with unprecedented selectivity. The Journal of Pharmacology and Experimental Therapeutics, vol. 310, No. 1, pp. 326-333 (2004).
Krondahl et al., Regional differences in bioavailability of an opioid tetrapeptide in vivo rats after administration to the respiratory tract. Peptides, vol. 23, No. 3, pp. 479-488 (2002).
Lee et al., Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. Regulatory Peptides, 152:101-107 (2009).
Selam, Jean-Louis. Inhaled Insulin: Promises and Concerns. Journal of Diabetes Science and Technology, vol. 2, Issue 2, pp. 311-315 (2008).
Fabio et al., Heat-stable dry powder oxytocin formulations or delivery by oral inhalation. AAPS PharmSciTech, (2015).
Lane et al., Influence of post-emulsification drying processes on the microencapsulation of Human Serum Albumin. International Journal of Pharmaceutics, 307: 16-22 (2006).
Mumenthaler et al., Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator. Pharm Res., 11(1):12-20 (1994).
U.S. Appl. No. 15/706,504, filed Sep. 15, 2017.
Design U.S. Appl. No. 29/553,303, filed Jan. 29, 2016.
Design U.S. Appl. No. 29/553,302, filed Jan. 29, 2016.
Design U.S. Appl. No. 29/553,305, filed Jan. 29, 2016.
Design U.S. Appl. No. 29/553,300, filed Jan. 29, 2016.
U.S. Appl. No. 15/711,916, filed Sep. 21, 2017.
Design U.S. Appl. No. 29/625,323, filed Nov. 8, 2017.
Design U.S. Appl. No. 29/579,594, filed Sep. 30, 2016.
Design U.S. Appl. No. 29/604,731, filed May 19, 2017.
European Search Report for European Application 13161157.6 dated Dec. 8, 2017.
Hache et al., Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit. Can. J. Anesth., 48:9, pp. 924-929 (2001).
Leone-Bay A., Pulmonary Delivery: Pulmonary peptide delivery with a pharmacokinetic profile that closely mimics endogenous peptide secretion. Drug Development & Delivery, vol. 11, No. 4, pp. 34-39 (2011).
Leone-Bay A., Pulmonary Drug Delivery—Simplified. www.ondrugdelivery.com, pp. 18-21 (2011).
Smutney et al., Special Report, Special Focus: Pulmonary Drug Delivery, Device factors affecting pulmonary delivery of dry powders. Ther. Deliv., 4(8):939-949 (2013).
Pfutzner et al. “Inhaled Technosphere/Insulin Shows a Low Variability in Metabolic Action in Type 2 Diabetic Patients.” Diabetes 49 Supplement, May 2000, A121.
Pfuetzner A, Rave K, Heise T, et al. Inhaled Technosphere™/insulin results in low variability in metabolic action in type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2000; 108:S161.
Pfuetzner A, Rave K, Heise T, et al. Low variability in metabolic action in type 2 diabetic patients with inhaled Technosphere/insulin. Diabetologia 2000; 43:Abstract 774.
Phillips M, Amin N, Boss AH, et al. Pulmonary functions (over 2 years) in diabetic subjects treated with Technosphere® insulin or usual antidiabetic treatment. Diabetologia 2009; 52 (suppl 1).
Pohl R, Muggenberg BA, Wilson BR, et al. A dog model as predictor of the temporal properties of pulmonary Technosphere/insulin in humans. Respiratory Drug Delivery 2000; VII: 463-465.
Polonsky et al. “Abnormal Patterns of Insulin Secretion in Non-insulin-Dependent Diabetes Mellitus.” N Eng J Med 318:1231-39,1988.
Potocka E, Amin N, Cassidy J, et al. Insulin pharmacokinetics following dosing with Technosphere® insulin in subjects with chronic obstructive pulmonary disease. Current Medical Research and Opinion 2010; 26:2347-2353.
Potocka E, Baughman R A, Derendorf H. Population pharmacokinetic model of human insulin following different routes of administration. Journal of Clinical Pharmacology 2011;51:1015-1024.
Potocka E, Baughman R, Derendort H. Population Pharmacokinetic Model of Regular Human Insulin Following Different Routes of Administration. AAPS Journal. 2009; 11(S1). Available from: http://www.aapsj.org. Presented at the 2009 AAPS (American Association of Pharmaceutical Scientists) National Biotechnology Conference, Jun. 21-24, Seattle, WA.
Potocka E, Baughman RA, Derendorf J. A population PK/PD model of Technosphere® insulin administered to healthy and type 2 diabetics. ADA 2010; Poster 624.
Potocka E, Baughman RA, Schwartz SL, et al. Pharmacokinetics of AFRESA® unchanged in patients with chronic obstructive pulmonary function ADA 2009; Poster 437.
Potocka E, Cassidy J P, Haworth P, et al. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. Journal of diabetes science and technology 2010;4:1164-1173.
Potocka E, Cassidy JP, Haworth P, et al. Pharmacokinetic characterization of fumaryl diketopiperazine. Third International Conference on Advanced Technologies and Treatments for Diabetes 2010; Poster 291.
Potocka E, Hovorka R, Baughman R, et al. Characterization of metabolism parameters following Technosphere® insulin and insulin Lispro. ADA 2010; Poster 1561.
Potocka E, Hovorka R, Baughman RA, et al. AFRESA™ supresses endogenous glucose production earlier than a rapid-acting analog (Lispro) and inhaled Exubera® ADA 2009; Oral 232.
Potocka E, Hovorka R, Baughman RA, et al. Technosphere® insulin suppresses endogenous glucose production earlier than a rapid-acting analog (lispro) and an inhaled insulin (exubera). Diabetologia 2009; 52 (suppl 1).
Prabhu et al. “A study of factors controlling dissolution kinetic of zinc complexed protein suspensions in various ionic species”, Int. J. Pharm. 217(1-2):71-8 (2001).
Laube et al., The lung as an alternative route for delivery for insulin in controlling postrprandial glucose levels in patients with diabetes. Chest, Preliminary Report 114 (6) : 1734-1739 (1998).
Quattrin et al. “Efficacy and Safety of Inhaled Insulin (Exubera) Compared with Subcutaneous Insulin Therapy in Patients with Type 1 Diabetes.” Diabetes Care, vol. 27, No. 11, Nov. 2004, p. 2622-2627.
Quddusi et al. “Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.” Diabetes Care 26:791, 2003.
Rachman et al. “Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.” Diabetes 45:1524, 1996.
Raju et al., Naseseazines A and B: a new dimeric diketopiperazine framework from a marine-derived actinomycete, Streptomyces sp. Organic letters, vol. 11, No. 17, pp. 3862-3865 (2009).
Raskin et al. “Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes.” Diabetes Care, vol. 26, No. 9, pp. 2598-2603, Sep. 2003.
Raskin P, Heller S, Hanka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere® Insulin or usual antidiabetes treatment: A randomized trial. Diabetes, Obesity and Metabolism 2012;14:163-173.
Raskin P, Phillips M, Amin N, et al. Hypoglycemia in patients with type 1 diabetes incorporating prandial inhaled Technosphere® insulin into their usual diabetes treatment regimen vs continuing their usual diabetes management. AACE 2010; Poster 283.
Raskin P, Phillips MD, Rossiter A, et al. A1C and hypoglycemia in patients with type 2 diabetes mellitus incorporating prandial inhaled Technosphere® insulin into their usual antihyperglycemic regimen vs continuing their usual antihyperglycemic regimen. ADA 2010; Abstract 359-OR.
Raufman et al., Exendin-3, a novel peptdie from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed aciin from guinea pig pancreas. J. Biol. Chem. 266(5) : 2897-2902 (1991).
Raufman et al., Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guina pig pancreas. J. Biol. Chem. 267(30) : 21432-21437 (1992).
Raun et al. “Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, where as a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.” Diabetes 56:8, 2007.
Rave et al. “Coverage of Postprandial Blood Glucose Excursions with Inhaled Technosphere Insulin in Comparison to Subcutaneously Injected Regular Human Insulin in Subjects with Type 2 Diabetes.” Diabetes Care, vol. 30, No. 9, pp. 2307-2308, Sep. 2007.
Rave et al. “Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro.” Diabetes Care 28:2400-2405, 2005.
Rave et al. “Inhaled Technosphere Insulin in Comparison to Subcutaneous Regular Human Insulin: Time Action Profile and Variability in Subjects with Type 2 Diabetes.” Journal of Diabetes Science and Technology, vol. 2, Issue 2, pp. 205-212, Mar. 2008.
Rave et al. “Results of a Dose-Response Study with a New Pulmonary Insulin Formulation and Inhaler.” Diabetes 49, Supplement, May 2000, A75.
Rave et al. “Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin.” Diabetes Care 28:1077, 2005.
Rave K, Heise T, Pfuetzner A, et al Assessment of dose-response characteristics for a new pulmonary insulin formulation and inhaler. Exp Clin Endocrinol Diabetes 2000; 108;S161.
Rave K, Potocka E, Boss AH, et al. Pharmacokinetics and linear exposure of AFRESA™ compared with the subcutaneous injection of regular human insulin Diabetes, Obesity and Metabolism 2009; 11:715-720.
Raz et al. “Pharmacodynamics and Pharmacokinetics of Dose Ranging Effects of Oralin versus S.C. Regular Insulin in Type 1 Diabetic Patients.” Fourth Annual Diabetes Technology Meeting, Philadelphia PA, 2004.
Razavi et al. “TRPVI+ sensory neurons control beta cell stress and islet inflammation in autoimmune disease.” Cell 127:1123, 2006.
Retrieved from website: http://groups.molbiosci.northwestern.edu/holmgren/Glossary/Definitions/Def-P/placebo.html, 1 page, Retrieved on Mar. 12, 2013.
Rhodes et al. “Technosphere: Microspherical Particles from Substituted Diketopiperazines for Use in Oral Drug Delivery.” 208th ACS National Meeting, Aug. 1994.
Richardson et al. “Technosphere Insulin Technology.” Diabetes Technology & Therapeutics, vol. 9, Supplement 1, pp. S65-S72, 2007.
Richardson PC, Potocka E, Baughman RA, et al. Pharmacokinetics of Technosphere® insulin unchanged in patients with chronic obstructive pulmonary disease. Diabetologia 2009; 52 (suppl 1).
Richter et al. “Characterization of glucagon-like peptide-1(7-36)amide receptors of rat membranes by covalent cross-linking.” FEBS Letters 280:247, 1991.
Richter et al. “Characterization of receptors for glucagon-like peptide-1 (7-36)amide on rat lung membranes.” FEBS Letters 267:78, 1990.
Riddle “Combining Sulfonylureas and Other Oral Agents.” Am J Med, 2000, vol. 108(6A), pp. 15S-22S.
Riddle et al. “Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.” Diabetes Care 29:435, 2006.
Ritzel et al. “Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Dose-response-relationships.” Diabetologia 38:720, 1995.
Rosen et al., Substance P microinjected into the periaqueductal gray matter induces antinociception and is released folloing morphine administration. Brain Research, 1001: 87-94 (2004).
Rosenmund et al., Diketopiperazines from Leuchs Anhydrides. Angew Chem Intern. Edit. vol. , No. 2 (1970).
Rosenstock “Dual therapy with inhaled human insulin (Exubera(R)) as add-on to metformin (with stopping sulfonurea) is better than triple therapy with rosiglitazone add-on to combination metformin and sulfonurea in poorly controlled Type 2 diabetes.” Diabetes 57:supplement 1:A557, Abstract 2018-PO, 2008.
Cheatham et al. “Prandial Technosphere® /Insulin inhalation provides significantly better control of meal-related glucose excursions than prandial subcutaneous insulin.” Presented at the Diabetes Technology Society meeting, Oct. 2004.
Chelikani et al., Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am J Physiol. Regul. Integr. Comp. Physiol., 288(6):R1695-706, 2005.
Chemical Abstracts, vol. No. 114(22), Abstract No. 214519x (1990).
Chemicaland21.com. Solvents. Dec. 12, 2008. Available from: <http://web.archive.org/web20081212035748/http://www.chemicalland21.com/info/SOLVENTS.htm.
Chow et al., Particle Engineering for Pulmonary Drug Delivery. Pharmaceutical Research, vol. 24, No. 3, pp. 411-437 (2007).
Clee et al. Nature Genetics 38:688-693, 2006.
Cobble “Initiating and Intensifying Insulin Therapy for Type 2 Diabetes: Why, When, and How.” Am J Ther. Jan. 8, 2009.
Coffey et al. “Valuing heath-related quality of life in diabetes.” Diabetes Care 25:2238, 2002.
Colagiuri et al., Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? Diabetes Care, vol. 25, pp. 1410-1417 (2002).
Combettes and Kargar, C, Newly Approved and Promising Antidiabetic Agents. Therapie, Jul.-Aug. 2007: 62 (4): 293-310.
Coors et al., Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann. Allergy Astha Immunol., 95(6): 593-599 (2005).
Costello et al., “Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism in prostate epithelial cells”, Journ. Biol. Chem. 272(46):28875-28881 (1997).
Cricket TM Single-Use Inhalers [on-line]. MannKind Technologies Website, posted in 2011, [retrieved on Jul. 30, 2012]. Retrieved from the Internet. <URL:mannkindtechnologies,com/DeviceTechnology/CricketSingleUselnhalers.aspx>.
Crosby, J. “Dog Normals”, <http://vetmedicine.about.com/od/diseasesconditionsfaqs/tp/TP_dogfacts.htm>, copyright 2013.
Cruetzfeldt et al. “Glucagonostatic actions and reduction of fasting hyerglycemia by exogenous glucagon-like peptide i(7-36) amide in type 1 diabetic patients.” Diabetes Care 19:580, 1996.
D'Alessio et al., Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J. Clin. Invest., 97:133-38 (1996).
Database adisinsight, “Gucagon-like peptide-1 inhalation-MannKind Corporation”, Database accession No. 2009:1048 Abstract.
Davis “Postprandial Physiology and the Pathogenesis of Type 2 Diabetes Mellitus.” Insulin, vol. 3, Apr. 1, 2008, pp. 132-140.
De Heer et al. “Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide-1.” Diabetes 56:438, 2007.
Deacon “Therapeutic strategies based on glucagon-like peptide 1.” Diabetes. Sep;53(9):2181-9, 2004.
Deacon et al., “Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig”, Am. J. Physiol. 271 (Endocrino. Metab. 34): E458-E464, 1996.
Decode study group. “Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria.” Lancet. Aug. 21, 1999;354(9179):617-21.
DedicatedPhase, “Preclinical Trials and Research”, <http://www.dedicatedphase1.com/preclinical-research.html>, copyright 2006-2011, p. 1.
Definition of analog from http://cancerweb.ncl.ac.uk/omd/about.html, pp. 1-5 Accessed on Jul. 7, 2005 and cited in Office Action dated Jul. 26, 2013 in U.S. Appl. No. 12/830,557.
Del Prato S “Unlocking the opportunity of tight glycemic control” Diabetes Obesity and Metabolism 7:S1-S4, 2005.
Delgado-Aros et al. “Effect of GLP-1 on gastric volume, emptying, maximum volume ingested and postprandial symptoms in humans.” Am J Physiol Gastrointest Liver Physiol 282:G424, 2002.
Diabetes: Counting Carbs if You Use Insulin, WedMD, http://diabetes.webmd.com/carbohydrate-counting-for-people-who-use-insulin#m Oct. 1, 2010.
Diez et al. “Inhaled insulin—a new therapeutic option in the treatment of diabetes mellitus” Expert Opin. Pharmacother., 2003, 4, 191-200.
Dorwald, F.A. Side reactions in organic synthesis. Wiley, (2005).
Doyle et al. “Glucagon-like peptide-1.” Recent Prog Horm Res. 2001;56:377-99.
Dreamboat TM Reusable Inhalers [on-line]. MannKind Technologies Website, posted in 2011, Retrieved from the Internet: <URL: mannkindtechnologies.com/Device Technology/Dream Boat Reuseable Inhalers.aspx>.
Drucker “Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.” Curr Pharma Design 7:1399, 2001.
Drucker et al., “The incretin system:glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes”, www.thelancet.com, vol. 368, pp. 1696-1705, Nov. 11, 2006.
Drug Delivery, Easing the drug delivery route, Jun. 2006, Pharmaceutical & Medical Packaging News, Canon Communications.
Dungan et al., Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exntadtide. Clinical Diabetes, 23: 56-62 (2005).
Dunn, “Zinc-ligand interactions modulate assembly and stability of the insulin hexamer”, Biometals, 18(4):295-303 (2005).
Edelman “Type II Diabetes Mellitus.” Adv Int Med, 43:449-500, 1998.
Edited by Fukushima, Masanori, “Arterial Sclerosis,” Merck Manual 17th, Japanese Edition, NIKKEI BP Corp., p. 1659-1663, 1999.
Edwards CMB et al. “Cardiovascular and pancreatic endocrine response to glucagon-like peptide-1(7-36) amide in the conscious calf.” Exp Physiol 82:709, 1997.
Edwards CMB et al. “Subcutaneous glucagon-like peptide-1(7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects.” Clinical Science 96:719, 1998.
Edwards et al., Recent advances in pulmonary drug delivery using large, porous inhaled particles. Journal of Applied Physiology, pp. 379-385 (1998).
Eggers et al., Molecular confinement influences protein structure and enhances thermal protein stability. Protein Sci., 10:250-261 (2001).
Ehlers et al. “Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.” Horm Metab Res 35:611, 2003.
Eissele et al., Rat gastric somatostatin and gastrin relase: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide. Life Sci., 55(8):629-634 (1994).
Elliot et al., Parenteral absorption of insulin from the lung in diabetic children. Austr. Paediatr. J. 23: 293-297 (1987).
Elrick et al. “Plasma insulin response to oral and intravenous glucose administration.” J Clin Endocr 24:1076, 1964.
Engelgau MM “Screening for type 2 diabetes.” Diabetes Care 23:1563-1580, 2000.
Engwerda et al., Improved pharmackinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care, vol. 34, Aug. 2011, pp. 1804-1808.
Erlanger et al., Phosphorous pentoxide as a reagent in peptide synthesis. College of Physicians and Surgeons—Columbia Univeristy, vol. 26, pp. 2534-2536 (1960).
Exubera indications, dosage, storage, stability. Http://www.rxlist.com/cgi/generic4/exubera_ids.htm, 2008.
Heine “Unlocking the opportunity of tight glycaemic control. Promise ahead: the role of inhaled insulin in clinical practice.” Diabetes, Obesity and Metabolism 7:S19, 2005.
Heinemann “Variability of Insulin Absorption and Insulin Action.” Diabetes Technology & Therapeutics, vol. 4, No. 5, pp. 673-682. 2002.
Heinemann et al. “Current status of the development of inhaled insulin.” Br. J. Diabetes Vasc. Dis. 4:295-301, 2004.
Heinemann L et al. “Time-action profile of inhaled insulin.” Diabetic Med 14:63-72, 1997.
Heinemann, L “Intra-individual Variability of the Metabolic Effect of Inhales Insulin Together with an Absorption Enhancer”, Diabetes Care, vol. 23, No. 9, Sep. 2000, p. 1343-1347.
Heise et al. “The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin.” Diabetes Care 28:2161, 2005.
Herbst et al., Insulin Strategies for Primary Care Providers. Clinical Diabetes, vol. 20, No. 1, pp. 11-17 (2002).
Heubner et al. “On inhalation of insulin” Klinische Wochenschrift 16:2342, 1924. (Original and English translation provided in one document).
Heyder “Particle Transport onto Human Airway Surfaces”, Eur. J. Respir. Dis, Suppl. 119, 29-50 (1982).
Heyder, “Alveolar deposition of inhaled particles in humans”, Am. Ind. Hyg. Assoc. J. 43(11): 864-866 (1982).
Hirsch IB “Insulin analogues.” N Engl J Med 352:174-83, 2005.
Hirsch, “Type 1 Diabetes Mellitus and the Use of Flexible Insulin Regimens” American Family Phyician, Nov. 15, 1999, p. 1-16.
Hirshberg B et al. “Islet transplantation: where do we stand now?” Diabetes Metab Res Rev 19:175-8, 2003.
Hite et al. “Exhuberance over Exubera.” Clin Diabetes 24(3):110-114, 2006.
Hoet et al., Review: Nanoparticles—known and unknown health risks. Journal of Nanobiotechnology, vol. 2, No. 12, (15 pages) (2004).
Hollander et al. “Efficacy and Safety of Inhaled Insulin (Exubera) Compared with Subcutaneous Insulin Therapy in Patients with Type 2 Diabetes.” Diabetes Care, vol. 27, No. 10, Oct. 2004, p. 2356-2362.
Holst “Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.” Diabetes Metab Res Rev 18:430, 2002.
Holst et al. “On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects.” Ann N Y Acad Sci. Dec. 26, 1996;805:729-36.
Howard C, Ren H, Rossiter A, et al. Reduced incidence and frequency of hypoglycemia in an integrated analysis of pooled data from clinical trials of subjects with type 1 diabetes using prandial inhaled Technosphere® insulin. Diabetologia 2009; 52 (suppl 1).
Howard CP, Gnudi L, Lorber D, et al. Prandial inhaled Technosphere® insulin plus insulin glargine vs. biaspart 70/30 insulin in type 2 diabetes inadequately controlled with/without oral agents. Third International Conference on Advanced Technologies and Treatments for Diabetes. 2010; Poster 300.
Howard CP, Lorber D, Ren H, et al. Reduced incidence and frequency of hypoglycemia in pooled data from trials of hype 2 diabetics using prandial inhaled Technosphere® insulin. Third International Conference on Advanced Technologies and Treatments for Diabetes 2010; Poster 304.
Howard CP, Petrucci R,Amin N, et al. Pulmonary function test remain similar in patients who received Technosphere® insulin and in patients currently receiving standard antidiabetic therapy. AACE 2010; Poster 267.
Howard CP, Ren H, Rossiter A, Boss AH. Reduced incidence and frequency of hypoglycemia in pooled data from trials of type 1 diabetics using prandial inhaled Technosphere® insulin. Third International Conference on Advanced Technologies and Treatments for Diabetes. 2010; Poster 302.
Howard CP, Ren H, Rossiter A, et al. Reduced incidence and frequency of hypoglycemia in an integrated analysis of pooled data from clinical trials of subjects with type 1 diabetes using prandial inhaled Technosphere® insulin. AACE 2010; Poster 269.
Howard CP, Rubin RR, Peyrot. M. Patient reported outcomes in adults with type 2 diabetes using mealtime AFRESA® (inhaled Technosphere® insulin) and basal insulin versus premixed insulin ADA 2009; Poster 551.
http://www.bilcaresolutions.com/en/products/pharma-packaging-innovations-pvc-aclar-films <URL:http://web.archive.org/web/20110127102552/http://www.bilcaresolutions.com/en/products/pharma-packaging-innovations-pvc-aclar-films> published on Jan. 27, 2011 as per “Wayback Engine”.
http://www.pmpnews.com/article/blister-packaging-materials (May 26, 2009).
Huda et al. “Gut peptides and the regulation of appetite.” Obesity Reviews 7:163, 2006.
Hui et al., The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. European Journal of Endocrinology, 146: 863-869 (2002).
Hussain et al. “State of insulin self-association does not affects its absorption from the pulmonary route.” Eur. J. Pharm. Sciences 25:289-298, 2005.
Ikeda, Kuniki et al. “Peptide Antibiotics. XXVI. Syntheses of Cyclodipeptides Containing N. delta.-p-aminobenzenesulfonyl Ornithine Residue.” Chemical & Pharmaceutical Bulletin, 20(9), 1849-55, 1972.
Imeryuz et al. “Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.” Am J Physiol 273 (Gastrointest Liver Physiol 36):G920, 1997.
Insulin inhalation NN 1998, Drugs R & D, 2004, pp. 46-49, Adis Data Information BV.
Insulin is a natural product from http://www.levemir.com/startingoninsulin/whatisinulin.aspx, pp. 1-3. Accessed on Apr. 30, 2014 and cited in Non-Final Office Action dated May 22, 2014 for U.S. Appl. No. 13/797,657 and cited in Non-Final Office Action dated May 22, 2014 for U.S. Appl. No. 12/883,369.
International Search Report for PCT International Application No. PCT/US2010/055323 filed on Nov. 3, 2010.
Written Opinion dated Jul. 1, 2013 for International Application No. PCT/US2013/032162 filed on Mar. 15, 2013.
International Search Report dated Jun. 21, 2010 for International Application No. PCT/US2010/027038 filed on Mar. 11, 2010.
Written Opinion for International Application No. PCT/US2011/060057 filed on Nov. 9, 2011.
International Search Report dated Mar. 18, 2013 for International Application No. PCT/US2012/061749 filed on Oct. 24, 2012.
International Search Report dated Jun. 20, 2012 for International Applicaion No. PCT/US2012/031695 filed on Mar. 30, 2012.
International Search Report dated Nov. 19, 2014 for International Application No. PCT/US2014/049817 filed on Aug. 5, 2014.
International Search Report for International Application No. PCT/US2010/020448 filed on Jan. 8, 2010.
International Search Report dated Mar. 11, 2010 for International Application No. PCT/US2009/069745 filed on Dec. 29, 2009.
International Search Report dated Oct. 17, 2011 for International Application No. PCT/US2010/026271 filed on Mar. 4, 2010.
International Search Report for International Application No. PCT/US2010/038287 filed on Jun. 11, 2010.
Ishibashi, Norio et al. “Studies on Flavord Peptides. Part V. A Mechanism for Bitter Taste Sensibility in Peptides.” Agricultural and Biological Chemistry, 52(3), 819-27, 1988.
Iwanij et al., Characterization of the Glucagon Receptor and its Functional Domains Using Monoclonal Antibodies. The Journal of Biological Chemistry, vol. 265, No. 34, pp. 21302-21308, 1990.
Jain et al. “Insulin Therapy in Type 2 Diabetic Subjects Suppresses Plasminogen Activator Inhibitor (PAI-1) Activity and Proinsulin-like Molecules Independently of Glycaemic Control.” Diabetic Medicine, vol. 10, No. 1, p. 27-32, 1993.
Johnson et al., Peptide turn mimetics. Biotechnology and Pharmacy, p. 366-378 (1993).
International Search Report for International Application No. PCT/US2013/050392 filed on Jul. 12, 2013.
EXUBERA package insert, p. 1, 2008.
Fadl et al., Effects of MDI spray angle on aerosol penetration efficiency through an oral airway cast. Journal of Aerosol Science, vol. 38, No. 8, pp. 853-864 (2007).
Falsone et al., The Biginelli dihydropyrimidone synthesis using polyphosphate ester as a mild and efficient cyclocondensation/dehydration reagent. Institute of Chemistry, Organic and Bioorganic Chemistry, Karl-Franzens-University, pp. 122-134 (2001).
Farr, S.J. et al., Pulmonary insulin administration using the AERx® system:physiological and physiochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Tech. Ther. 2:185-197, 2000.
Fehmann et al. “Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide.” Endocrine Reviews 16:390, 1995.
Ferrin et al, Pulmonary retention of ultrafine and fine particles in rats. Am. J. Repir. Cell Mol. Biol., pp. 535-542 (1992).
Festa et al., “LDL particle size in relation to insulin, proinsulin, and insulin sensitivity” Diabetes Care, 22 (10):1688-1693 (1999).
Forst et al., “Metabolic Effects of Mealtime Insulin Lispro in Comparison to Glibenclamide in Early Type 2 Diabetes”, Exp. Clin. Endocnnol. Diabetes, 2003, 111, 97-103.
Fritsche et al. “Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorm Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes.” American College of Physicians 2003.
Galinsky et al., A synthesis of diketopiperazine's using polyphosphoric acid. Journal of the American Pharmaceutical Association, vol. 46, No. 7, pp. 391-393 (1957).
Garber, “Premixed insulin analogues for the treatment of diabetes mellitus”, Drugs, 66(1):31-49 (2006).
Garg et al. “Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.” Diabetes Research and Clinical Practice 66 (2004) 49-56.
Garg SK, Kelly W, Freson B, et al. Treat-to-target Technosphere® insulin in patients with type 1 diabetes. ADA 2011; Abstract 941-P.
Garg SK, McGill JB, Rosenstock J, et al. Technosphere® insulin vs insulin lispro in patients with type 1 diabetes using multiple daily injections. ADA, Abstract 917-P (2011).
Gates BJ “Update on advances in alternative insulin therapy.” Advances in Pharmacy 1:159-168, 2003.
Glucagon for Injection (1999) glucagon for injection (rDNA origin), pp. 1-7.
Glucagon-like peptide-1; http://en.wikipedia.org/wiki/Glucagon-like peptide-1 (accessed Apr. 24, 2015).
GLUCOPHAGE Product Insert. Jan. 2009.
GLUCOTROL Product Insert. Sep. 2006.
Gnudi L, Lorber D, Rosenstock J, et al. Basal/bolus with prandial inhaled Technosphere® insulin (TI) plus insulin glargine qd vs biaspart 70/30 insulin bid in type T2 diabetes mellitus inadequately controlled on insulin with/without oral agents. Diabetologia 2009; 52 (suppl 1).
Goke et al., Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 268(26):19650-19655 (1993).
Golpon et al. “Vasorelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat.” Regulatory Peptides 102:81, 2001.
Gonzalez et al., Actualizacion del tratamiento farmacologico de la diabetes mellitus tipo 2. Del Sistema Nacional de Salud. vol. 32, No. 1, pp. 3-16 (2008)—full article in Spanish with English abstract.
Gotfried M, Cassidy JP, Marino MT, et al. Lung deposition and absorption of insulin from Technosphere® insulin. Diabetologia 2009; 52 (suppl 1).
Grant et al “Both insulin sensitivity and maximal glucose elimination rate are reduced in type 2 diabetes.” Presented at the American Diabetes Association 65th Scientific Sessions, Jun. 2005, abstract 2202-PO.
Grant et al. “The distribution of 14C-labeled particles following intra-tracheal liquid installation in the Sprague-Dawley rat.” Presented at the American Diabetes Association 64th Scientific Sessions, Jun. 2004, abstract 461-P.
Grant M, Harris E, Leone-Bay A, Rousseau K. Technosphere®/insulin: Method of action. Diabetes Technology Meeting 2006; Poster.
Grant ML, Greene S, Stowell GW, et al. Mimicking endogenous peptide secretion by inhalation APS 2009; poster.
Greene et al. “Effects of GLP-1 Technosphere(TM) powder: administered by pulmonary insufflation in male obese Zucker diabetic fat (ZDF) rats.” Diabetes Technology Meeting, San Francisco, Oct. 2007.
Greene et al., Greene's protective groups in organic synthesis. 4th ed., pp. 781-783 (2007).
Gupta et al. “Contemporary Approaches in Aerosolized Drug Delivery to the Lung.” J. Controlled Research, 17:129-148, 1991.
Gurrieri et al., Thermal condensation of some alpha-aminoacids with phatalic acid. Thermochimica Acta, 7 (1973) 231-239.
Gutniak et al. “Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.” J Int Med 250:81, 2001.
Gutniak et al. “Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.” NEJM 326:1316, 1992.
Gutniak et al. “GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.” Diabetes Care 20:1874, 1997.
Gutniak et al. “Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet.” Diabetes Care 19:843, 1996.
Gutniak et al. “Subcutaneious injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.” Diabetes Care 17:1039, 1994.
Guyton et al., “Acute Control of Llocal Blood Flow”, Textbook of Medical Physiology, Chapter 17, 10th Edition, W.B. Saunders Company, pp. 176-177, 2000.
Gyore et al., Thermal Analysis, vol. 2—Proceedding Fourth ICTA Budapest 1974; 387-394.
Haak “New developments in the treatment of type 1 diabetes mellitus.” Exp Clin Endocrinol Diabetes 107:Suppl 3: S108, 1999.
Haffner et al., “Proinsulin and insulin concentrations I relation to carotid wall thickness”, Strock 29:1498-1503 (1998).
Hagedorn et al. “Protamine Insulin”, JAMA, 106:177-180 (1936).
Haino, Takeharu et al. “On-beads Screening of Solid-Attached Diketopiperzines for Calix[5]Arene-Based Receptor.” Tetrahedron Letters, 40(20), 3889-3892, 2003.
Halozyme Press Release. Jun. 6, 2009.
Hanley et al., “Cross-sectional and prospective associations between proinsulin and cardovascular disease risk factors in a population experiencing rapid cultural transition” Diabetes Care 24(7): 1240-1247 (2001).
Harsch IA “Inhaled insulins. Their potential in the treatment of diabetes mellitus.” Traat. Endicrinol 4:131-138, 2005.
Hassan et al. “A Randomized, Controlled Trial Comparing Twice-a-Day Insulin Glargine Mixed with Rapid-Acting Insulin Analogs Versus Standard Neutral Protamine Hagedorn (NPH) Therapy in Newly Diagnosed Type 1 Diabetes.” Pediatrics, 121(3), e466-e472, 2008.
Hassan et al. “In vivo dynamic distribution of 131I-glucagon0like peptide-1 (7-36) amide in the rat studied by gamma camera.” Nucl Med Biol 26:413, 1999.
Hausmann et al. “Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof of concept study.” Diabetes Obesity and Metabolism 8:574, 2006.
Hayasaka et al. “Proliferation of type II pneumocytes and alteration in their apical surface membrane antigenicity in pulmonary sarcoidosis.” Chest 116:477, 1999.
Amorij et al., Development of stable infleunza vaccine powder formulations challenges and possibilities. Pharmaceutical Research, vol. 25, No. 6, pp. 1256-1273 (2008).
Audouy et al., Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine, vol. 29, pp. 4345-4352 (2011).
Volund “Conversion of insulin units to SI units.” American Journal of Clinical Nutrition, Nov. 1993, 58(5), pp. 714-715.
Wachters-Hagedoorn et al. “The rate of intestinal glucose absorption is correlated with plasma glucose-dependent insulinotropic polypeptide concentrations in healthy men.” J Nutr 136:1511, 2006.
Wang et al., Glucagon-like peptide-1 is a physiological incretin in rat J. Clin. Invest., 95 : 417-421 (1995).
Wang et al., Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia, 47:478-487, 2004.
Wareham et al., “Fasting Proinsulin Concentrations Predict the Development of Type 2 Diabetes”, Diabetes Care, 1999, 22, 262-70.
Warren et al. “Postprandial versus prandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients.” Diabetes Res Clin Pract 66:23-29, 2004.
Waterhouse et al., “Comparatie assessment of a new breath-actuated inhaler in patients with reversible airways obstruction”, Respiration 59:155-158 (1992).
WebMD (retrieved from http://www.webmd.com/pain-management/tc/pain-management-side-effects-of-pain-medicines in 2012, 4 pages).
Wei et al. “Tissue-specific expression of the human receptor for glucagon-like peptide-1: brain and pancreatic forms have the same deduced amino acid sequence.” FEBS Letters 358:219, 1995.
Weir et al. “Glucagonlike peptide 1 (7-37) actions on endocrine pancreas.” Diabetes 38:338, 1989.
Weiss, SR et al. “Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents.” Arch Intern Med 163:2277-2282, 2003.
Weissberger, “Mannkind: Overlooked Biotech with Excellent Prospects (Part V),”http://www.investorvillage.com/smbd.asp?mb=2885&mn=45817&pt=msg&mid=5021385 (posted on Jun. 19, 2008, accessed on Oct. 18, 2012).
West, Solid State Chemistry and its Applications, Chp 10, Solid Solutions. Wiley, New York, 358 (1998).
Wettergren A et al. “Truncated GLP-1 (proglucagon 78-107-Amide) inhibits gastric and pancreatic functions in man.” Digestive Diseases and Sciences 38:665, 1993.
White JR et al. “Inhaled insulin: an overview.” Clinical Diabetes 19:13-16, 2001.
Wigley et al., Insulin across respiratory mucosae by aerosol delivery. Diabetes 20(8): 552-556 (1971).
Willms B et al. “Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.” J. Clin Endocrinol Metab 81:327, 1996.
Wilson BR et al. “Technospheres(TM) for pulmonary and nasal applications.” Respiratory Drug Delivery VIII, 2002,p. 545.
Wilson et al., Spray-drying, a viable technosphere formulation process option to lyophilization, http://www.aapsj.org/abstracts/AM_2004/AAPS2004-002724.PDF, 1 page, 2004.
Witchert, Low molecular weight PLA: A suitable polymer for pulmonary administered microparticles. J. Microencapsulation, 10(2): 195-207 (1993).
Wright et al., Inhaled Insulin: Breathing new life into diabetes therapy. Nursing, vol. 37, No. 1, p. 46-48 (2007).
Wong et al. “From cradle to grave: pancreatic b-cell mass and glucagon-like peptide-1.” Minerva Endocrinologica 31:107, 2006.
Wuts et al. “The Role of Protective Groups in Organic Synthesis,” John Wiley, New York, 2nd Ed. 1991.
Yan et al., Analgesic action of microinjection of neurokinin A into the lateral reticular nucleus and nucleus raphe magnus in rats. Acta Physiologica Sinica, vol. 48, No. 5, pp. 493-496 (1996)—abstract.
Yang et al., Division and differentiation of natural antibody-producing cells in mouse spleen. PNAS, 104(11): 4542-4546 (2007).
Yoshida et al., Absorption of insulin delivered to rabbit trachea using aerosol dosage form. J. Pharm. Sci. 68(5): 670-671 (1979).
Yoshioka et al., “Serum proinsulin levels at fasting and after oral glucose load in patients with Type 2 (non-insulin dependent) diabetes mellitus”, Diabetogia, 1988, 31, 355-60.
Yu W, Marino MT, Cassidy JP, et al. Insulin antibodies associated with Technosphere® insulin. ADA 2010; Abstract 216-OR.
Yusta B et al. “GLP-1 receptor activation improves b-cell function and survival following induction of endoplasmic reticulum stress.” Cell Metabolism 4:391, 2006.
Zander et al., Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet, 359:824 -830, 2002.
Zethelius et al., “Proinsulin is an Independent Predictor of Coronary Heart Disease”, Circulation 105:2153-2158 (2002).
Zimmerman, K., “Respiratory System: Fats, Function, and Diseases”, <www.livescience.com/22616-respiratory-system.html>, copyright 2013, p. 1.
Zisser et al. “In Patients Using Technospere Insulin. Variation in PPG Stayed Within ADA-recommended Targets Despite Large Variations in Glucose Load.” Mannkind Corporation (2010), ADA 2010; Poster 554.
Zisser H, Jovanovic L, Markova K, et al. Technosphere® insulin effectively controls postprandial glycemia in patients with type 2 diabetes mellitus. Diabetes Technology and Therapeutics 2012;14:997-1001.
Wasada, Glucagon-like peptide-1 (GLP-1). Nihon Rinsho, vol. 62, No. 6, pp. 1175-1180 (2004) (full Japanese article with English abstract).
Bosquillon et al., Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rates. Journal of Controlled Release 96: 233-244 (2004).
Cho et al., Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacology & Therapeutics 135: 247-278 (2012).
Definition of medicament from http://medical-dictionary.thefreedictionary.com/medicament, retrieved on Mar. 20, 2015 and cited in Office Action dated Mar. 26, 2015 in U.S. Appl. No. 13/942,482.
Definition of matrix from http://medical-dictionary.thefreedictionary.com/matrix, retrieved on Mar. 5, 2015 and cited in Office Action dated Mar. 26, 2015 in U.S. Appl. No. 12/471,260.
Diabetes Frontier, vol. 10, No. 5, p. 647-657 (1999) (full Japanese article with translated English portion provided in separate attachment, portion translated in English is the bottom of p. 655 and the left column of p. 656).
Ely et al., Effervescent dry powder for respiratory drug delivery. European Journal of Pharmaceutics and Biopharmaceutics 65: 346-353 (2007).
European Search report for European Application 14192154.4 dated Mar. 19, 2015.
Extended European Search report for European Application 14187552.6 dated Mar. 2, 2015.
Gillespie et al., Using carbohydrate counting in diabetes clinical practice. Journal of the American Diabetic Association, vol. 98, No. 8, p. 897-905 (1998).
Yamamoto et al., Engineering of Poly (DL-lactic-co-glycolic acid) Nano-composite particle for dry powder inhalation dosage forms of insulin with spray fludized bed granulating system. J. Soc. Powder Technol., Japan, 41: 514-521 (2004).
Related Publications (1)
Number Date Country
20160346212 A1 Dec 2016 US
Provisional Applications (2)
Number Date Country
60717524 Sep 2005 US
60744882 Apr 2006 US
Divisions (1)
Number Date Country
Parent 12883369 Sep 2010 US
Child 14746656 US
Continuations (2)
Number Date Country
Parent 14746656 Jun 2015 US
Child 15233794 US
Parent 11532065 Sep 2006 US
Child 12883369 US